

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/06/01 to 2023/06/15. "COVID-19 vaccine" (Title/Abstract) 580 records.

[COVID-19 vaccines adverse events: potential molecular mechanisms.](#)

Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6. PMID: 36607502

[Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.](#)

Kim S, Seok HY. Neurol Sci. 2023 Jun;44(6):1841-1848. doi: 10.1007/s10072-023-06676-1. Epub 2023 Feb 13. PMID: 36781562

[COVID-19 anti-vaccine attitude and hesitancy.](#)

Hasanzad M, Namazi H, Larijani B. J Diabetes Metab Disord. 2022 Nov 5;22(1):1-4. doi: 10.1007/s40200-022-01018-y. eCollection 2023 Jun. PMID: 36373157

[Trust and COVID-19 vaccine hesitancy.](#)

Carrieri V, Guthmuller S, Wübker A. Sci Rep. 2023 Jun 7;13(1):9245. doi: 10.1038/s41598-023-35974-z. PMID: 37286569

[COVID-19: The disease, the vaccine and the heart.](#)

Turner CJ. J Paediatr Child Health. 2023 Jun;59(6):786-793. doi: 10.1111/jpc.16407. Epub 2023 May 9. PMID: 37158762

[COVID-19 vaccine equity in Africa.](#)

Turyasingura N, James WG, Vermund SH. Trans R Soc Trop Med Hyg. 2023 Jun 2;117(6):470-472. doi: 10.1093/trstmh/trac130. PMID: 36622662

[Factors, enablers and challenges for COVID-19 vaccine development.](#)

Excler JL, Saville M, Privor-Dumm L, Gilbert S, Hotez PJ, Thompson D, Abdool-Karim S, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011879. doi: 10.1136/bmjgh-2023-011879. PMID: 37277195

[COVID-19 and splenectomy: Education matters.](#)

Crickx E. Br J Haematol. 2023 Jun;201(6):1023-1024. doi: 10.1111/bjh.18767. Epub 2023 Mar 30. PMID: 36994879

[Obesity and Viral Infections.](#)

Jaisinghani P, Kumar R. Gastroenterol Clin North Am. 2023 Jun;52(2):393-402. doi: 10.1016/j.gtc.2023.03.012. PMID: 37197881

[Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023.](#)

Hoang TNA, Quach HL, Hoang VN, Tran VT, Pham QT, Vogt F. Euro Surveill. 2023 Jun;28(22):2200706. doi: 10.2807/1560-7917.ES.2023.28.22.2200706. PMID: 37261728

[Vaccination in pregnancy.](#)

Nassar AH, Hobeika E, Chamsy D, El-Kak F, Usta IM. Int J Gynaecol Obstet. 2023 Jun 7. doi: 10.1002/ijgo.14876. Online ahead of print. PMID: 37283471

[COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.](#)

Limaye RJ, Singh P, Paul A, Fesshaye B, Lee C, Zavala E, Wade S, Ali H, Rahman H, Akter S, Karron R, Jahan Siddiqua T. Vaccine. 2023 Jun 13;41(26):3885-3890. doi: 10.1016/j.vaccine.2023.05.024. Epub 2023 May 15. PMID: 37208208

[Acute hepatitis of unknown origin in children: Behind the statistics.](#)

Elsheikh R, Tien HT, Makram AM, Van NT, Le TTB, Vasanthakumaran T, Huy NT. Hepatology. 2023 Jun 1;77(6):2118-2127. doi: 10.1002/hep.32682. Epub 2022 Aug 9. PMID: 35862247

[COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults.](#)

Willis DE, Andersen JA, Montgomery BEE, Selig JP, Shah SK, Zaller N, Bryant-Moore K, Scott AJ, Williams M, McElfish PA. J Racial Ethn Health Disparities. 2023 Jun;10(3):1025-1034. doi: 10.1007/s40615-022-01290-x. Epub 2022 Apr 7. PMID: 35391714

[Vaccine access, equity and justice: COVID-19 vaccines and vaccination.](#)

Privor-Dumm L, Excler JL, Gilbert S, Abdool Karim SS, Hotez PJ, Thompson D, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011881. doi: 10.1136/bmjgh-2023-011881. PMID: 37290896

[COVID-19 Vaccine Hesitancy, Medical Mistrust, and Mattering in Ethnically Diverse Communities.](#)

Charura D, Hill AP, Etherson ME. J Racial Ethn Health Disparities. 2023 Jun;10(3):1518-1525. doi: 10.1007/s40615-022-01337-z. Epub 2022 May 31. PMID: 35641735

[Associations between COVID-19 vaccine uptake, race/ethnicity, and political party affiliation.](#)

Andersen JA, Gloster E, Hall S, Rowland B, Willis DE, Kraleti SS, McElfish PA. J Behav Med. 2023 Jun;46(3):525-531. doi: 10.1007/s10865-022-00379-2. Epub 2022 Nov 22. PMID: 36417011

[Views and perceptions of the public toward COVID-19 vaccine in Saudi Arabia.](#)

Thabit AK, Badr AF, Jad L, Jose J, Kaae S, Jacobsen R, Al-Saudi G. Saudi Pharm J. 2023 Jun;31(6):942-947. doi: 10.1016/j.jsps.2023.05.001. Epub 2023 May 8. PMID: 37197386

[COVID-19 vaccine uptake and hesitancy in Chinese patients with asthma.](#)

Chang C, Zhang X, Feng Y, Jin R, Sun L, Liang Y, Liu X, Ma Y, Song J, Xiang P, Zhang E, Chen L, Jiang Y, Huang K, Wang W, Chen Y, Sun Y. J Asthma. 2023 Jun 9:1-10. doi: 10.1080/02770903.2023.2220790. Online ahead of print. PMID: 37272671

[Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.](#)

Xu K, Gao B, Li J, Xiang Y, Cao L, Zhao M. Hum Vaccin Immunother. 2023 Jun 6:2220630. doi: 10.1080/21645515.2023.2220630. Online ahead of print. PMID: 37282614

[COVID-19 Vaccine Perspective Among University Lecturers and Students: A Qualitative Study of Pre Implementation of Vaccination.](#)

Rahayuwati L, Mutyara K, Nugraha RR, Khatiwada M, Dochez C, Kartasasmita C. J Multidiscip Healthc. 2023 Jun 10;16:1619-1629. doi: 10.2147/JMDH.S416123. eCollection 2023. PMID: 37325125

[Are surgeons ready to get the COVID-19 vaccine?](#)

Farid Y, Vissers G, Ortiz S, Tondou T, Thiessen F, Coppieters Y, Wauthy P. Acta Chir Belg. 2023 Jun;123(3):238-243. doi: 10.1080/00015458.2021.1975892. Epub 2021 Sep 20. PMID: 34474635

[Anetoderma after mRNA COVID-19 vaccine.](#)

Massi A, Rapparini L, Misciali C, Baraldi C, Pileri A. Ital J Dermatol Venerol. 2023 Jun;158(3):269-270. doi: 10.23736/S2784-8671.23.07305-X. PMID: 37278506

[Social media use and COVID-19 vaccine status among a nationally representative population sample in Uganda.](#)

Greenleaf AR, Croker-Benn A, Aibo D, Biraro S, Mugisha V, Kwizera MH, Kabanda R, Justman J, El-Sadr WM. Digit Health. 2023 Jun 7;9:20552076231180733. doi: 10.1177/20552076231180733. eCollection 2023 Jan-Dec. PMID: 37325068

[The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications.](#)

Chih S, Clarke BA, Albert M, Buchan CA, Kafil TS, Kim DH, Kumar D, Smith SJ, Solera Rallo JT, Stubbs MJ, McDonald MA. Can J Cardiol. 2023 Jun;39(6):853-864. doi: 10.1016/j.cjca.2023.03.014. Epub 2023 Mar 23. PMID: 36965667

[Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.](#)

Rodriguez DM, Major CG, Sánchez-González L, Jones E, Delorey MJ, Alonso C, Rivera-Amill V, Paz-Bailey G, Adams LE. Vaccine. 2023 Jun 1;41(24):3627-3635. doi: 10.1016/j.vaccine.2023.04.081. Epub 2023 May 5. PMID: 37173267

[Characterizing Responses to COVID-19 Vaccine Promotion on TikTok.](#)

Southwick L, Francisco A, Bradley M, Klinger E, Chandra Guntuku S. Am J Health Promot. 2023 Jun;37(5):638-645. doi: 10.1177/08901171221141974. Epub 2022 Dec 9. PMID: 36494184

[COVID-19 vaccines and increased blood pressure.](#)

Kleebayoon A, Wiwanitkit V. Eur J Intern Med. 2023 Jun;112:121. doi: 10.1016/j.ejim.2023.03.030. Epub 2023 Mar 30. PMID: 37003922

[Covid-19 vaccine roll-out in England: A qualitative evaluation.](#)

Mounier-Jack S, Paterson P, Bell S, Letley L, Kasstan B, Chantler T. PLoS One. 2023 Jun 2;18(6):e0286529. doi: 10.1371/journal.pone.0286529. eCollection 2023. PMID: 37267295

[Management of COVID-19 and vaccination in Nepal: A qualitative study.](#)

Karki A, Rijal B, Koirala B, Makai P, Kc P, Adhikary P, Joshi S, Basnet S, Bhattarai S, Karki J. Health Expect. 2023 Jun;26(3):1170-1179. doi: 10.1111/hex.13732. Epub 2023 Feb 16. PMID: 36797845

[Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants.](#)

Fleming-Dutra KE, Zauche LH, Roper LE, Ellington SR, Olson CK, Sharma AJ, Woodworth KR, Tepper N, Havers F, Oliver SE, Twentyman E, Jatlaoui TC. Obstet Gynecol Clin North Am. 2023 Jun;50(2):279-297. doi: 10.1016/j.ogc.2023.02.003. Epub 2023 Feb 21. PMID: 37149310

[Using Twitter to Understand COVID-19 Vaccine-Related Ageism during the Pandemic.](#)

Bacsu JR, Andrew MK, Azizi M, Berger C, Cammer A, Chasteen AL, Fraser SA, Grewal KS, Green S, Gowda-Sookchoff R, Mah JC, McGilton KS, Middleton L, Nanson K, Spiteri RJ, Tang Y, O'Connell ME. *Gerontologist*. 2023 Jun 2:gnad061. doi: 10.1093/geront/gnad061. Online ahead of print. PMID: 37267449

[COVID-19 vaccine acceptance and predictors among pregnant women in Ethiopia: Systematic Review and Meta-Analysis.](#)

Worede DT, Kassahun M, Endalew B. *Public Health Pract (Oxf)*. 2023 Jun;5:100386. doi: 10.1016/j.puhip.2023.100386. Epub 2023 Apr 23. PMID: 37122635

[Coronavirus Disease-2019 in the Immunocompromised Host.](#)

Bertini CD Jr, Khawaja F, Sheshadri A. *Clin Chest Med*. 2023 Jun;44(2):395-406. doi: 10.1016/j.ccm.2022.11.012. Epub 2022 Nov 22. PMID: 37085228

[Predictors of COVID-19 vaccine hesitancy among Jordanian older adults.](#)

Abu Kamel AM, Alnazly E, Shawish NS. *Int J Nurs Pract*. 2023 Jun;29(3):e13144. doi: 10.1111/ijn.13144. Epub 2023 Mar 6. PMID: 36879519

[Adolescent autonomy for the COVID-19 vaccine.](#)

Ting P. *J Public Health Policy*. 2023 Jun;44(2):325-328. doi: 10.1057/s41271-023-00398-6. Epub 2023 Feb 14. PMID: 36788273

[COVID-19 Vaccine Hesitancy in an Underrepresented Minority Community.](#)

Balhotra K, Chahal K, Silver M, Atallah F, Narayanamoorthy S, Minkoff H. *J Community Health*. 2023 Jun;48(3):489-495. doi: 10.1007/s10900-022-01184-3. Epub 2023 Jan 24. PMID: 36692822

[Explaining the gender gap in COVID-19 vaccination attitudes.](#)

Toshkov D. *Eur J Public Health*. 2023 Jun 1;33(3):490-495. doi: 10.1093/eurpub/ckad052. PMID: 37178211

[How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022.](#)

Lai CC, Lee PI, Hsueh PR. *J Microbiol Immunol Infect*. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6. PMID: 37061349

[Socioeconomic status and disparities in COVID-19 vaccine uptake in Eastern Oslo, Norway.](#)

Lillebråten A, Todd M, Dimka J, Bakkeli NZ, Mamelund SE. *Public Health Pract (Oxf)*. 2023 Jun;5:100391. doi: 10.1016/j.puhip.2023.100391. Epub 2023 May 28. PMID: 37293528

[A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.](#)

Villarraza J, Fuselli A, Gugliotta A, Garay E, Rodríguez MC, Fontana D, Antuña S, Gastaldi V, Battagliotti JM, Tardivo MB, Alvarez D, Castro E, Cassataro J, Ceaglio N, Prieto C. *Appl Microbiol Biotechnol*. 2023 Jun;107(11):3429-3441. doi: 10.1007/s00253-023-12520-5. Epub 2023 Apr 24. PMID: 37093307

[Acute cardiac events after COVID-19 vaccines and during spontaneous SARS-CoV-2 infection.](#)

Marabotti C, Pingitore A. *J Cardiovasc Med (Hagerstown)*. 2023 Jun 1;24(6):323-325. doi: 10.2459/JCM.0000000000001464. PMID: 37129927

[COVID-19 Vaccine Videos: Health Literacy Considerations.](#)

Feinberg I, Ogrodnick M, Bernhardt J. Health Lit Res Pract. 2023 Jun;7(2):e111-e118. doi: 10.3928/24748307-20230523-02. Epub 2023 Jun 1. PMID: 37306321

[Das sind die neuen Ziffern für die Covid-Impfung.](#)

Zimmermann GW. MMW Fortschr Med. 2023 Jun;165(11):30-31. doi: 10.1007/s15006-023-2575-y. PMID: 37258829

[Evaluation of a Community COVID-19 Vaccine Ambassador Train-the-Trainer Program.](#)

Corley AMS, Gomes SM, Martin KJ, Watkins S, Lindsey K, Frenck RW Jr, Mitchell MJ, Rule ARL, Crosby LE. J Immigr Minor Health. 2023 Jun 5:1-5. doi: 10.1007/s10903-023-01502-4. Online ahead of print. PMID: 37273119

[Safety of COVID-19 vaccines.](#)

Virginia R, Guido R. Eur J Intern Med. 2023 Jun;112:15-16. doi: 10.1016/j.ejim.2023.04.009. Epub 2023 Apr 10. PMID: 37045709

[Female reproduction and abnormal uterine bleeding after COVID-19 vaccination.](#)

Paik H, Kim SK. Clin Exp Reprod Med. 2023 Jun;50(2):69-77. doi: 10.5653/cerm.2023.05925. Epub 2023 May 16. PMID: 37258099

[Determinants of COVID-19 vaccine Hesitancy: 2020 California Health Interview Survey.](#)

Moon I, Han J, Kim K. Prev Med Rep. 2023 Jun;33:102200. doi: 10.1016/j.pmedr.2023.102200. Epub 2023 Apr 5. PMID: 37034299

[COVID-19 vaccination and changes in preventive behaviours: findings from the 2021 vaccine roll-out in Switzerland.](#)

Hitchman SC, Geber S, Tribelhorn L, Friemel TN. Eur J Public Health. 2023 Jun 1;33(3):482-489. doi: 10.1093/eurpub/ckad050. PMID: 37015103

[COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.](#)

Hotez PJ, Gilbert S, Saville M, Privor-Dumm L, Abdool-Karim S, Thompson D, Excler JL, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011883. doi: 10.1136/bmjgh-2023-011883. PMID: 37277196

[Benefit-risk assessment of Covid-19 vaccine, MRNA \(MRNA-1273\) for males age 18-64 years.](#)

Yogurtcu ON, Funk PR, Forshee RA, Anderson SA, Marks PW, Yang H. Vaccine X. 2023 Aug;14:100325. doi: 10.1016/j.jvacx.2023.100325. Epub 2023 Jun 2. PMID: 37324525

[Broadly neutralizing antibodies against COVID-19.](#)

Zhou D, Ren J, Fry EE, Stuart DI. Curr Opin Virol. 2023 Jun 5;61:101332. doi: 10.1016/j.coviro.2023.101332. Online ahead of print. PMID: 37285620

[Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.](#)

Ciapponi A, Berrueta M, P K Parker E, Bardach A, Mazzoni A, Anderson SA, Argento FJ, Ballivian J, Bok K, Comandé D, Goucher E, Kampmann B, Munoz FM, Rodriguez Cairolí F, Santa María V, Stergachis AS, Voss G, Xiong X, Zamora N, Zaraa S, Buekens PM. Vaccine. 2023 Jun 7;41(25):3688-3700. doi: 10.1016/j.vaccine.2023.03.038. Epub 2023 Mar 27. PMID: 37012114

[A COVID-19 perspective of Vogt-Koyanagi-Harada disease.](#)

Dutta Majumder P, Sadhu S, González-López JJ, Mochizuki M. Indian J Ophthalmol. 2023 Jun;71(6):2587-2591. doi: 10.4103/IJO.IJO_172_23. PMID: 37322685

[Burden of COVID-19 disease and vaccine coverages in Apulian splenectomized patients: A retrospective observational study.](#)

Bianchi FP, Stefanizzi P, Rizzi D, Signorile N, Cuscianna E, Daleno A, Migliore G, Tafuri S. Br J Haematol. 2023 Jun;201(6):1072-1080. doi: 10.1111/bjh.18731. Epub 2023 Mar 21. PMID: 36942786

[Social-political and vaccine related determinants of COVID-19 vaccine hesitancy in Tanzania: A qualitative inquiry.](#)

Mtenga S, Mhalu G, Osetinsky B, Ramaiya K, Kassim T, Hooley B, Tediosi F. PLOS Glob Public Health. 2023 Jun 14;3(6):e0002010. doi: 10.1371/journal.pgph.0002010. eCollection 2023. PMID: 37315101

[COVID-19 vaccine hesitancy and attitudes in Pakistan: a cross-sectional phone survey of major urban cities.](#)

Khan AA, Abdullah M, Aliani R, Mohiuddin AF, Sultan F. BMC Public Health. 2023 Jun 9;23(1):1112. doi: 10.1186/s12889-023-15905-3. PMID: 37296386

[Lipid nanoparticle-mediated drug delivery to the brain.](#)

Khare P, Edgecomb SX, Hamadani CM, Tanner EEL, S Manickam D. Adv Drug Deliv Rev. 2023 Jun;197:114861. doi: 10.1016/j.addr.2023.114861. Epub 2023 May 6. PMID: 37150326

[Overview of the cardio-metabolic impact of the COVID-19 pandemic.](#)

Barkhordarian M, Behbood A, Ranjbar M, Rahimian Z, Prasad A. Endocrine. 2023 Jun;80(3):477-490. doi: 10.1007/s12020-023-03337-3. Epub 2023 Apr 27. PMID: 37103684

[COVID-19 vaccination and governance in the case of low, middle and high-income countries.](#)

Lupu D, Tiganasu R. BMC Public Health. 2023 Jun 5;23(1):1073. doi: 10.1186/s12889-023-15975-3. PMID: 37277743

[Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca \(AZD1222\) COVID-19 vaccine: A case report and brief review.](#)

Ansari B, Najafi MA, Kheradmand M, Najafi F, Najafi MR. Rev Neurol (Paris). 2023 Jun;179(6):630-635. doi: 10.1016/j.neurol.2022.11.009. Epub 2023 Feb 1. PMID: 36754672

[Upper extremity deep vein thrombosis following BBIBP-CorV COVID-19 vaccine \(Sinopharm vaccine\): A case report.](#)

Riazi A, Faghieh Dinevari M, Abbasian S, Jabbaripour Sarmadian A. Clin Case Rep. 2023 Jun 13;11(6):e7535. doi: 10.1002/ccr3.7535. eCollection 2023 Jun. PMID: 37323251

[COVID-19 vaccination and household savings: An economic recovery channel.](#)

Ren H, Zheng Y. Financ Res Lett. 2023 Jun;54:103711. doi: 10.1016/j.frl.2023.103711. Epub 2023 Feb 23. PMID: 36852174

[COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".](#)

Kühlbrandt C, McGowan CR, Stuart R, Grenfell P, Miles S, Renedo A, Marston C. Vaccine. 2023 Jun 13;41(26):3891-3897. doi: 10.1016/j.vaccine.2023.04.080. Epub 2023 May 1. PMID: 37202271

[Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.](#)

Smith K, Hegazy K, Cai MR, McKnight I, Rousculp MD, Alves K. Vaccine. 2023 Jun 13;41(26):3930-3936. doi: 10.1016/j.vaccine.2023.05.016. Epub 2023 May 10. PMID: 37211453

[COVID-19 vaccination-related myocarditis: a Korean nationwide study.](#)

Cho JY, Kim KH, Lee N, Cho SH, Kim SY, Kim EK, Park JH, Choi EY, Choi JO, Park H, Kim HY, Yoon HJ, Ahn Y, Jeong MH, Cho JG. Eur Heart J. 2023 Jun 2;ehad339. doi: 10.1093/eurheartj/ehad339. Online ahead of print. PMID: 37264895

[COVID-19 Vaccine and Health Care Visits for Menstrual Changes.](#)

Harris E. JAMA. 2023 Jun 6;329(21):1817. doi: 10.1001/jama.2023.8658. PMID: 37195725

[Estimating the impact of COVID-19 vaccine inequities: a modeling study.](#)

Gozzi N, Chinazzi M, Dean NE, Longini IM Jr, Halloran ME, Perra N, Vespignani A. Nat Commun. 2023 Jun 6;14(1):3272. doi: 10.1038/s41467-023-39098-w. PMID: 37277329

[Threat of resurgence or hope for global eradication of poliovirus?](#)

Kim CY, Piamonte B, Allen R, Thakur KT. Curr Opin Neurol. 2023 Jun 1;36(3):229-237. doi: 10.1097/WCO.0000000000001156. Epub 2023 Apr 18. PMID: 37078665

[Social media and COVID-19 vaccination hesitancy during pregnancy: a mixed methods analysis.](#)

Golder S, McRobbie-Johnson ACE, Klein A, Polite FG, Gonzalez Hernandez G. BJOG. 2023 Jun;130(7):750-758. doi: 10.1111/1471-0528.17481. Epub 2023 Apr 20. PMID: 37078279

[Experiences from COVID-19 vaccination in patients with epilepsy.](#)

Yang L, He J, Song Z, Zhen W, Chen R, Zhang C, Yang H, Liu D. Epilepsia Open. 2023 Jun;8(2):307-312. doi: 10.1002/epi4.12667. Epub 2023 Mar 25. PMID: 36305698

[Does covid-19 affect pregnancies?](#)

Marshall M. New Sci. 2023 Jun 3;258(3441):14-15. doi: 10.1016/S0262-4079(23)00987-9. Epub 2023 Jun 2. PMID: 37292183

[Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19.](#)

Taboe HB, Asare-Baah M, Iboi EA, Ngonghala CN. Math Biosci. 2023 Jun;360:108981. doi: 10.1016/j.mbs.2023.108981. Epub 2023 Feb 16. PMID: 36803672

[Motivators and Barriers to COVID-19 Vaccination in Young Adults Living in the USA.](#)

Lee YM, Simonovich SD, Li S, Amer L, Wagner L, Hill J, Spulark R, Aquino E. Clin Nurs Res. 2023 Jul;32(6):971-982. doi: 10.1177/10547738231177331. Epub 2023 Jun 2. PMID: 37264835

[Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.](#)

Filippini F, Giacomelli M, Bazzani C, Fredi M, Semeraro P, Tomasi C, Franceschini F, Caruso A, Cavazzana I, Giagulli C. BMC Med. 2023 Jun 14;21(1):210. doi: 10.1186/s12916-023-02868-w. PMID: 37316832

[Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.](#)

Boing AF, Boing AC, Barberia L, Borges ME, Subramanian SV. *Vaccine*. 2023 Jun 13;41(26):3937-3945. doi: 10.1016/j.vaccine.2023.05.030. Epub 2023 May 17. PMID: 37221119

[Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.](#)

Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, Ahmad S, Mohd-Zahid MH, Rahman ENSEA, Yean CY, Alias IZ, Uskoković V, Mohamud R. *J Taibah Univ Med Sci*. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17. PMID: 36570799

[Limb Lymphedema After COVID-19 Vaccine Booster: Reply.](#)

Tang CYL, Chua WM. *Clin Nucl Med*. 2023 Jun 6. doi: 10.1097/RLU.0000000000004741. Online ahead of print. PMID: 37276502

[Political network composition predicts vaccination attitudes.](#)

Facciani M, Lazić A, Viggiano G, McKay T. *Soc Sci Med*. 2023 Jul;328:116004. doi: 10.1016/j.socscimed.2023.116004. Epub 2023 Jun 2. PMID: 37295206

[COVID-19-related adrenal haemorrhage: Multicentre UK experience and systematic review of the literature.](#)

Elhassan YS, Iqbal F, Arlt W, Baldeweg SE, Levy M, Stewart PM, Wass J, Pavord S, Aled Rees D, Ronchi CL. *Clin Endocrinol (Oxf)*. 2023 Jun;98(6):766-778. doi: 10.1111/cen.14881. Epub 2023 Feb 5. PMID: 36710422

[Vaccine hesitancy in cancer patients: A rapid review.](#)

Butow P, Shaw J, Bartley N, Milch V, Sathiaraj R, Turnbull S, Der Vartanian C. *Patient Educ Couns*. 2023 Jun;111:107680. doi: 10.1016/j.pec.2023.107680. Epub 2023 Feb 24. PMID: 36842287

[Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.](#)

Zhang W, Kedzierski L, Chua BY, Mayo M, Lonzi C, Rigas V, Middleton BF, McQuilten HA, Rowntree LC, Allen LF, Purcell RA, Tan HX, Petersen J, Chaurasia P, Mordant F, Pogorelyy MV, Minervina AA, Crawford JC, Perkins GB, Zhang E, Gras S, Clemens EB, Juno JA, Audsley J, Khoury DS, Holmes NE, Thevarajan I, Subbarao K, Krammer F, Cheng AC, Davenport MP, Grubor-Bauk B, Coates PT, Christensen B, Thomas PG, Wheatley AK, Kent SJ, Rossjohn J, Chung AW, Boffa J, Miller A, Lynar S, Nelson J, Nguyen THO, Davies J, Kedzierska K. *Nat Immunol*. 2023 Jun;24(6):966-978. doi: 10.1038/s41590-023-01508-y. Epub 2023 May 29. PMID: 37248417

[Seesaw Effect Between COVID-19 and Influenza From 2020 to 2023 in World Health Organization Regions: Correlation Analysis.](#)

Wang Q, Jia M, Jiang M, Liu W, Yang J, Dai P, Sun Y, Qian J, Yang W, Feng L. *JMIR Public Health Surveill*. 2023 Jun 12;9:e44970. doi: 10.2196/44970. PMID: 37191650

[Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19.](#)

Dogan M, Yilmaz B. *Acta Pharm*. 2023 Jun 12;73(2):257-268. doi: 10.2478/acph-2023-0020. Print 2023 Jun 1. PMID: 37307370

[Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.](#)

Bozio CH, Butterfield KA, Briggs Hagen M, Grannis S, Drawz P, Hartmann E, Ong TC, Fireman B, Natarajan K, Dascomb K, Gaglani M, DeSilva MB, Yang DH, Midgley CM, Dixon BE, Naleway AL, Grisel N, Liao IC, Reese SE, Fadel WF, Irving SA, Lewis N, Arndorfer J, Murthy K, Riddles J, Valvi NR, Mamawala M, Embi PJ, Thompson MG, Stenehjem E. J Infect Dis. 2023 Jun 15;227(12):1348-1363. doi: 10.1093/infdis/jjad040. PMID: 36806690

[COVID-19 Vaccination and Community Management: A Qualitative Study.](#)

Fernández-Basanta S, López-Villasenín S, Freijomil-Vázquez C, Movilla-Fernández MJ, Coronado C. J Nurs Educ. 2023 Jun;62(6):343-350. doi: 10.3928/01484834-20230404-02. Epub 2023 Jun 1. PMID: 37279977

[Multidimensional futuristic approaches to address the pandemics beyond COVID-19.](#)

Kotwal SB, Orekondey N, Saradadevi GP, Priyadarshini N, Puppala NV, Bhushan M, Motamarry S, Kumar R, Mohannath G, Dey RJ. Heliyon. 2023 Jun;9(6):e17148. doi: 10.1016/j.heliyon.2023.e17148. Epub 2023 Jun 11. PMID: 37325452

[The effect of COVID-19 vaccine literacy on attitudes towards COVID-19 vaccine among university students.](#)

Durmus Iskender M, Eren H, Durmuş A. Health Info Libr J. 2023 Jun 1. doi: 10.1111/hir.12489. Online ahead of print. PMID: 37264270

[SARS-CoV-2 infection \(COVID-19\) and male fertility: Something we should be worried about?](#)

Zeginiadou T, Symeonidis EN, Symeonidis A, Vakalopoulos I. Urologia. 2023 Jun 5;3915603231175941. doi: 10.1177/03915603231175941. Online ahead of print. PMID: 37278004

[COVID-19 vaccine side effects on menstrual disturbances among Iranian women.](#)

Rastegar T, Feryduni L, Fakhraei M. New Microbes New Infect. 2023 Jun;53:101114. doi: 10.1016/j.nmni.2023.101114. Epub 2023 Apr 11. PMID: 37065964

[Conspiracy beliefs, COVID-19 vaccine uptake and adherence to public health interventions during the pandemic in Europe.](#)

Regazzi L, Lontano A, Cadeddu C, Di Padova P, Rosano A. Eur J Public Health. 2023 Jun 8;ckad089. doi: 10.1093/eurpub/ckad089. Online ahead of print. PMID: 37290405

[Imaging for Cardiovascular Complications of COVID-19: Cardiac Manifestations in Context.](#)

Crosier R, Kafil TS, Paterson DI. Can J Cardiol. 2023 Jun;39(6):779-792. doi: 10.1016/j.cjca.2023.01.022. Epub 2023 Jan 31. PMID: 36731604

[Supply chain planning of vaccine and pharmaceutical clusters under uncertainty: The case of COVID-19.](#)

Kochakkashani F, Kayvanfar V, Haji A. Socioecon Plann Sci. 2023 Jun;87:101602. doi: 10.1016/j.seps.2023.101602. Epub 2023 Apr 18. PMID: 37255585

[Strategies That Promote Equity in COVID-19 Vaccine Uptake for Latinx Communities: a Review.](#)

Demeke J, Ramos SR, McFadden SM, Dada D, Nguemo Djiometio J, Vlahov D, Wilton L, Wang M, Nelson LE. J Racial Ethn Health Disparities. 2023 Jun;10(3):1349-1357. doi: 10.1007/s40615-022-01320-8. Epub 2022 May 6. PMID: 35524004

[Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity.](#)

Provine NM, Klenerman P. Eur J Immunol. 2023 Jun;53(6):e2250022. doi: 10.1002/eji.202250022. Epub 2022 Nov 20. PMID: 36330560

[The lockdown and vaccination distribution in Thailand's COVID-19 epidemic: A model study.](#)

Polwiang S. Infect Dis Model. 2023 Jun;8(2):551-561. doi: 10.1016/j.idm.2023.05.002. Epub 2023 May 28. PMID: 37275749

[Cowpox to COVID: History of vaccination in the immunocompromised host.](#)

Schaenman J, Avery R. Transpl Infect Dis. 2023 Jun;25(3):e14051. doi: 10.1111/tid.14051. Epub 2023 Apr 7. PMID: 37029494

[Timing and sequence of vaccination against COVID-19 and influenza \(TACTIC\): a single-blind, placebo-controlled randomized clinical trial.](#)

Dulfer EA, Geckin B, Taks EJM, GeurtsvanKessel CH, Dijkstra H, van Emst L, van der Gaast-de Jongh CE, van Mourik D, Koopmans PC, Domínguez-Andrés J, van Crevel R, van de Maat JS, de Jonge MI, Netea MG. Lancet Reg Health Eur. 2023 Apr 12;29:100628. doi: 10.1016/j.lanepe.2023.100628. eCollection 2023 Jun. PMID: 37261212

[Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.](#)

Joudeh AI, Lutf AQ, Mahdi S, Tran G. Vaccine. 2023 Jun 13;41(26):3801-3812. doi: 10.1016/j.vaccine.2023.05.048. Epub 2023 May 22. PMID: 37244811

[Behavioral and Social Drivers of COVID-19 Vaccination in the United States, August-November 2021.](#)

Bonner KE, Vashist K, Abad NS, Kriss JL, Meng L, Lee JT, Wilhelm E, Lu PJ, Carter RJ, Boone K, Baack B, Masters NB, Weiss D, Black C, Huang Q, Vangala S, Albertin C, Szilagyi PG, Brewer NT, Singleton JA. Am J Prev Med. 2023 Jun;64(6):865-876. doi: 10.1016/j.amepre.2023.01.014. Epub 2023 Jan 25. PMID: 36775756

[COVID-19 Vaccine Acceptance, Attitude, Hesitancy, and Its Associated Factors among Wolaita Sodo University Students: A Mixed-Method Study.](#)

Lombebo AA, Wolde GD, Shomoro BT, Efa AG, Bscho MT, Suleiman EH, Temesgen AS, Arega MZ, Obsa MS. J Environ Public Health. 2023 Jun 1;2023:2082695. doi: 10.1155/2023/2082695. eCollection 2023. PMID: 37305076

[COVID-19 immunotherapy: a mathematical model.](#)

Tavares JN, Gomes E. Math Med Biol. 2023 Jun 14;40(2):199-221. doi: 10.1093/imammb/dqad003. PMID: 37038322

[Understanding Stakeholders' Perspectives to Increase COVID-19 Vaccine and Booster Uptake among Black Individuals with Rheumatic Conditions.](#)

Ezeh N, Sirek G, Ulysse SN, Williams JN, Chandler MT, Ojikutu BO, York M, Crespo-Bosque M, Jean-Jacques M, Roberson T, Mancera-Cuevas K, Milaeger H, Losina E, Dhand A, Son MB, Ramsey-Goldman R, Feldman CH. *Arthritis Care Res (Hoboken)*. 2023 Jun 13. doi: 10.1002/acr.25172. Online ahead of print. PMID: 37309724

[Does COVID-19 Vaccination Disturb Menstrual Cycling?](#)

Weinberg CR. *Am J Epidemiol*. 2023 Jun 2;192(6):849-850. doi: 10.1093/aje/kwad039. PMID: 36799647

[Mitigating COVID-19 Risk and Vaccine Hesitancy Among Underserved African American and Latinx Individuals with Mental Illness Through Mental Health Therapist-Facilitated Discussions.](#)

Venegas-Murillo AL, Bazargan M, Grace S, Cobb S, Vargas R, Givens S, Li-Sarain S, Delgado C, Villatoro J, Goodall A, Tesimale R, Ramirez S, Brown M, Uyanne J, Assari S. *J Racial Ethn Health Disparities*. 2023 Jun;10(3):1358-1370. doi: 10.1007/s40615-022-01321-7. Epub 2022 May 9. PMID: 35534682

[Health care workers' self-perceived infection risk and COVID-19 vaccine uptake: A mixed methods study.](#)

Nyamuryekung'e KK, Amour M, Mboya I, Ndumwa H, Kengia J, Njiro BJ, Mhamilawa L, Shayo E, Ngalesoni F, Kapologwe N, Kalolo A, Metta E, Msuya S. *PLOS Glob Public Health*. 2023 Jun 7;3(6):e0001223. doi: 10.1371/journal.pgph.0001223. eCollection 2023. PMID: 37285332

[Attitudes towards COVID-19 vaccination and intention to get vaccinated in Western Balkans: cross-sectional survey.](#)

Jeremic Stojkovic V, Cvjetkovic S, Jankovic J, Mandic-Rajcevic S, Matovic Miljanovic S, Stevanovic A, Jovic Vranes A, Stamenkovic Z. *Eur J Public Health*. 2023 Jun 1;33(3):496-501. doi: 10.1093/eurpub/ckad066. PMID: 37119531

[Vaccine Attitudes Mediate Relationships Between Caregiver Political Ideology and Likelihood of Child Vaccination for COVID-19.](#)

Durkin LK, Flynn EM, Johnson ML, Davies WH, Greenley RN. *Matern Child Health J*. 2023 Jun;27(6):984-990. doi: 10.1007/s10995-023-03642-3. Epub 2023 Mar 30. PMID: 36995648

[Increasing the COVID-19 immunization rate through allergy testing.](#)

Bent RK, Weinbrenner J, Faihs V, Steffens S, Nau T, Vitus M, Mathes S, Darsow U, Biedermann T, Brockow K. *J Eur Acad Dermatol Venereol*. 2023 Jun;37(6):1228-1235. doi: 10.1111/jdv.18979. Epub 2023 Mar 4. PMID: 36808753

[Systemic lupus erythematosus myocarditis and COVID-19 vaccination: Comment.](#)

Kleebayoon A, Wiwanitkit V. *Reumatol Clin (Engl Ed)*. 2023 Jun-Jul;19(6):349. doi: 10.1016/j.reumae.2023.02.008. Epub 2023 May 24. PMID: 37258399

[Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.](#)

Kana BD, Arbuthnot P, Botwe BK, Choonara YE, Hassan F, Louzir H, Matsoso P, Moore PL, Muhairwe A, Naidoo K, Ndomondo-Sigonda M, Madhi SA. *Lancet Infect Dis*. 2023 Jun 5:S1473-3099(22)00878-7. doi: 10.1016/S1473-3099(22)00878-7. Online ahead of print. PMID: 37290473

[In vitro high-content tissue models to address precision medicine challenges.](#)

Afewerki S, Stocco TD, Rosa da Silva AD, Aguiar Furtado AS, Fernandes de Sousa G, Ruiz-Esparza GU, Webster TJ, Marciano FR, Strømme M, Zhang YS, Lobo AO. Mol Aspects Med. 2023 Jun;91:101108. doi: 10.1016/j.mam.2022.101108. Epub 2022 Aug 17. PMID: 35987701

[A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.](#)

Laranjeira P, Rodrigues T, Silva A, Barbosa P, Reis T, Lopes C, Pinho A, Silva S, Silva I, Carvalho A, Pacheco V, Rodrigues F, Araújo L, Antunes I, Paiva A. Clin Exp Med. 2023 Jun;23(2):529-537. doi: 10.1007/s10238-022-00801-8. Epub 2022 Feb 21. PMID: 35190936

[COVID-19, post-acute COVID-19 syndrome \(PACS, "long COVID"\) and post-COVID-19 vaccination syndrome \(PCVS, "post-COVIDvac-syndrome"\): Similarities and differences.](#)

Scholkmann F, May CA. Pathol Res Pract. 2023 Jun;246:154497. doi: 10.1016/j.prp.2023.154497. Epub 2023 May 3. PMID: 37192595

[Resident Factors Associated With Breakthrough SARS-CoV-2 Infections.](#)

Montoya A, Wen K, Travers JL, Rivera-Hernandez M, White E, Mor V, Berry SD. J Am Med Dir Assoc. 2023 Jun;24(6):901-905. doi: 10.1016/j.jamda.2023.02.102. Epub 2023 Mar 2. PMID: 36965506

[Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.](#)

Noh Y, Ko HY, Kim JH, Yoon D, Choe YJ, Choe SA, Jung J, Shin JY. Epidemiol Health. 2023 Jun 7:e2023054. doi: 10.4178/epih.e2023054. Online ahead of print. PMID: 37309115

[Impact of the COVID-19 pandemic on uveitis patient care.](#)

Vu AF, Kodati S, Lin P, Bodaghi B, Emami-Naeini P; COVID-19 Practice Patterns Study Group. Br J Ophthalmol. 2023 Jun;107(6):790-794. doi: 10.1136/bjophthalmol-2021-320368. Epub 2022 Jan 24. PMID: 35074784

[Biological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients.](#)

Hazan G, Duek OA, Alapi H, Mok H, Ganninger A, Ostendorf E, Gierasch C, Chodick G, Greenberg D, Haspel JA. J Clin Invest. 2023 Jun 1;133(11):e167339. doi: 10.1172/JCI167339. PMID: 37053011

[Redirected vaccine imprinting by co-administration of COVID-19 and influenza vaccines.](#)

Boyton RJ, Altmann DM. Lancet Reg Health Eur. 2023 May 10;29:100644. doi: 10.1016/j.lanepe.2023.100644. eCollection 2023 Jun. PMID: 37261213

[COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.](#)

Jiang M, Väisänen E, Kolehmainen P, Huttunen M, Ylä-Herttuala S, Meri S, Österlund P, Julkunen I. Vaccine. 2023 Jun 13;41(26):3813-3823. doi: 10.1016/j.vaccine.2023.04.049. Epub 2023 Apr 25. PMID: 37142461

[Imagine distant-future outcome: Mental simulation of COVID-19 vaccinations.](#)

Motoki K, Saito T, Takano Y. J Exp Psychol Appl. 2023 Jun;29(2):207-220. doi: 10.1037/xap0000472. Epub 2023 Apr 13. PMID: 37053430

[Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency.](#)

Durand J, Dogné JM, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, Zaccaria C, Genov G. Clin Pharmacol Ther. 2023 Jun;113(6):1223-1234. doi: 10.1002/cpt.2828. Epub 2023 Feb 6. PMID: 36524423

[Adhesive Capsulitis After COVID-19 Vaccination: A Case Series.](#)

Ghosh S, Pandey SK, Biswas A, Pandey J. Am J Phys Med Rehabil. 2023 Jun 1;102(6):e79-e82. doi: 10.1097/PHM.0000000000002194. Epub 2023 Jan 23. PMID: 36722847

[Interaction of Biochemical Processes between Chronic Obstructive Pulmonary Disease \(COPD\), Pulmonary Arterial Hypertension \(PAH\), and Coronavirus Disease 2019 \(COVID-19\).](#)

Tian Z, Cen L. Pol J Microbiol. 2023 Jun 14;72(2):143-154. doi: 10.33073/pjm-2023-015. eCollection 2023 Jun 1. PMID: 37216361

[Attitudes and beliefs towards COVID-19 and COVID-19 vaccination among rheumatology patients in a Los Angeles County safety net clinic.](#)

Ward NKZ, Pal S, Ruddy K, Savvas S. BMC Rheumatol. 2023 Jun 1;7(1):13. doi: 10.1186/s41927-023-00338-7. PMID: 37259135

[Respiratory syncytial virus infection in the modern era.](#)

Ludlow M. Curr Opin Infect Dis. 2023 Jun 1;36(3):155-163. doi: 10.1097/QCO.0000000000000917. Epub 2023 Mar 20. PMID: 36939556

[Delirium after COVID-19 vaccination in older adults.](#)

Armstrong K. Nursing. 2023 Jun 1;53(6):42-45. doi: 10.1097/01.NURSE.0000927432.51378.e7. PMID: 37212818

[Inequalities in COVID-19 vaccination coverage in Peru: An ecological study.](#)

Al-Kassab-Córdova A, Mendez-Guerra C, Silva-Perez C, Herrera-Añazco P, Benites-Zapata VA. Public Health Pract (Oxf). 2023 Jun;5:100384. doi: 10.1016/j.puhip.2023.100384. Epub 2023 Apr 6. PMID: 37038538

[COVID-19 vaccination willingness in peri-urban Tanzanian communities: Towards contextualising and moving beyond the individual perspective.](#)

Van Espen M, Dewachter S, Holvoet N. SSM Popul Health. 2023 Jun;22:101381. doi: 10.1016/j.ssmph.2023.101381. Epub 2023 Mar 15. PMID: 36936725

[Coronavirus disease 2019 vaccine in pediatric post-kidney transplantation.](#)

Ajlan AA, Aleid H, Ali T, DeVol E, Marquez KAH, Aldhaferi R, Karar EM, Mohammed AEI, Tiba M, Fajji L, Aldakhil H, Al-Awwami M, Almslam MS, Assiri A, Algoufi T, Broering DC. Clin Transplant. 2023 Jun;37(6):e14983. doi: 10.1111/ctr.14983. Epub 2023 Apr 7. PMID: 37026809

[Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity.](#)

Tan SY, Foo C, Verma M, Hanvoravongchai P, Cheh PLJ, Pholpark A, Marthias T, Hafidz F, Prawidya Putri L, Mahendradhata Y, Giang KB, Nachuk S, Wang H, Lim J, Legido-Quigley H. Soc Sci Med. 2023 Jul;328:116007. doi: 10.1016/j.socscimed.2023.116007. Epub 2023 Jun 2. PMID: 37279639

[Fast-tracking development and regulatory approval of COVID-19 vaccines in the EU: A review of ethical implications.](#)

Beretta G, Marelli L. *Bioethics*. 2023 Jun;37(5):498-507. doi: 10.1111/bioe.13151. Epub 2023 Mar 11. PMID: 36905651

[Evaluation of the Community Health Worker Model for COVID-19 Response and Recovery.](#)

Nawaz S, Moon KJ, Vazquez R, Navarrete JR, Trinh A, Escobedo L, Montiel GI. *J Community Health*. 2023 Jun;48(3):430-445. doi: 10.1007/s10900-022-01183-4. Epub 2023 Jan 6. PMID: 36604393

[Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager.](#)

Pucchio A, Akiva MH, Evangelidou H, Papenburg J, Salvadori MI. *Pediatr Nephrol*. 2023 Jun;38(6):1979-1983. doi: 10.1007/s00467-022-05808-7. Epub 2022 Nov 21. PMID: 36409362

[Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.](#)

Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. *Open Forum Infect Dis*. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun. PMID: 37274183

[Sensorineural Hearing Loss Among COVID-19 Patients and BNT162b2 Vaccine Recipients: Comment.](#)

Mungmunpuntipatip R, Wiwanitkit V. *Otol Neurotol*. 2023 Jun 1;44(5):e358. doi: 10.1097/MAO.0000000000003871. Epub 2023 Apr 6. PMID: 37026804

[Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination.](#)

Katoto PDMC, Byamungu LN, Brand AS, Tamuzi JL, Kakubu MAM, Wiysonge CS, Gray G. *NPJ Vaccines*. 2023 Jun 9;8(1):89. doi: 10.1038/s41541-023-00681-3. PMID: 37296167

[Cutaneous Adverse Events After COVID-19 Vaccination.](#)

Weschawalit S, Pongcharoen P, Suthiwartnarueput W, Srivilaithon W, Daorattanachai K, Jongrak P, Chakkavittumrong P. *Clin Cosmet Investig Dermatol*. 2023 Jun 8;16:1473-1484. doi: 10.2147/CCID.S410690. eCollection 2023. PMID: 37313511

[Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia.](#)

Cheung ECL, Leung MTY, Chen K, Wan EYF, Li X, Lai FTT, Wong CKH, Qin XS, Chan EW, Lau KK, Luo H, Lin CC, Wong ICK, Chui CSL. *J Am Med Dir Assoc*. 2023 Jun;24(6):892-900.e12. doi: 10.1016/j.jamda.2023.04.003. Epub 2023 Apr 21. PMID: 37156470

[Safety and incidence of COVID-19 following ChAdOx1\(AZD1222\) COVID-19 vaccination in Botswana.](#)

Shava E, Izu A, Gaolathe T, Walker A, Carty L, Georgiou P, Kuate L, Kgathi C, Sekoto T, Seonyatseng N, Mogashoa T, Maphorisa C, Mohammed T, Ntalabgwe T, Frank TT, Matlhaku B, Diphoko A, Phindela T, Kaunda A, Kgari P, Kanyakula T, Palalani G, Phakedi I; (Botswana AZD1222 study team); Taylor S, Mmalane M, Moyo S, Makhema J. *J Infect*. 2023 Jun;86(6):603-606. doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1. PMID: 36863535

[Vertigo and Dizziness After Coronavirus Disease-2019 Vaccination: A Nationwide Analysis.](#)

Kim SH, Yon DK, Choi YS, Lee J, Park KH, Lee YJ, Park DC, Kim SS, Rim HS, Yeo SG. *J Int Adv Otol*. 2023 Jun;19(3):228-233. doi: 10.5152/iao.2023.22937. PMID: 37272641

[Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.](#)

Feddema JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM. *Vaccine*. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.05.027. Online ahead of print. PMID: 37277250

[Projection of healthcare demand in Germany and Switzerland urged by Omicron wave \(January-March 2022\).](#)

Gorji H, Stauffer N, Lunati I, Caduff A, Bühler M, Engel D, Chung HR, Loukas O, Feig S, Renz H. *Epidemics*. 2023 Jun;43:100680. doi: 10.1016/j.epidem.2023.100680. Epub 2023 Mar 14. PMID: 36963246

[Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives.](#)

Chen C, He W, Wang DW. *Herz*. 2023 Jun;48(3):173-179. doi: 10.1007/s00059-023-05176-4. Epub 2023 Apr 27. PMID: 37106075

[The effectiveness of nonfinancial interventions and monetary incentives on COVID-19 vaccination: A meta-analysis.](#)

Huang Y, Huang X, Yu R. *Health Psychol*. 2023 Jun;42(6):411-424. doi: 10.1037/hea0001288. Epub 2023 May 1. PMID: 37126030

[Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.](#)

Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. *Clin Lymphoma Myeloma Leuk*. 2023 Jun;23(6):456-462. doi: 10.1016/j.clml.2023.03.002. Epub 2023 Mar 7. PMID: 37003846

[Power, place, and access: Why history is at the center of black D.C. residents of wards 7 and 8 decisions to receive the COVID-19 vaccine.](#)

Cho A, Mendenhall E, Griffith DM. *SSM Qual Res Health*. 2023 Jun;3:100270. doi: 10.1016/j.ssmqr.2023.100270. Epub 2023 Apr 13. PMID: 37073370

[Cardiac inflammation associated with COVID-19 mRNA vaccination in patients with and without previous myocarditis.](#)

Kaufmann CC, Villatore A, Heugl M, Kvakani H, Zweiker D, Sala S, Mazzone P, Huber K, Peretto G. *Minerva Cardiol Angiol*. 2023 Jun;71(3):242-248. doi: 10.23736/S2724-5683.22.06204-4. Epub 2023 Mar 10. PMID: 36897270

[Breastfeeding provides a protective hug and the benefits have outweighed the risks during the COVID-19 pandemic.](#)

Briana DD, Malamitsi-Puchner A. *Acta Paediatr*. 2023 Jun;112(6):1177-1181. doi: 10.1111/apa.16769. Epub 2023 Mar 29. PMID: 36945791

[BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum.](#)

Seneviratne CJ, Balan P, de Alwis R, Udawatte NS, Herath T, Toh JZN, Tin GB, Ooi EE, Hong JLG, Ying JSX. *Int Dent J.* 2023 Jun;73(3):435-442. doi: 10.1016/j.identj.2022.09.005. Epub 2022 Nov 17. PMID: 36402577

[Susac syndrome following COVID-19 vaccination: a case-based review.](#)

Fisher L, David P, Sobeh T, Liberman RB, Amital H. *Clin Rheumatol.* 2023 Jun;42(6):1713-1717. doi: 10.1007/s10067-023-06564-1. Epub 2023 Mar 6. PMID: 36877303

[Vaccine attributes and vaccine uptake in Hungary: evidence from a conjoint experiment.](#)

Thompson J, Stöckli S, Spälti AK, Phillips J, Stoeckel F, Barnfield M, Lyons B, Méröla V, Szewach P, Reifler J. *Eur J Public Health.* 2023 Jun 1;33(3):476-481. doi: 10.1093/eurpub/ckad043. PMID: 37004246

[Analysis of COVID-19 vaccine uptake among people with underlying chronic conditions in 2022: A cross-sectional study.](#)

Bulusu A, Segarra C, Khayat L. *SSM Popul Health.* 2023 Jun;22:101422. doi: 10.1016/j.ssmph.2023.101422. Epub 2023 May 2. PMID: 37151914

[Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection.](#)

Zhang A, Stacey HD, D'Agostino MR, Tugg Y, Marzok A, Miller MS. *Nat Rev Immunol.* 2023 Jun;23(6):381-396. doi: 10.1038/s41577-022-00813-1. Epub 2022 Dec 19. PMID: 36536068

[COVID-19 infection in people living with HIV.](#)

Brolly J, Chadwick DR. *Br Med Bull.* 2023 Jun 13;ldac031. doi: 10.1093/bmb/ldac031. Online ahead of print. PMID: 37312594

[COVID-19 infection- and vaccination-related exacerbation of Darier's disease in a single patient.](#)

Fukaura R, Takeichi T, Ebata A, Muro Y, Akiyama M. *J Dermatol.* 2023 Jun;50(6):833-836. doi: 10.1111/1346-8138.16725. Epub 2023 Jan 18. PMID: 36651040

[Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities.](#)

Fan S, Wang H, Wu D, Liu L. *Acta Pharm.* 2023 Jun 12;73(2):157-173. doi: 10.2478/acph-2023-0014. Print 2023 Jun 1. PMID: 37307372

[Adolescents Who Have Undergone Human Papillomavirus Vaccination Are More Likely to Get a COVID-19 Vaccine.](#)

Coronado GD, Petrik AF, Slaughter M, Kepka D, Naleway AL. *J Adolesc Health.* 2023 Jun;72(6):985-988. doi: 10.1016/j.jadohealth.2022.12.022. Epub 2023 Feb 11. PMID: 36781325

[Association between distance to community health care facilities and COVID-19-related mortality across U.S. counties in the COVID-19-vaccine era.](#)

Huang W, Hernandez I, Tang S, Dickson S, Berenbrok LA, Guo J. *BMC Res Notes.* 2023 Jun 5;16(1):96. doi: 10.1186/s13104-023-06366-3. PMID: 37277859

[BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England.](#)

Andrews N, Stowe J, Miller E, Ramsay M. *JAMA.* 2023 Jun 15. doi: 10.1001/jama.2023.10123. Online ahead of print. PMID: 37318811

[\[Headache associated with COVID-19 vaccination: how to classify?\].](#)

Straube A, Ruscheweyh R, Klonowski T. Schmerz. 2023 Jun;37(3):185-194. doi: 10.1007/s00482-022-00687-1. Epub 2023 Jan 16. PMID: 36645522

[Safety of mRNA COVID-19 vaccinations in patients with allergic diseases.](#)

Rosada T, Napiórkowska-Baran K, Gała Ł, Alska E, Paulina K, Czarnowska M, Bartuzi Z. Public Health Pract (Oxf). 2023 Jun;5:100354. doi: 10.1016/j.puhip.2022.100354. Epub 2022 Dec 24. PMID: 36590876

[Necrotizing pancreatitis, microangiopathic hemolytic anemia and thrombocytopenia following the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine.](#)

Stöllberger C, Kastrati K, Dejaco C, Scharitzer M, Finsterer J, Bugingo P, Melichart-Kotik M, Wilfing A. Wien Klin Wochenschr. 2023 Jun 6:1-5. doi: 10.1007/s00508-023-02225-0. Online ahead of print. PMID: 37280395

[Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.](#)

Alsuhebany N, Alowais SA, Aldairem A, Almohareb SN, Bin Saleh K, Kahtani KM, Alnashwan LI, Alay SM, Alamri MG, Alhathlol GK, Asiri I. Vaccine. 2023 Jun 1;41(24):3611-3616. doi: 10.1016/j.vaccine.2023.04.057. Epub 2023 Apr 26. PMID: 37164821

[A rapid increase in coverage of COVID-19 vaccination, Central African Republic.](#)

Amani A, Atuhebwe P, Mboussou FF, Ngoy N, M'boufoungou NE, Osei-Sarpong F, Traore C, Mihigo R, Chaiban T. Bull World Health Organ. 2023 Jun 1;101(6):431-436. doi: 10.2471/BLT.22.289155. Epub 2023 Mar 31. PMID: 37265680

[Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.](#)

Bai X, Schountz T, Buckle AM, Talbert JL, Sandhaus RA, Chan ED. Biochem Soc Trans. 2023 Jun 9:BST20230078. doi: 10.1042/BST20230078. Online ahead of print. PMID: 37294003

[The effect of mixed vaccination rollout strategy: A modelling study.](#)

Stollenwerk N, Estadilla CDS, Mar J, Bidaurrazaga Van-Dierdonck J, Ibarondo O, Blasco-Aguado R, Aguiar M. Infect Dis Model. 2023 Jun;8(2):318-340. doi: 10.1016/j.idm.2023.03.002. Epub 2023 Mar 10. PMID: 36945695

[A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.](#)

Singh RS, Singh A, Masih GD, Batra G, Sharma AR, Joshi R, Prakash A, Suroy B, Sarma P, Prajapat M, Kaur H, Bhattacharyya A, Upadhyay S, Medhi B. Heliyon. 2023 Jun;9(6):e16813. doi: 10.1016/j.heliyon.2023.e16813. Epub 2023 Jun 7. PMID: 37303517

[COVID-19 vaccine safety profile in Republic of Korea, February 26, 2021 through April 30, 2022.](#)

Lee YK, Kwon Y, Lim D, Seo SY, Kim EK, Kim SY, Heo Y, Cho E. Clin Exp Pediatr. 2023 Jun 13. doi: 10.3345/cep.2022.00815. Online ahead of print. PMID: 37309116

[COVID-19 vaccine effectiveness in people with substance use disorder.](#)

Huang Y. Lancet Psychiatry. 2023 Jun;10(6):372-373. doi: 10.1016/S2215-0366(23)00149-9. Epub 2023 May 1. PMID: 37141908

[Experiences, coping strategies and perspectives of people in Malaysia during the COVID-19 pandemic.](#)

Cheah PK, Jalloh MB, Cheah PK, Ongkili D, Schneiders ML, Osterrieder A, Peerawaranun P, Waithira N, Davies A, Mukaka M, Cheah PY. BMC Public Health. 2023 Jun 6;23(1):1085. doi: 10.1186/s12889-023-15892-5. PMID: 37280573

[Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.](#)

Singh RB, Parmar UPS, Ichhpujani P, Jeng BH, Jhanji V. Cornea. 2023 Jun 1;42(6):731-738. doi: 10.1097/ICO.0000000000003246. Epub 2023 Jan 25. PMID: 36706232

[The role of trained immunity in COVID-19: Lessons for the next pandemic.](#)

Netea MG, Ziegler A, Benn CS, Giamarellos-Bourboulis EJ, Joosten LAB, Arditi M, Chumakov K, van Crevel R, Gallo R, Aaby P, van der Meer JWM. Cell Host Microbe. 2023 Jun 14;31(6):890-901. doi: 10.1016/j.chom.2023.05.004. PMID: 37321172

[CATCH-UP vaccines: protocol for a randomized controlled trial using the multiphase optimization strategy \(MOST\) framework to evaluate education interventions to increase COVID-19 vaccine uptake in Oklahoma.](#)

Janitz AE, Neil JM, Bray LA, Jervis LL, Ross L, Campbell JE, Doescher MP, Spicer PG, Williams ML, Lopez AK, Uribe-Frias CA, Chen S, James JA, VanWagoner TM. BMC Public Health. 2023 Jun 14;23(1):1146. doi: 10.1186/s12889-023-16077-w. PMID: 37316843

[Determination of factors influencing young adults' intention to have COVID-19 vaccine in the Philippines: An integration of Health Belief Model and the Theory of Planned Behavior.](#)

Ong AKS, Prasetyo YT, Lagura FC, Ramos RN, Salazar JML, Sigua KM, Villas JA, Nadlifatin R, Persada SF. Public Health Pract (Oxf). 2023 Jun;5:100359. doi: 10.1016/j.puhip.2023.100359. Epub 2023 Feb 10. PMID: 36818574

[COVID-19 vaccine hesitancy among women planning for pregnancy, pregnant or breastfeeding mothers in Jordan: A cross-sectional study.](#)

Masa'deh R, Momani A, Rayan A, Hamaideh SH, Masadeh OM, Al-Yateem N. PLoS One. 2023 Jun 1;18(6):e0286289. doi: 10.1371/journal.pone.0286289. eCollection 2023. PMID: 37262063

[Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2.](#)

Lin G, Yan H, Sun J, Zhao J, Zhang Y. Mol Ther Nucleic Acids. 2023 Jun 13;32:650-666. doi: 10.1016/j.omtn.2023.04.021. Epub 2023 Apr 23. PMID: 37151990

[Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by COVID-19 mRNA Vaccine \(Pfizer-BioNTech, BNT162b2\): A Case Report and Literature Review.](#)

Kim JH, Chae HB, Woo S, Song MS, Kim HJ, Woo CG. Int J Surg Pathol. 2023 Jun 4:10668969231177877. doi: 10.1177/10668969231177877. Online ahead of print. PMID: 37272061

[Graves' disease after exposure to the SARS-CoV-2 vaccine: a case report and review of the literature.](#)

Takedani K, Notsu M, Ishiai N, Asami Y, Uchida K, Kanasaki K. BMC Endocr Disord. 2023 Jun 15;23(1):132. doi: 10.1186/s12902-023-01387-2. PMID: 37316819

[Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.](#)

Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H, Kobayashi M, Mori A, Morioka M, Kondo T. *Ann Hematol.* 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12. PMID: 37041299

[COVID-19 vaccination status and related process of care outcomes among U.S. adults with active epilepsy-National Health Interview Survey, United States, 2021.](#)

Kobau R, Luncheon C, Pastula DM, Greenlund KJ. *Epilepsy Behav.* 2023 Jun;143:109223. doi: 10.1016/j.yebeh.2023.109223. Epub 2023 Apr 14. PMID: 37119577

[Empowering Youth Vaccine Ambassadors to Promote COVID-19 Vaccination in Local Communities: A 7-Step Approach.](#)

Minkah PA, Borg A, Ryan GW, Goulding M, Perrone D, Castiel M, Rosal MC, Lemon SC. *Health Promot Pract.* 2023 Jun 11:15248399231178542. doi: 10.1177/15248399231178542. Online ahead of print. PMID: 37303187

[Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.](#)

Geraci G, Bernat J, Rodier C, Acha V, Acquah J, Beakes-Read G. *Ther Innov Regul Sci.* 2023 Jun 2:1-12. doi: 10.1007/s43441-023-00536-y. Online ahead of print. PMID: 37266868

[Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.](#)

Wang W, Goguet E, Paz Padilla S, Vassell R, Pollett S, Mitre E, Weiss CD. *J Infect Dis.* 2023 Jun 6:jiad111. doi: 10.1093/infdis/jiad111. Online ahead of print. PMID: 37279924

[Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System.](#)

Jaffry M, Aftab OM, Mostafa FB, Faiz I, Jaffry K, Mandava K, Rosario S, Jedidi K, Khan H, Souayah N. *J Neuroophthalmol.* 2023 Jun 14. doi: 10.1097/WNO.0000000000001900. Online ahead of print. PMID: 37314860

[Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.](#)

Xue Y, Mei H, Chen Y, Griffin JD, Liu Q, Weisberg E, Yang J. *MedComm (2020).* 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun. PMID: 37193304

[A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors.](#)

Yoon D, Jeon HL, Noh Y, Choe YJ, Choe SA, Jung J, Shin JY. *J Korean Med Sci.* 2023 Jun 5;38(22):e170. doi: 10.3346/jkms.2023.38.e170. PMID: 37272559

[Investigating preferences of the covid-19 vaccine among individuals in Iran: Discrete choice experiment analysis.](#)

Parvizi S, Mehrara M, Taiebnia A. *Health Sci Rep.* 2023 Jun 12;6(6):e1332. doi: 10.1002/hsr2.1332. eCollection 2023 Jun. PMID: 37313535

[Examining the Relationship Between Rurality, Risk Perception, and COVID-19 Vaccine Willingness Among Rural Latinos in Arizona and California.](#)

Straus A, Sharma N, Mattie H, Pine KH, Lopez G. J Community Health. 2023 Jun 15. doi: 10.1007/s10900-023-01217-5. Online ahead of print. PMID: 37316613

[Self-reported symptoms after COVID-19 vaccination. Distinct sex, age, and geographical outcomes in Lebanese and Italian cohorts.](#)

Khalil M, Bonfrate L, Di Ciuala A, Portincasa P; LEITvax Group[^]. Intern Emerg Med. 2023 Jun 15. doi: 10.1007/s11739-023-03321-9. Online ahead of print. PMID: 37322183

[Forecasting recovery from COVID-19 using financial data: An application to Vietnam.](#)

Lastunen J, Richiardi M. World Dev Perspect. 2023 Jun;30:100503. doi: 10.1016/j.wdp.2023.100503. Epub 2023 Mar 22. PMID: 36987404

[Is the COVID-19 bad news game good news? Testing whether creating and disseminating fake news about vaccines in a computer game reduces people's belief in anti-vaccine arguments.](#)

Rędzio AM, Izydorczak K, Muniak P, Kulesza W, Doliński D. Acta Psychol (Amst). 2023 Jun;236:103930. doi: 10.1016/j.actpsy.2023.103930. Epub 2023 May 1. PMID: 37146384

[Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2.](#)

Wu J, Shi X, Tao B, Zhan Y, Lu X, Wang J. Int J Infect Dis. 2023 Jun;131:26-31. doi: 10.1016/j.ijid.2023.03.028. Epub 2023 Mar 21. PMID: 36948448

[Do different platforms of coronavirus vaccines have different impacts on psoriasis flares?](#)

Chularojanamontri L, Likittanasombat S, Chaiyabutr C, Silpa-Archa N, Wongpraparut C. Exp Dermatol. 2023 Jun;32(6):922-929. doi: 10.1111/exd.14793. Epub 2023 Mar 20. PMID: 36940925

[Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.](#)

Ahmadizar F, Luxi N, Raethke M, Schmikli S, Riefolo F, Saraswati PW, Bucsa C, Osman A, Liddiard M, Maques FB, Petrelli G, Sonderlichová S, Thurin NH, Villalobos F, Trifirò G, Sturkenboom M; ilmiovaccinoCOVID19 collaborating group. Drug Saf. 2023 Jun;46(6):575-585. doi: 10.1007/s40264-023-01304-5. Epub 2023 Apr 27. PMID: 37103643

[The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.](#)

Borralleras C, Castrodeza Sanz J, Arrazola P, Cámara Hijón C, Eiros JM, Castrodeza Sanz J, Arrazola P, Cámara Hijón C, Fernández-Prada M, Gil de Miguel A, Mirada Masip G, Moraga-Llop F, Ocaña Rodríguez D, Puig-Barberà J, Vázquez J, Vergara-Alert J, de Cambra S. Rev Esp Quimioter. 2023 Jun 12:cambra12jun2023. doi: 10.37201/req/046.2023. Online ahead of print. PMID: 37303137

[Endemic, epidemic and pandemic infections: the roles of natural and acquired herd immunity.](#)

Stevens DL, Bryant AE. Curr Opin Infect Dis. 2023 Jun 1;36(3):171-176. doi: 10.1097/QCO.0000000000000916. Epub 2023 Mar 20. PMID: 36939580

[Healthcare workers' \(HCWs\) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review.](#)

Li M, Luo Y, Watson R, Zheng Y, Ren J, Tang J, Chen Y. Postgrad Med J. 2023 Jun 15;99(1172):520-528. doi: 10.1136/postgradmedj-2021-140195. PMID: 37319159

[SARS-CoV-2 infection in technology-dependent children: a multicenter case series.](#)

Robinson J, Dewan T, Morris SK, Bitnun A, Gill P, Tal TE, Laxer RM, Yeh EA, Yea C, Ulloa-Gutierrez R, Brenes-Chacon H, Yock-Corrales A, Ivankovich-Escoto G, Soriano-Fallas A, Mezerville MH, Papenburg J, Lefebvre MA, Nateghian A, Aski BH, Manafi A, Dwilow R, Bullard J, Cooke S, Restivo L, Lopez A, Sadarangani M, Roberts A, Le Saux N, Bowes J, Purewal R, Lautermilch J, Wong JK, Piche D, Top KA, Foo C, Panetta L, Merckx J, Barton M. *Infection*. 2023 Jun;51(3):737-741. doi: 10.1007/s15010-022-01910-y. Epub 2022 Aug 29. PMID: 36038707

[The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines.](#)

Almalki OS, Santali EY, Alhothali AA, Ewis AA, Shady A, Fathelrahman AI, Abdelwahab SF. *BMC Infect Dis*. 2023 Jun 6;23(1):378. doi: 10.1186/s12879-023-08363-0. PMID: 37280542

[Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.](#)

Wahid M, Jawed A, Mandal RK, Areeshi MY, El-Shall NA, Mohapatra RK, Tuli HS, Dhama K, Pellicano R, Fagoonee S, Haque S. *Minerva Med*. 2023 Jun 9. doi: 10.23736/S0026-4806.23.08509-9. Online ahead of print. PMID: 37293890

[Keeping you posted: analysis of fertility-related social media posts after introduction of the COVID-19 vaccine.](#)

Pecoriello J, Yoder N, Smith MB, Blakemore JK. *Eur J Contracept Reprod Health Care*. 2023 Jun;28(3):168-172. doi: 10.1080/13625187.2023.2189501. Epub 2023 Mar 30. PMID: 36995737

[The impacts of the COVID-19 pandemic on patients with viral hepatitis B infection: follow-up, compliance with antiviral treatment, and vaccine preferences.](#)

Ozdemir B, Altunsoy A, Akinci E, Guner R. *Eur Rev Med Pharmacol Sci*. 2023 Jun;27(11):5310-5317. doi: 10.26355/eurrev_202306_32650. PMID: 37318505

[Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.](#)

Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, Kothari K, Grummich K, Braun C, Kapp P, Labonté V, Wichmann O, Meerpohl JJ, Harder T. *Lancet Child Adolesc Health*. 2023 Jun;7(6):379-391. doi: 10.1016/S2352-4642(23)00078-0. Epub 2023 Apr 18. PMID: 37084750

[Immunogenicity and safety of a single booster dose of NVX-CoV2373 \(TAK-019\) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.](#)

Kuriyama K, Murakami K, Masuda T, Sugiura K, Sakui S, Schuring RP, Mori M. *Vaccine*. 2023 Jun 7;41(25):3763-3771. doi: 10.1016/j.vaccine.2023.05.001. Epub 2023 May 8. PMID: 37198021

[Dementia, infections and vaccines: 30 years of controversy.](#)

Ecarnot F, Boccardi V, Calcagno A, Franceschi C, Fülöp T, Itzhaki RF, Michel JP, Panza F, Rainero I, Solfrizzi V, Ticinesi A, Veronese N, Maggi S. *Aging Clin Exp Res*. 2023 Jun;35(6):1145-1160. doi: 10.1007/s40520-023-02409-8. Epub 2023 May 9. PMID: 37160649

[Dataset on safety and protective efficacy studies of COVID-19 vaccine candidates based on structurally modified plant virus in female hamsters.](#)

Kovalenko AO, Ryabchevskaya EM, Evtushenko EA, Kondakova OA, Ivanov PA, Arkhipenko MV, Nikitin NA, Karpova OV. Data Brief. 2023 Jun;48:109158. doi: 10.1016/j.dib.2023.109158. Epub 2023 Apr 19. PMID: 37095758

[Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.](#)

Stowe J, Miller E, Andrews N, Whitaker HJ. PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. Online ahead of print. PMID: 37285378

[Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years - United States, June 17, 2022-May 7, 2023.](#)

Hause AM, Marquez P, Zhang B, Moro PL, Myers TR, Bradley C, Bazel S, Panchanathan SS, Shimabukuro TT, Shay DK. MMWR Morb Mortal Wkly Rep. 2023 Jun 9;72(23):621-626. doi: 10.15585/mmwr.mm7223a2. PMID: 37289661

[Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.](#)

Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, Johansen IS, Omland LH, Wiese L, Helleberg M, Storgaard M, Dalager-Pedersen M, Rasmussen TA, Benfield T, Petersen TS, Andersen ÅB, Gram MA, Stegger M, Edslev SM, Obel N. Br J Clin Pharmacol. 2023 Jun;89(6):1820-1833. doi: 10.1111/bcp.15644. Epub 2023 Jan 13. PMID: 36519217

[COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs.](#)

Langgartner D, Winkler R, Brunner-Weisser J, Rohleder N, Jarczok MN, Gündel H, Weimer K, Reber SO. Sci Rep. 2023 Jun 12;13(1):9496. doi: 10.1038/s41598-023-35731-2. PMID: 37308487

[Why should I vaccinate? The role of mindfulness and health-protective behaviours during the COVID-19 pandemic.](#)

Rufai OH, Chu J, Sayibu M, Shahani R, Amosun TS, Lugu BK, Gonlepa MK, Cherisol MP. Health Policy Technol. 2023 Jun;12(2):100749. doi: 10.1016/j.hlpt.2023.100749. Epub 2023 Apr 23. PMID: 37287500

[COVID-19 vaccination rates among adolescents \(12-17 years\) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.](#)

Hussaini L, Labberton AS, Winje BA, Kraft KB, Kjøllesdal MKR, Gleditsch RN, Godøy AA. Vaccine. 2023 Jun 1;41(24):3673-3680. doi: 10.1016/j.vaccine.2023.04.079. Epub 2023 May 1. PMID: 37179165

[The Effect of Combining the COVID-19 Vaccine with the Seasonal Influenza Vaccine on Reducing COVID-19 Vaccine Rejection Among Libyans.](#)

Ghazy RM, Sallam M, Abdullah FSA, Hussein M, Hussein MF. J Epidemiol Glob Health. 2023 Jun;13(2):292-302. doi: 10.1007/s44197-023-00107-2. Epub 2023 May 12. PMID: 37171545

[Implementation During a Pandemic: Findings, Successes, and Lessons Learned from Community Grantees.](#)

Mathias W, Nichols KA, Golden-Wright J, Fairman CM, Felder TM, Workman L, Wickersham KE, Flicker KJ, Sheng J, Noblet SB, Adams SA, Eberth JM, Heiney SP, Wilcox S, Hébert JR, Friedman DB. J Cancer Educ. 2023 Jun;38(3):957-962. doi: 10.1007/s13187-022-02213-4. Epub 2022 Sep 3. PMID: 36056185

[Subacute cutaneous lupus erythematosus induced by Pfizer COVID-19 vaccine.](#)

Magnaterra E, Magliulo M, Mariotti EB, Ruffo DI Calabria V, Quintarelli L, Corrà A, Aimo C, Verdelli A, Caproni M. Ital J Dermatol Venerol. 2023 Jun;158(3):266-267. doi: 10.23736/S2784-8671.23.07373-5. Epub 2023 Mar 7. PMID: 36881332

[Companies hoard COVID-19 vaccines, stalling future research.](#)

Cohen J. Science. 2023 Jun 9;380(6649):1001-1002. doi: 10.1126/science.adj1033. Epub 2023 Jun 8. PMID: 37289896

[Understanding the concept of trust and other factors related to COVID-19 vaccine intentions among Black/African American older adults prior to vaccine development.](#)

Harris OO, Perry TE, Johnson JK, Lichtenberg P, Washington T, Kitt B, Shaw M, Keiser S, Tran T, Vest L, Maloof M, Portacolone E. SSM Qual Res Health. 2023 Jun;3:100230. doi: 10.1016/j.ssmqr.2023.100230. Epub 2023 Feb 4. PMID: 36785539

[Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.](#)

Huang C, Wei Y, Yan VKC, Ye X, Kang W, Yiu HHE, Shami JJP, Cowling BJ, Tse ML, Castle DJ, Chui CSL, Lai FTT, Li X, Wan EYF, Wong CKH, Hayes JF, Chang WC, Chung AKK, Lau CS, Wong ICK, Chan EW. Lancet Psychiatry. 2023 Jun;10(6):403-413. doi: 10.1016/S2215-0366(23)00111-6. Epub 2023 May 1. PMID: 37141907

[A Review on Artificial Intelligence Approaches and Rational Approaches in Drug Discovery.](#)

Srivathsa AV, Sadashivappa NM, Hegde AK, Radha S, Mahesh AR, Ammunje DN, Sen D, Theivendren P, Govindaraj S, Kunjiappan S, Pavadai P. Curr Pharm Des. 2023 Jun 6;29(15):1180-1192. doi: 10.2174/1381612829666230428110542. PMID: 37132148

[COVID-19 vaccination in pregnancy: How discrepant public health discourses shape responsibility for fetal health.](#)

Manca TA, Top KA, Graham JE. SSM Qual Res Health. 2023 Jun;3:100265. doi: 10.1016/j.ssmqr.2023.100265. Epub 2023 Apr 10. PMID: 37069999

[Broad-spectrum pan-genus and pan-family virus vaccines.](#)

Tan CW, Valkenburg SA, Poon LLM, Wang LF. Cell Host Microbe. 2023 Jun 14;31(6):902-916. doi: 10.1016/j.chom.2023.05.017. PMID: 37321173

["Solidarity:" A failed call to action during the COVID-19 pandemic.](#)

Bulled N. Public Health Pract (Oxf). 2023 Jun;5:100379. doi: 10.1016/j.puhip.2023.100379. Epub 2023 Mar 16. PMID: 36987526

[Menstrual abnormalities post-COVID vaccination: a cross-sectional study on adult Lebanese women.](#)

Dabbousi AA, El Masri J, El Ayoubi LM, Ismail O, Zreika B, Salameh P. Ir J Med Sci. 2023 Jun;192(3):1163-1170. doi: 10.1007/s11845-022-03089-5. Epub 2022 Jul 26. PMID: 35881229

[Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition.](#)

Silva CA, de Vinci Kanda Kupa L, Medeiros-Ribeiro AC, Pasoto SG, Saad CGS, Yuki EFN, Landim JIVD, Léda VHFE, de Camargo Correia LS, Sartori AF, Martins CCMF, Ribeiro CT, Waridel F, de Oliveira Martins VA, Shinjo SK, Andrade DCO, Barros PDS, Neto EFB, Aikawa NE, Bonfa E. *Adv Rheumatol*. 2023 Jun 8;63(1):26. doi: 10.1186/s42358-023-00309-z. PMID: 37291679

[Dendrobium officinale aqueous extract influences the immune response following vaccination against SARS-CoV-2.](#)

Gao X, Ye T, Lei Y, Zhang Q, Luo Y, Yang H, Zeng X, Zhou W, Wen Q, Liu J, Xiong H, Wan R. *Biomed Pharmacother*. 2023 Jun;162:114702. doi: 10.1016/j.biopha.2023.114702. Epub 2023 Apr 13. PMID: 37062221

[Potentiating the Cross-Reactive IFN- \$\gamma\$ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine.](#)

Seo YB, Ko A, Shin D, Kim J, Suh YS, Na J, Ryu JI, Lee S, Oh MJ, Sung YC. *Int J Mol Sci*. 2023 Jun 5;24(11):9753. doi: 10.3390/ijms24119753. PMID: 37298704

[How do psychobehavioural variables shed light on heterogeneity in COVID-19 vaccine acceptance? Evidence from United States general population surveys on a probability panel and social media.](#)

Charles GK, Braunstein SP, Barker JL, Fung H, Coome L, Kumar R, Huang VS, Kemp H, Grant E, Bernard D, Barefoot D, Sgaier SK. *BMJ Open*. 2023 Jun 6;13(6):e066897. doi: 10.1136/bmjopen-2022-066897. PMID: 37280023

[Updated Guidance Regarding The Risk of Allergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach.](#)

Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DB, Akin C, Anagnostou A, ALMuhizi F, Alqurashi W, Arkwright P, Baldwin JL, Banerji A, Bégin P, Ben-Shoshan M, Bernstein J, Bingeman TA, Bindslev-Jensen C, Blumenthal K, Byrne A, Cahil J, Cameron S, Campbell D, Campbell R, Cavender M, Chan ES, Chinthrajah S, Comberiatti P, Eastman JJ, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrero PA, Gagnon R, Garvey LH, Grayson MH, Clarisse Isabwe GA, Hartog N, Hendron D, Horner CC, O'B Hourihane J, Iglesia E, Kan M, Kaplan B, Katelaris CH, Kim H, Kelso JM, Kahn DA, Lang D, Ledford D, Levin M, Lieberman JA, Loh R, Mack DP, Mazer B, Mody K, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Nathan R, Oppenheimer J, Otani IM, Park M, Pawankar R, Perrett KP, Peter J, Phillips EJ, Picard M, Pitlick M, Ramsey A, Rasmussen TH, Rathkopf MM, Reddy H, Robertson K, Rodriguez Del Rio P, Sample S, Sheshradi A, Shiek J, Sindher SB, Spergel JM, Stone CA, Stukus D, Tang ML, Tracy JM, Turner PJ, Vander Leek TK, Wallace DV, Wang J, Wasserman S, Weldon D, Wolfson AR, Worm M, Yacoub MR. *J Allergy Clin Immunol*. 2023 Jun 7:S0091-6749(23)00746-7. doi: 10.1016/j.jaci.2023.05.019. Online ahead of print. PMID: 37295474

[Guillain-Barré Syndrome due to COVID-19 Vero Cell Vaccination Associated with Concomitant COVID-19 Infection-induced ARDS and Treated Successfully by Therapeutic Plasma Exchange: A First Case Report from Vietnam.](#)

Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Quang T, Nguyen-Thi-Kim T, Tran-Ngoc-Anh T, Nguyen-Van-Hoai N, Do-Thi-Thu M, Nguyen-Van T, Tang-Thi-Thao T, Nguyen-Tuan A, Nguyen-Van T, Tran-Xuan Q, Vu-Tran-Thien Q, Trinh-Du T, Tran-Thai T, Nguyen-Duy T, Tran-Van H, Vo-Thi-Kim A. *Pulm Ther*. 2023 Jun;9(2):271-280. doi: 10.1007/s41030-023-00219-x. Epub 2023 Mar 29. PMID: 36991236

[An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection.](#)

Rosa L, Cutone A, Conte MP, Campione E, Bianchi L, Valenti P. Biometals. 2023 Jun;36(3):417-436. doi: 10.1007/s10534-022-00427-z. Epub 2022 Aug 3. PMID: 35920949

[Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study.](#)

Volpe GJ, Vessoni SCS, Soares LB, Leite Dos Santos Almeida MAA, Braga PE, de Moraes GR, Ferreira NN, Garibaldi PMM, Kashima S, Fonseca BAL, Calado RT, García HAB, de França JID, de Lima MA, Pacheco PHM, Borges MC, Covas DT. IJID Reg. 2023 Jun;7:222-229. doi: 10.1016/j.ijregi.2023.04.003. Epub 2023 Apr 6. PMID: 37102137

[Parents' COVID-19, HPV, and Monkeypox vaccination intention: A multilevel structural equation model of risk, benefit, barrier, and efficacy perceptions and individual characteristics.](#)

Liu S, Chu H. Patient Educ Couns. 2023 Jun 7;114:107842. doi: 10.1016/j.pec.2023.107842. Online ahead of print. PMID: 37301013

[A deep learning predictive model for public health concerns and hesitancy toward the COVID-19 vaccines.](#)

Farghaly HM, Gomaa MM, Elgeldawi E, Askr H, Elshaier YAMM, Ella HA, Darwish A, Hassanien AE. Sci Rep. 2023 Jun 6;13(1):9171. doi: 10.1038/s41598-023-36319-6. PMID: 37280253

[Correction of vaccine effectiveness derived from test-negative case-control studies.](#)

Habibzadeh F. BMC Med Res Methodol. 2023 Jun 10;23(1):137. doi: 10.1186/s12874-023-01962-0. PMID: 37301843

[Intention to receive COVID-19 vaccine and its health belief model \(HBM\)-based predictors: Comment.](#)

Kleebayoon A, Wiwanitkit V. Hum Vaccin Immunother. 2023 Jun 4:2219181. doi: 10.1080/21645515.2023.2219181. Online ahead of print. PMID: 37271581

[Drug-induced radiation recall reactions and non-anticancer drugs: A descriptive analysis from VigiBase®.](#)

Aubin-Beale E, Giorgi L, Beurrier M, Granel-Brocard F, Gillet P, Fresse A. Fundam Clin Pharmacol. 2023 Jun;37(3):673-679. doi: 10.1111/fcp.12866. Epub 2023 Jan 11. PMID: 36607138

[SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.](#)

Kim E, Khan MS, Ferrari A, Huang S, Sammartino JC, Percivalle E, Kenniston TW, Cassaniti I, Baldanti F, Gambotto A. Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10. PMID: 37162333

[Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.](#)

Alves K, Pledsted JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Vaccine. 2023 Jun 2:S0264-410X(23)00612-6. doi: 10.1016/j.vaccine.2023.05.051. Online ahead of print. PMID: 37271706

[Getting Human Papillomavirus Vaccination Back on Track: A National Survey.](#)

Kahn BZ, Huang Q, Thompson P, Gilkey MB, Alton Dailey S, Brewer NT. J Adolesc Health. 2023 Jun;72(6):950-957. doi: 10.1016/j.jadohealth.2023.01.004. Epub 2023 Mar 13. PMID: 36922312

[ChAdOx1 nCoV-19 \(AZD1222\) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.](#)

Kaplonek P, Cizmeci D, Kwatra G, Izu A, Lee JS, Bertera HL, Fischinger S, Mann C, Amanat F, Wang W, Koen AL, Fairlie L, Cutland CL, Ahmed K, Dheda K, Barnabas SL, Bhorat QE, Briner C, Krammer F, Sapphire EO, Gilbert SC, Lambe T, Pollard AJ, Nunes M, Wuhrer M, Lauffenburger DA, Madhi SA, Alter G. Nat Immunol. 2023 Jun 15. doi: 10.1038/s41590-023-01513-1. Online ahead of print. PMID: 37322179

[Analysis of Socio-demographic, Economic and Individual Reasons for COVID-19 Vaccination Hesitancy in Ecuador: A Nationwide Longitudinal Study.](#)

Lapo-Talledo GJ, Talledo-Delgado JA, Portalanza D, Ballaz S, Siteneski A. J Community Health. 2023 Jun;48(3):467-479. doi: 10.1007/s10900-023-01188-7. Epub 2023 Jan 18. PMID: 36652158

[Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.](#)

Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Florea A, Bruxvoort KJ, Talarico CA, Qiu S, Tian Y, Tseng HF. Vaccine. 2023 Jun 1;41(24):3636-3646. doi: 10.1016/j.vaccine.2023.04.075. Epub 2023 May 3. PMID: 37173268

[COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.](#)

Yeo T, Siew RWE, Gulam MY, Tye JSN, Aw AYY, Sivalingam T, Peng X, Yong KP, Saffari SE, Chao Y, Tan K. J Neurol. 2023 Jun;270(6):2817-2825. doi: 10.1007/s00415-023-11692-4. Epub 2023 Apr 7. PMID: 37027019

[Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.](#)

Fukunaga R, Kaplan ZE, Rodriguez T, Hagan L, Aarvig K, Dusseau C, Crockett M, Long M. Vaccine. 2023 Jun 1;41(24):3604-3610. doi: 10.1016/j.vaccine.2023.04.077. Epub 2023 May 2. PMID: 37164822

[mRNA COVID-19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry.](#)

Mansour O, Hernandez-Diaz S, Wyszynski DF. Pharmacoepidemiol Drug Saf. 2023 Jun;32(6):685-693. doi: 10.1002/pds.5600. Epub 2023 Feb 15. PMID: 36750979

[Trust Associated with South Korean Sojourners' Chinese COVID-19 Vaccination Intent and Concerns: A Qualitative Study.](#)

Lin Y, Liu X. J Epidemiol Glob Health. 2023 Jun 1;1:1-9. doi: 10.1007/s44197-023-00123-2. Online ahead of print. PMID: 37261712

[Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.](#)

Huang CF, Jang TY, Wu PH, Kuo MC, Yeh ML, Wang CW, Liang PC, Wei YJ, Hsu PY, Huang CI, Hsieh MY, Lin YH, Hsiao HH, Hsu CM, Huang CT, Lee CY, Chen YH, Chen TC, Lin KD, Wang SH, Wang SF, Huang JF, Dai CY, Chuang WL, Yu ML. Virol J. 2023 Jun 2;20(1):112. doi: 10.1186/s12985-023-02056-5. PMID: 37268999

[Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country.](#)

Kaboré OD, Poda A, Ouattara CA, Michodigni FN, Belem AA, Sawadogo Y, Zoungrana J, Galal L, Meda CZ, Godreuil S, Ouédraogo AS. PLoS One. 2023 Jun 14;18(6):e0286665. doi: 10.1371/journal.pone.0286665. eCollection 2023. PMID: 37315090

[A call to action: securing an uninterrupted supply of Africa's medical products and technologies post COVID-19.](#)

Ejekam CS, Emeje M, Lukulay P, Uche CR, Odibeli O, Sanusi O, Anyakora C. J Public Health Policy. 2023 Jun;44(2):276-284. doi: 10.1057/s41271-023-00405-w. Epub 2023 Mar 30. PMID: 36997622

[Vulvar Aphthous Ulcers in Perimenarchal Adolescents after COVID-19 Vaccination: A Multicenter Case Series.](#)

Sartor RA, Lawson A, Moncada-Madrazo M, Altchek C, Vash-Margita A, Cron J. J Pediatr Adolesc Gynecol. 2023 Jun;36(3):268-272. doi: 10.1016/j.jpag.2023.01.003. Epub 2023 Jan 25. PMID: 36708984

[Public trust is earned: Historical discrimination, carceral violence, and the COVID-19 pandemic.](#)

Anderson A, Lewis DF 4th, Shafer P, Anderson J, LaVeist TA. Health Serv Res. 2023 Jun 6. doi: 10.1111/1475-6773.14187. Online ahead of print. PMID: 37279782

[The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists.](#)

Visser C, Yousefi A, Nierman MC, Huisman MV, Gulpen AJW, van Ommen CH, Kruij MJHA; Dutch COVID and Thrombosis Coalition. Thromb Res. 2023 Jun 12;228:121-127. doi: 10.1016/j.thromres.2023.06.005. Online ahead of print. PMID: 37321159

[Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.](#)

Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C. Mult Scler. 2023 Jun 15:13524585231179669. doi: 10.1177/13524585231179669. Online ahead of print. PMID: 37322880

[Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.](#)

Parsons C, Rubio J, Boulougoura A, Krishfield S, Kyttaris V. Rheumatol Int. 2023 Jun 13. doi: 10.1007/s00296-023-05347-w. Online ahead of print. PMID: 37310438

[Metabolic Adaptations Correlated with Antibody Response after Immunization with Inactivated SARS-CoV-2 in Brazilian Subjects.](#)

de Souza Nogueira J, Santos-Rebouças CB, Piergiorgio RM, Valente AP, Gama-Almeida MC, El-Bacha T, Lopes Moreira ML, Baptista Marques BS, de Siqueira JR, de Carvalho EM, da Costa Ferreira O Jr, Porto LC, Kelly da Silva Fidalgo T, Costa Dos Santos G Jr. J Proteome Res. 2023 Jun 2;22(6):1908-1922. doi: 10.1021/acs.jproteome.3c00014. Epub 2023 May 11. PMID: 37167433

[Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report.](#)

Makiyama A, Abe Y, Furusawa H, Kogami M, Ando T, Tada K, Onimaru M, Ishizu A, Yamaji K, Tamura N. Mod Rheumatol Case Rep. 2023 Jun 15:rxad037. doi: 10.1093/mrcr/rxad037. Online ahead of print. PMID: 37319013

[Understanding Factors Impacting Coronavirus Disease 2019 Vaccine Hesitancy in a Rural Surgical Clinic.](#)

Thakur S, Cervantes JD, Thakur A. Surg Infect (Larchmt). 2023 Jun;24(5):456-461. doi: 10.1089/sur.2022.378. Epub 2023 Apr 20. PMID: 37083508

[The effectiveness of COVID-19 vaccination against all-cause mortality in patients with type 2 diabetes mellitus: The observation during the initial period of the cancellation of the "Dynamic Zero Policy" in mainland China.](#)

Liu S, Jiang C, Liu Y, Zhang Y, Qiu X, Luo J, Xu Y, Wang J. Diabetes Res Clin Pract. 2023 Jun;200:110694. doi: 10.1016/j.diabres.2023.110694. Epub 2023 May 8. PMID: 37164159

[Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study.](#)

Moreno-Torres V, Soriano V, Calderón-Parra J, Martínez-Urbistondo M, Treviño A, de San Vicente Z, de Mendoza C, Ruiz-Irastorza G. Autoimmun Rev. 2023 Jun;22(6):103341. doi: 10.1016/j.autrev.2023.103341. Epub 2023 Apr 14. PMID: 37062441

[Letter to the Editor Response: Exploring COVID-19 Vaccine Hesitancy Among Stakeholders in African American and Latinx Communities in the Deep South Through the Lens of the Health Belief Model.](#)

Bateman LB, Hall AG, Anderson WA, Cherrington AL, Helova A, Judd S, Kimberly R, Oates GR, Osborne T, Ott C, Ryan M, Strong C, Fouad MN. Am J Health Promot. 2023 Jun;37(5):720-721. doi: 10.1177/08901171221146436. Epub 2023 Jan 11. PMID: 36630288

[Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2.](#)

Bannick MS, Gao F, Brown ER, Janes HE. Am J Epidemiol. 2023 Jun 2;192(6):1016-1028. doi: 10.1093/aje/kwad046. PMID: 36883907

[Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease: Comment.](#)

Kleebayoon A, Wiwanitkit V. J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):e89-e90. doi: 10.1097/MPG.0000000000003761. Epub 2023 Mar 12. PMID: 36913710

[Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workers.](#)

AlBahrani S, AlBarrak A, AlGubaisi N, Alkurdi H, Alburaiqi D, AlGhamdi A, AlOthaiqy M, Tayeb S, Tayeb N, Abdrahob S, Khairi A, Alshareef L, AlHarbi A, AlRabeeah S, Alqahtani AS, Alqahtani JS, Hakami FH, Al-Maqati TN, Alkhraishi SA, Almershad MM, AlAbbadi A, Hakami MH, Faqihi O, Altawfiq KJA, Jebakumar AZ, Al-Tawfiq JA. J Infect Public Health. 2023 Jun 5;16(8):1276-1280. doi: 10.1016/j.jiph.2023.05.037. Online ahead of print. PMID: 37315430

[Safety and efficacy of Sinopharm vaccine \(BBIBP-CorV\) in elderly population of Faisalabad district of Pakistan.](#)

Nadeem I, Ul Munamm SA, Ur Rasool M, Fatimah M, Abu Bakar M, Rana ZK, Khatana UF, Jordon L, Saqlain M, Mahdi N, McLoughlin H. Postgrad Med J. 2023 Jun 8;99(1171):463-469. doi: 10.1136/postgradmedj-2022-141649. PMID: 37294716

[Rural-Urban Differences in Vaccination and Hesitancy Rates and Trust: US COVID-19 Trends and Impact Survey on a Social Media Platform, May 2021-April 2022.](#)

Soorapanth S, Cheung R, Zhang X, Mokdad AH, Mensah GA. Am J Public Health. 2023 Jun;113(6):680-688. doi: 10.2105/AJPH.2023.307274. Epub 2023 Apr 13. PMID: 37053528

[Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis.](#)

Al-Haideri M, Mohammad TAM, Darvishzadehdeldari S, Karbasi Z, Alimohammadi M, Faramarzi F, Khorasani S, Rasouli A, Tahmasebi S, Darvishi M, Akhavan-Sigari R. Int J Rheum Dis. 2023 Jun 12. doi: 10.1111/1756-185X.14713. Online ahead of print. PMID: 37309305

[A new look on politicized reticence to vaccination: populism and COVID-19 vaccine refusal.](#)

Roccatto M, Russo S. Psychol Med. 2023 Jun;53(8):3769-3770. doi: 10.1017/S0033291721004736. Epub 2021 Nov 4. PMID: 34734558

[Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.](#)

Black SB, Chandler RE, Edwards KM, Sturkenboom MCJM. Vaccine. 2023 Jun 7;41(25):3790-3795. doi: 10.1016/j.vaccine.2023.04.055. Epub 2023 May 15. PMID: 37198019

[Audiometry-Confirmed Sudden Sensorineural Hearing Loss Incidence Among COVID-19 Patients and BNT162b2 Vaccine Recipients.](#)

Cohen Michael O, Tamir SO, O'Rourke N, Marom T. Otol Neurotol. 2023 Jun 1;44(5):e358-e359. doi: 10.1097/MAO.0000000000003872. Epub 2023 Apr 6. PMID: 37026821

[Declining trends in vaccine confidence across sub-Saharan Africa: A large-scale cross-sectional modeling study.](#)

de Figueiredo A, Temfack E, Tajudeen R, Larson HJ. Hum Vaccin Immunother. 2023 Jun 8:2213117. doi: 10.1080/21645515.2023.2213117. Online ahead of print. PMID: 37290478

[HLA-DR4 and DRB4: Potential risk alleles for COVID-19 vaccination-related ANCA-associated vasculitis.](#)

Loo HT, Hsu CH, Chen LF. Ther Apher Dial. 2023 Jun;27(3):593-594. doi: 10.1111/1744-9987.13925. Epub 2022 Sep 16. PMID: 36074724

[Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.](#)

George TK, Nair NP, Singh AK, Dilesh Kumar A, Roy AD, Mohan VN, Kang G. Vaccine. 2023 Jun 7;41(25):3755-3762. doi: 10.1016/j.vaccine.2023.04.062. Epub 2023 May 12. PMID: 37183072

[Inter-hospital transfer and clinical outcomes for people with COVID-19 admitted to intensive care units in Australia: an observational cohort study.](#)

Cini C, Neto AS, Burrell A, Udy A; SPRINT-SARI Australia investigators. Med J Aust. 2023 Jun 5;218(10):474-481. doi: 10.5694/mja2.51917. Epub 2023 Apr 10. PMID: 37037671

[Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.](#)

Stafford LS, Valcarce V, Henry M, Neu J, Parker L, Mueller M, Vicuna V, Gowen T, Cato E, Kosik I, Yewdell JW, Atkinson M, Cacho N, Li N, Larkin J 3rd. J Perinatol. 2023 Jun;43(6):775-781. doi: 10.1038/s41372-022-01581-5. Epub 2023 Jan 12. PMID: 36631564

[Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron \(BA.1\) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease.](#)

Stich M, Di Cristanziano V, Tönshoff B, Weber LT, Dötsch J, Rammer MT, Rieger S, Heger E, Garbade SF, Burgmaier K, Benning L, Speer C, Habbig S, Haumann S. *Pediatr Nephrol.* 2023 Jun;38(6):1935-1948. doi: 10.1007/s00467-022-05806-9. Epub 2022 Nov 21. PMID: 36409368

[Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.](#)

Diem G, Jäger M, Dichtl S, Bauer A, Lass-Flörl C, Reindl M, Wilflingseder D, Posch W. *Microbiol Spectr.* 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26. PMID: 37098903

[Impact of pandemics and disruptions to vaccination on infectious diseases epidemiology past and present.](#)

Hamson E, Forbes C, Wittkopf P, Pandey A, Mendes D, Kowalik J, Czudek C, Mugwagwa T. *Hum Vaccin Immunother.* 2023 Jun 8:2219577. doi: 10.1080/21645515.2023.2219577. Online ahead of print. PMID: 37291691

[Supporting One Health for Pandemic Prevention: The Need for Ethical Innovation.](#)

Diller ER, Williamson L. *J Bioeth Inq.* 2023 Jun 2:1-8. doi: 10.1007/s11673-023-10264-5. Online ahead of print. PMID: 37266851

[VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.](#)

Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías-Iñesta J, Davis RJ, Barta I, Azzini AM, Askling HH, Argyropoulos CD, Álvarez-Barco E, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Flisiak R, Husa P, Jancoriene L, Koscalova A, Launay O, Lundgren J, Mallon P, Marques L, Naucclér P, Ochando J, Pana ZD, Tacconelli E, Tóth K, Trelle S, van Damme P, Zaoutis TE, Zeitlinger M, Albus K, Stewart FA, Hofstraat SHI, Bruijning-Verhagen P, Cornely OA; VACCELERATE Consortium. Electronic address: trialsites@vaccelerate.eu. *Vaccine.* 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006. Epub 2023 May 18. PMID: 37210309

[TNFepitope: A webserver for the prediction of TNF- \$\alpha\$ inducing epitopes.](#)

Dhall A, Patiyal S, Choudhury S, Jain S, Narang K, Raghava GPS. *Comput Biol Med.* 2023 Jun;160:106929. doi: 10.1016/j.combiomed.2023.106929. Epub 2023 Apr 20. PMID: 37126926

[Well Child Wednesdays: An interprofessional pilot-program to increase pediatric immunizations Post-COVID.](#)

Stewart-Lynch A, Lombardo S, Ceriani D, Mastrangelo S. *J Interprof Educ Pract.* 2023 Jun;31:100606. doi: 10.1016/j.xjep.2023.100606. Epub 2023 Jan 18. PMID: 36688206

[Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.](#)

Su WJ, Liu YL, Chang CH, Lin YC, Huang WI, Wu LC, Chen SF, Lin YS, Hsieh YL, Yang CA, Lin CH, Chan KA, Lee PI, Chuang JH, Yang CH. *J Microbiol Immunol Infect.* 2023 Jun;56(3):558-565. doi: 10.1016/j.jmii.2023.01.016. Epub 2023 Feb 8. PMID: 36804307

[Self-Destructive Structural Color Liquids for Time-Temperature Indicating.](#)

Huang C, Shang Y, Hua J, Yin Y, Du X. ACS Nano. 2023 Jun 13;17(11):10269-10279. doi: 10.1021/acsnano.3c00467. Epub 2023 May 31. PMID: 37255215

["Effect of COVID-19 Vaccination on Menstrual Cycle Patterns of Reproductive-Age Women: A Multi-centric Observational Study."](#)

Kumar N, Gangane N, Mohapatra I, Rukadikar C, Sharmila V, Pushpalatha K, Eerike M, Santhoshi G, Samantaray SR, Seth S, Trigunait P, Reddy NJ, Patel S, Rani S, Mishra R, Negi K. Curr Drug Res Rev. 2023 Jun 8. doi: 10.2174/2589977515666230608140606. Online ahead of print. PMID: 37291775

[Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study.](#)

Visos-Varela I, Zapata-Cachafeiro M, Piñeiro-Lamas M, Carracedo-Martínez E, Saez M, Herdeiro MT, Figueiras A, Salgado-Barreira Á. Eur Neuropsychopharmacol. 2023 Jun;71:96-108. doi: 10.1016/j.euroneuro.2023.03.011. Epub 2023 Apr 4. PMID: 37094487

[Short-term adverse effects of COVID-19 vaccines after the first, second, and booster doses: a cross-sectional survey from Punjab, Pakistan, and the implications.](#)

Mustafa ZU, Maqbool F, Wahid M, Salman M, Haroon S, Khan YH, Mallhi TH, Godman B. Rev Soc Bras Med Trop. 2023 Jun 2;56:e0044. doi: 10.1590/0037-8682-0044-2023. eCollection 2023. PMID: 37283345

[Jerne's "immune network theory", of interacting anti-idiotypic antibodies applied to immune responses during COVID-19 infection and after COVID-19 vaccination.](#)

Kurbel S. Bioessays. 2023 Jun 9:e2300071. doi: 10.1002/bies.202300071. Online ahead of print. PMID: 37300287

[Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients.](#)

Bernal E, García-Villalba E, Pons E, Vicente MR, Tomás C, Minguela A; GERS. Med Clin (Barc). 2023 Jun 9;160(11):476-483. doi: 10.1016/j.medcli.2022.12.018. Epub 2023 Jan 23. PMID: 36813683

[Strategic planning for the optimal distribution of COVID-19 vaccines.](#)

Ochoa-Barragán R, Munguía-López ADC, Ponce-Ortega JM. Socioecon Plann Sci. 2023 Jun;87:101559. doi: 10.1016/j.seps.2023.101559. Epub 2023 Mar 14. PMID: 37255586

[Guillain-Barré syndrome following COVID-19 vaccination: An updated systematic review of cases.](#)

Shaheen N, Ramadan A, Nashwan AJ, Shaheen A, Ahmad S, Motawea KR, Mohamed S, Mohamed RS, Swed S, Aiash H. Clin Case Rep. 2023 Jun 7;11(6):e7456. doi: 10.1002/ccr3.7456. eCollection 2023 Jun. PMID: 37305891

[Translatability scoring in prospective and retrospective COVID drug development cases.](#)

Wendler A, Wehling M. Eur J Clin Pharmacol. 2023 Jun 6:1-21. doi: 10.1007/s00228-023-03517-0. Online ahead of print. PMID: 37278822

[Antibody Response to the BA.5 Bivalent Vaccine Shot: a Two-Year Follow-Up Study following Initial COVID-19 mRNA Vaccination.](#)

Hirotsu Y, Sugiura H, Takatori M, Mochizuki H, Omata M. Microbiol Spectr. 2023 Jun 15;11(3):e0131623. doi: 10.1128/spectrum.01316-23. Epub 2023 May 16. PMID: 37191496

[Multisystem inflammatory syndrome in children associated with COVID-19: from pathophysiology to clinical management and outcomes.](#)

Lee S, Erdem G, Yasuhara J. *Minerva Pediatr* (Torino). 2023 Jun 7. doi: 10.23736/S2724-5276.23.07205-1. Online ahead of print. PMID: 37284807

[Multiple evanescent white dot syndrome following COVID-19 vaccines.](#)

Bouhout S, Hébert M, Vadboncoeur J, Aubin MJ. *Can J Ophthalmol*. 2023 Jun;58(3):e122-e124. doi: 10.1016/j.jcjo.2022.10.002. Epub 2022 Oct 23. PMID: 36288774

[Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.](#)

Langlete P, Tesli M, Veneti L, Starrfelt J, Elstrøm P, Meijerink H. *Vaccine*. 2023 Jun 13;41(26):3923-3929. doi: 10.1016/j.vaccine.2023.05.022. Epub 2023 May 10. PMID: 37211454

[The identification and phylogenetic analysis of SARS-CoV-2 delta variants in Taiwan.](#)

Liu LT, Tsai JJ, Chu JJH, Chen CH, Chen LJ, Lin PC, Tsai CY, Hsu MC, Chuang WL, Hwang SJ, Chong IW. *Kaohsiung J Med Sci*. 2023 Jun;39(6):624-636. doi: 10.1002/kjm2.12665. Epub 2023 Mar 23. PMID: 36951529

[Cytokine levels in maternal and infant blood after COVID-19 vaccination during pregnancy: Correspondence.](#)

Kleebayoon A, Wiwanitkit V. *J Reprod Immunol*. 2023 Jun;157:103947. doi: 10.1016/j.jri.2023.103947. Epub 2023 Apr 6. PMID: 37087817

[Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children.](#)

Ziv N, Gimmelraikh Y, Ashkenazi-Hoffnung L, Alfandary H, Borovitz Y, Dagan A, Levi S, Hamdani G, Levy-Erez D, Landau D, Koren G, Talgam-Horshi E, Haskin O. *Transpl Immunol*. 2023 Jun;78:101839. doi: 10.1016/j.trim.2023.101839. Epub 2023 Apr 17. PMID: 37076050

[Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.](#)

Verburgh ML, van Pul L, Grobden M, Boyd A, Wit FWNM, van Nuenen AC, van Dort KA, Tejjani K, van Rijswijk J, Bakker M, van der Hoek L, Schim van der Loeff MF, van der Valk M, van Gils MJ, Kootstra NA, Reiss P. *Microbiol Spectr*. 2023 Jun 15;11(3):e0115523. doi: 10.1128/spectrum.01155-23. Epub 2023 May 11. PMID: 37166335

[Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.](#)

Sutton WJH, Branham PJ, Williamson YM, Cooper HC, Najjar FN, Pierce-Ruiz CL, Barr JR, Williams TL. *Vaccine*. 2023 Jun 13;41(26):3872-3884. doi: 10.1016/j.vaccine.2023.04.044. Epub 2023 May 8. PMID: 37202272

[Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.](#)

Uzun S, Zinner C, Beenen AC, Alborelli I, Bartoszek EM, Yeung J, Calgua B, Reinscheid M, Bonsert P, Stalder AK, Haslbauer J, Vosbeck J, Mazzucchelli L, Hoffmann T, Terracciano LM, Hutter G, Manz M,

Panne I, Böttler T, Hofmann M, Bengsch B, Heim MH, Bernsmeier C, Jiang S, Tzankov A, Beretta-Piccoli BT, Matter MS. *J Hepatol.* 2023 Jun 6:S0168-8278(23)00348-3. doi: 10.1016/j.jhep.2023.05.020. Online ahead of print. PMID: 37290592

[COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies.](#)
Andreoli L, Sen P, Lini D, Vincze MN, Schreiber K, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. *Rheumatology (Oxford).* 2023 Jun 1;62(6):e175-e179. doi: 10.1093/rheumatology/keac644. PMID: 36370070

[Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study.](#)

Golec M, Zembala-John J, Fronczek M, Konka A, Bochenek A, Wystyrk K, Botor H, Zalewska M, Chrapiec M, Kasperczyk S, Brzoza Z, Bułdak RJ. *PLoS One.* 2023 Jun 13;18(6):e0287128. doi: 10.1371/journal.pone.0287128. eCollection 2023. PMID: 37310975

[Evaluation of Correctional Facility COVID-19 Outbreaks With Layered Mitigation Strategies Including Vaccination: Colorado, 2020-2021.](#)

Martinez HE, Marshall KE, Showell VW 4th, Tate JE, Kirking HL, Broudy M, Matzinger SR, Burakoff A, Deng L, Payne DC, Fleming-Dutra K, Jervis RH. *J Correct Health Care.* 2023 Jun;29(3):198-205. doi: 10.1089/jchc.21.12.0146. Epub 2023 Mar 29. PMID: 36989514

[Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK.](#)

Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, Cheung BMY, Tang SCW, Lau CS, Wan EYF, Wong ICK. *EClinicalMedicine.* 2023 Jun;60:102000. doi: 10.1016/j.eclinm.2023.102000. Epub 2023 May 11. PMID: 37197226

[Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study.](#)

Cappetto KD, Brown JC, Englund JA, Zerr DM, Dickerson JA, Wang X, Strelitz B, Klein EJ. *IJID Reg.* 2023 Jun;7:281-286. doi: 10.1016/j.ijregi.2023.05.001. Epub 2023 May 12. PMID: 37234562

[Harnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein.](#)

Moustafa RI, Faraag AHI, El-Shenawy R, Agwa MM, Elsayed H. *Saudi J Biol Sci.* 2023 Jun;30(6):103661. doi: 10.1016/j.sjbs.2023.103661. Epub 2023 Apr 28. PMID: 37163156

[Decisions about adopting novel COVID-19 vaccines among White adults in a rural state, USA: A qualitative study.](#)

Kohut M, Scharnetzki L, Pajka J, Jacobs EA, Fairfield KM. *Health Expect.* 2023 Jun;26(3):1052-1064. doi: 10.1111/hex.13714. Epub 2023 Mar 2. PMID: 36864735

[Burgeoning therapeutic strategies to curb the contemporary surging viral infections.](#)

Akram F, Waheed HM, Shah FI, Haq IU, Nasir N, Akhtar MT, Farooq Gohar U. *Microb Pathog.* 2023 Jun;179:106088. doi: 10.1016/j.micpath.2023.106088. Epub 2023 Mar 31. PMID: 37004965

[Chronic and delayed neurological manifestations of persistent infections.](#)

Pandya D, Johnson TP. *Curr Opin Neurol*. 2023 Jun 1;36(3):198-206. doi: 10.1097/WCO.0000000000001154. Epub 2023 Apr 19. PMID: 37078647

[Assessing the Role of Trust in Public Health Agencies and COVID-19 Vaccination Status Among a Community Sample of African Americans in North Carolina.](#)

Lloyd SL, Foy CG, Caban-Holt A, Gwathmey T, Williams KL, Starks TD, Mathews A, Vines AI, Richmond A, Byrd GS. *J Racial Ethn Health Disparities*. 2023 Jun 5:1-11. doi: 10.1007/s40615-023-01646-x. Online ahead of print. PMID: 37273163

[Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses - fall 2021, Wisconsin.](#)

DeJonge PM, Lambrou AS, Segaloff HE, Bateman A, Sterkel A, Griggs C, Baggott J, Kelly P, Thornburg N, Epperson M, Desamu-Thorpe R, Abedi G, Hsu CH, Nakayama JY, Ruffin J, Turner-Harper D, Matanock A, Almendares O, Whaley M, Chakrabarti A, DeGruy K, Daly M, Westergaard R, Tate JE, Kirking HL. *BMC Infect Dis*. 2023 Jun 5;23(1):374. doi: 10.1186/s12879-023-08332-7. PMID: 37277736

[Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.](#)

van Iersel SCJL, McDonald SA, de Gier B, Knol MJ, de Melker HE, Henri van Werkhoven CH, Hahné SJM; RIVM COVID-19 epidemiology and surveillance team. *Vaccine*. 2023 Jun 13;41(26):3847-3854. doi: 10.1016/j.vaccine.2023.05.018. Epub 2023 May 10. PMID: 37202273

[\[Evaluation of the Dunning Kruger effect in relation to vaccination: a study of messages on the social network LinkedIn.\]](#)

Sánchez Ordóñez M, Bermejo Velasco PE, Rubio Moraga ÁL. *Rev Esp Salud Publica*. 2023 Jun 15;97:e202306051. PMID: 37325904

[Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias.](#)

Andrejko KL, Pry JM, Myers JF, Mehrotra M, Lamba K, Lim E, Fukui N, DeGuzman JL, Openshaw J, Watt J, Jain S, Lewnard JA, Covid-Case-Control Study Team OBOTC. *Am J Epidemiol*. 2023 Jun 2;192(6):895-907. doi: 10.1093/aje/kwad017. PMID: 36702469

[Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.](#)

Kehagia E, Papakyriakopoulou P, Valsami G. *Vaccine*. 2023 Jun 1;41(24):3589-3603. doi: 10.1016/j.vaccine.2023.05.011. Epub 2023 May 11. PMID: 37179163

[From iatrogenesis to vaccine skepticism: US mothers' negative vaccine perceptions and non-vaccination practices as reverberations of medical harm.](#)

Richlin JB. *Med Anthropol Q*. 2023 Jun;37(2):118-133. doi: 10.1111/maq.12764. Epub 2023 May 10. PMID: 37161842

[Comparison of the first and sixth waves of the SARS-COV-2 coronavirus pandemic in patients with immune-mediated disease.](#)

Lobo Rodríguez C, López-Calleja AM, Morales de Los Ríos Luna P, Sánchez Vázquez S, Molinero Sampedro Á, López-Esteban A. *Reumatol Clin (Engl Ed)*. 2023 Jun 1:S2173-5743(23)00110-7. doi: 10.1016/j.reumae.2023.02.011. Online ahead of print. PMID: 37286470

[SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022.](#)

Bloomfield LE, Ngeh S, Cadby G, Hutcheon K, Effler PV. *Emerg Infect Dis*. 2023 Jun;29(6):1162-1172. doi: 10.3201/eid2906.230130. Epub 2023 May 4. PMID: 37141626

[Estimating global and regional between-country inequality in routine childhood vaccine coverage in 195 countries and territories from 2019 to 2021: a longitudinal study.](#)

Lai X, Zhang H, Pouwels KB, Patenaude B, Jit M, Fang H. *EClinicalMedicine*. 2023 Jun;60:102042. doi: 10.1016/j.eclinm.2023.102042. Epub 2023 Jun 8. PMID: 37304497

[Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry.](#)

Kurbegov D, Bruinooge SS, Lei XJ, Kirkwood MK, Dickson N, Hattiangadi T, Mileham KF, Patrick A, Williams JH, Kaltenbaugh M, Gralow JR, Garrett-Mayer E. *Cancer*. 2023 Jun 1;129(11):1752-1762. doi: 10.1002/cncr.34726. Epub 2023 Mar 15. PMID: 36920457

[Predominantly defective CD8+ T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients.](#)

Taus E, Shino MY, Ibarrodo FJ, Hausner MA, Hofmann C, Yang OO. *J Transl Med*. 2023 Jun 8;21(1):374. doi: 10.1186/s12967-023-04234-z. PMID: 37291575

[Correlates of breakthrough Omicron \(B.1.1.529\) infections in a prospective cohort of vaccinated patients with rheumatic diseases.](#)

Benny L, Mehta P, Ahmed S, Paul A, Sukumaran A, Mohanan M, Vijayan A, Kaveri K, Padmaja R, Shenoy P. *Rheumatol Int*. 2023 Jun;43(6):1033-1039. doi: 10.1007/s00296-023-05314-5. Epub 2023 Apr 8. PMID: 37029793

[The location of unilateral axillary lymphadenopathy after COVID-19 vaccination compared with that of metastasis from breast cancer without vaccination.](#)

Mukai K, Tsunoda H, Imai R, Numata A, Kida K, Oba K, Yagishita K, Yamauchi H, Kanomata N, Kurihara Y. *Jpn J Radiol*. 2023 Jun;41(6):617-624. doi: 10.1007/s11604-023-01387-1. Epub 2023 Jan 10. PMID: 36626076

[Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.](#)

Arabi M, Al-Najjar Y, Mhaimed N, Salameh MA, Paul P, AlAnni J, Abdelati AA, Laswi I, Khanjar B, Al-Ali D, Elshafeey A, Mhaimed O, Burney Z, D'Souza A, Sinha P, Bhatti M, Pillai KV, Homssi M, Bshesh K, Yagan L, Zakaria D. *J Cell Mol Med*. 2023 Jun;27(11):1443-1464. doi: 10.1111/jcmm.17747. Epub 2023 May 18. PMID: 37203288

[Patients with Post-COVID-19 Vaccination Myocarditis Have More Favorable Strain in Cardiac Magnetic Resonance Than Those With Viral Myocarditis.](#)

Vaiyani D, Elias MD, Biko DM, Whitehead KK, Harris MA, Partington SL, Fogel MA. *Pediatr Cardiol*. 2023 Jun;44(5):1108-1117. doi: 10.1007/s00246-023-03150-9. Epub 2023 Apr 1. PMID: 37004523

[Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2.](#)

Lombardi L, Maiorca F, Marrapodi R, Sabetta A, Scafa N, Pallucci D, Miglionico M, Romiti GF, Corica B, Piconese S, Polimeni A, Pulcinelli F, Cangemi R, Visentini M, Basili S, Stefanini L. *J Thromb Haemost.* 2023 Jun;21(6):1636-1649. doi: 10.1016/j.jtha.2023.03.003. Epub 2023 Mar 12. PMID: 36918114

[Human inherited complete STAT2 deficiency underlies inflammatory viral diseases.](#)

Buccioli G, Moens L, Ogishi M, Rinchai D, Matuozzo D, Momenilandi M, Kerrouche N, Cale CM, Treffeisen ER, Al Salamah M, Al-Saud BK, Lachaux A, Duclaux-Loras R, Meignien M, Bousfiha A, Benhsaien I, Shcherbina A, Roppelt A; COVID Human Genetic Effort; Gothe F, Houhou-Fidouh N, Hackett SJ, Bartnikas LM, Maciag MC, Alosaimi MF, Chou J, Mohammed RW, Freij BJ, Jouanguy E, Zhang SY, Boisson-Dupuis S, Béziat V, Zhang Q, Duncan CJ, Hambleton S, Casanova JL, Meyts I. *J Clin Invest.* 2023 Jun 15;133(12):e168321. doi: 10.1172/JCI168321. PMID: 36976641

[Recurring nodular scleritis following inactivated vaccination for COVID-19.](#)

Peyman A, Pourazizi M, Dehghani S, Ghorbani S. *Clin Case Rep.* 2023 Jun 13;11(6):e7420. doi: 10.1002/ccr3.7420. eCollection 2023 Jun. PMID: 37323271

[Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.](#)

Chaudhury S, Kaur P, Gupta D, Anand P, Chaudhary M, Tiwari S, Mittal A, Gupta J, Kaur S, Singh VD, Dhawan D, Singh P, Sahu SK. *Curr Mol Med.* 2023 Jun 13. doi: 10.2174/1566524023666230613141746. Online ahead of print. PMID: 37312440

[Projected Health Outcomes Associated With 3 US Supreme Court Decisions in 2022 on COVID-19 Workplace Protections, Handgun-Carry Restrictions, and Abortion Rights.](#)

Gaffney A, Himmelstein DU, Dickman S, Myers C, Hemenway D, McCormick D, Woolhandler S. *JAMA Netw Open.* 2023 Jun 1;6(6):e2315578. doi: 10.1001/jamanetworkopen.2023.15578. PMID: 37289459

[Indiana Parental Perceptions of the Acceptability of General and HPV-Specific State Vaccine Requirements.](#)

Walker KK, Kasting ML, Head KJ, Sturm L, Zimet GD. *J Community Health.* 2023 Jun;48(3):528-538. doi: 10.1007/s10900-023-01198-5. Epub 2023 Feb 6. PMID: 36745356

[Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.](#)

Ergun T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, Seckin D, Adiyay C, Enul H, Yilmaz S, Ay P, Haklar G, Sili U. *Vaccine.* 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.05.052. Online ahead of print. PMID: 37277251

[Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.](#)

van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabrita A, Farina F, Besson C, Weinbergerová B, Van Praet J, Schönlein M, López-García A, Lamure S, Guidetti A, De Ramón-Sánchez C, Batinić J, Gavrilaki E, Tragiannidis A, Tisi MC, Plantefeve G, Petzer V, Ormazabal-Vélez I, Marques de Almeida J, Marchetti M, Maertens J, Machado M, Kulasekararaj A, Hernández-Rivas JÁ, Gomes da Silva M, Fernández N, Espigado I, Dragoña L, Dragonetti G, Metafuni E, Calbacho M, Blennow O, Wolf D, van Anrooij B, Nunes Rodrigues R, Nordlander A, Martín-González JA, Liévin R,

Jiménez M, Gräfe SK, García-Sanz R, Córdoba R, Rahimli L, van Meerten T, Cornely OA, Pagano L. Blood Adv. 2023 Jun 13;7(11):2645-2655. doi: 10.1182/bloodadvances.2022009578. PMID: 37058479

[One year safety and immunogenicity of AZD1222 \(ChAdOx1 nCoV-19\): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.](#)

Ishikawa K, Nascimento MC, Asano M, Hirata H, Itoh Y, Kelly EJ, Matsui A, Olsson U, Shoemaker K, Green J. Vaccine. 2023 Jun 2:S0264-410X(23)00542-X. doi: 10.1016/j.vaccine.2023.05.015. Online ahead of print. PMID: 37271703

[Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China.](#)

Tang S, Wang X, Tang B, He S, Yan D, Huang C, Shao Y, Xiao Y, Cheke RA. BMC Public Health. 2023 Jun 6;23(1):1084. doi: 10.1186/s12889-023-16009-8. PMID: 37280554

[A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.](#)

Brown AC, Koshute PT, Cowley HP, Robinette MS, Gravelyn SR, Patel SV, Ju EY, Frommer CT, Zambidis AE, Schneider EJ, Zhao MY, Mugo BK, Clarke W, Kruczynski K, Pisanic N, Heaney C, Colella TA. Microbiol Spectr. 2023 Jun 8:e0276522. doi: 10.1128/spectrum.02765-22. Online ahead of print. PMID: 37289070

[Impact of coronavirus disease 2019 \(COVID-19\) vaccination on menstrual bleeding quantity: An observational cohort study.](#)

Darney BG, Boniface ER, Van Lamsweerde A, Han L, Matteson KA, Cameron S, Male V, Acuna J, Benhar E, Pearson JT, Edelman A. BJOG. 2023 Jun;130(7):803-812. doi: 10.1111/1471-0528.17471. Epub 2023 Apr 10. PMID: 37035899

[Assessment of immunoglobulin G \(spike and nucleocapsid protein\) response to COVID-19 vaccination in Palestine.](#)

Asmar I, Almahmoud O, Yaseen K, Jamal J, Omar A, Naseef H, Hasan S. Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101330. doi: 10.1016/j.cegh.2023.101330. Epub 2023 Jun 3. PMID: 37293133

[Facial Dermal Filler Injection and Vaccination: A 12-Year Review of Adverse Event Reporting and Literature Review.](#)

Sun AH, Tiongco RFP, Manahan MA. Aesthet Surg J. 2023 Jun 14;43(7):NP544-NP557. doi: 10.1093/asj/sjad031. PMID: 36788718

[Aortic thrombosis and acute limb ischemia after ChAdOx1 nCov-19 \(Oxford-AstraZeneca\) vaccination: a case of vaccine-induced thrombocytopenia and thrombosis \(VITT\).](#)

Vierstraete M, Sabbe T. Acta Chir Belg. 2023 Jun;123(3):329-332. doi: 10.1080/00015458.2021.2017600. Epub 2021 Dec 27. PMID: 34890294

[Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?](#)

Haji A, Alkattan A, Mahmoud N, Elkagam E, Hassanein M, Alfaifi A, Al-Tawfiq JA, Alabdulkareem K, Jokhdar H, Radwan N. IJID Reg. 2023 Jun;7:159-163. doi: 10.1016/j.ijregi.2023.03.003. Epub 2023 Mar 11. PMID: 37025346

[Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings.](#)

Islam MR, Haque MA, Ahamed B, Tanbir M, Khan MR, Eqbal S, Rahman MA, Shahriar M, Bhuiyan MA. PLoS One. 2023 Jun 8;18(6):e0286322. doi: 10.1371/journal.pone.0286322. eCollection 2023. PMID: 37289746

[Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction.](#)

Malik JA, Agrewala JN. Int Immunopharmacol. 2023 Jun;119:110210. doi: 10.1016/j.intimp.2023.110210. Epub 2023 Apr 24. PMID: 37099943

[Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis.](#)

Breu M, Lechner C, Schneider L, Tobudic S, Winkler S, Siegert S, Baumann M, Seidl R, Berger T, Kornek B. Pediatr Neurol. 2023 Jun;143:19-25. doi: 10.1016/j.pediatrneurol.2023.02.017. Epub 2023 Mar 2. PMID: 36966598

[Cerebral Venous Sinus Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia in Middle-Income Countries.](#)

van de Munckhof A, Borhani-Haghighi A, Aaron S, Krzywicka K, Sanchez van Kammen M, Cordonnier C, Kleinig T, Field TS, Poli S, Lemmens R, Scutelnic A, Lindgren E, Duan J, Arslan Y, van Gorp ECM, Hovinga JAK, Guenther A, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, Aguiar de Sousa D, Wasay M, Arauz-Góngora A, Conforto A, Ferro JM, Coutinho JM. Int J Stroke. 2023 Jun 5:17474930231182901. doi: 10.1177/17474930231182901. Online ahead of print. PMID: 37277922

[Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.](#)

Rosenthal JA, Papa MP, Sanz M, Nicholes S, Holmberg CS, Bosque A, Keswani A, Amdur R, Lynch RM, Soriano-Sarabia N, Ein D. Ann Allergy Asthma Immunol. 2023 Jun;130(6):743-751.e3. doi: 10.1016/j.anai.2023.01.025. Epub 2023 Feb 2. PMID: 36736722

[Translocator protein \(TSPO\)-PET as diagnostic and monitoring tool in COVID-19 related MRI-negative brainstem encephalitis: a case report.](#)

Wischmann J, Bartos LM, Brendel M, Albert NL, Forbrig R, Straube A, Masouris I. J Neurol. 2023 Jun;270(6):2853-2856. doi: 10.1007/s00415-023-11691-5. Epub 2023 Apr 3. PMID: 37012466

[Cogan's sign in a patient with suspected post-COVID-19 vaccine-associated myasthenia gravis.](#)

Tavares-Júnior JW, Sobreira-Neto MA, Braga-Neto P. Rev Soc Bras Med Trop. 2023 Jun 2;56:e0007. doi: 10.1590/0037-8682-0007-2023. eCollection 2023. PMID: 37283341

[The Rise of SARS-CoV-2 \(COVID-19\) Omicron Subvariant Pathogenicity.](#)

DeGrasse DC, Black SD. Cureus. 2023 Jun 8;15(6):e40148. doi: 10.7759/cureus.40148. eCollection 2023 Jun. PMID: 37313287

[Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.](#)

Woo EJ, Gee J, Marquez P, Baggs J, Abara WE, McNeil MM, Dimova RB, Su JR. Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.06.023. Online ahead of print. PMID: 37321898

[Myopericarditis Associated with the Novavax COVID-19 Vaccine \(NVX-CoV2373\): A Retrospective Analysis of Individual Case Safety Reports from VigiBase.](#)

Macías Saint-Gerons D, Ibarz MT, Castro JL, Forés-Martos J, Tabarés-Seisdedos R. *Drugs Real World Outcomes*. 2023 Jun;10(2):263-270. doi: 10.1007/s40801-023-00355-5. Epub 2023 Feb 14. PMID: 36788170

[Impact of the COVID-19 pandemic on antimicrobial stewardship support for general practices in England: a qualitative interview study.](#)

Campbell A, Borek AJ, McLeod M, Tonkin-Crine S, Pouwels KB, Roope L, Hayhoe BW, Majeed A, Walker AS, Holmes A; STEP-UP team. *BJGP Open*. 2023 Jun 8:BJGPO.2022.0193. doi: 10.3399/BJGPO.2022.0193. Online ahead of print. PMID: 37290780

[Impact of maternal SARS-CoV-2 booster vaccination on blood and breastmilk antibodies.](#)

Rick AM, Lentscher A, Xu L, Wilkins MS, Nasser A, Tuttle DJ, Megli C, Marques ETA, McElroy AK, Williams JV, Martin JM. *PLoS One*. 2023 Jun 13;18(6):e0287103. doi: 10.1371/journal.pone.0287103. eCollection 2023. PMID: 37310982

[Public Libraries for Public Health: COVID-19 Response Efforts in Prince George's County, Maryland.](#)

Acosta D, Brown NA, Zukowski R, Mann E, Dawson-Hahn E. *Am J Public Health*. 2023 Jun;113(6):623-626. doi: 10.2105/AJPH.2023.307246. Epub 2023 Mar 9. PMID: 36893364

[Incidence of ventricular arrhythmias related to COVID infection and vaccination in patients with Brugada syndrome: Insights from a large Italian multicenter registry based on continuous rhythm monitoring.](#)

Casella M, Conti S, Compagnucci P, Ribatti V, Narducci ML, Marcon L, Massara F, Valeri Y, De Francesco L, Martino AM, Ghiglieno C, Schiavone M, Balla C, Dell'Era G, Pelargonio G, Forleo GB, Iacopino S, Sgarito G, Calò L, Tondo C, Russo AD, Patti G. *J Cardiovasc Electrophysiol*. 2023 Jun;34(6):1386-1394. doi: 10.1111/jce.15929. Epub 2023 May 17. PMID: 37194742

[Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.](#)

Goddard K, Donahue JG, Lewis N, Hanson KE, Weintraub ES, Fireman B, Klein NP. *Pediatrics*. 2023 Jun 6:e2023061894. doi: 10.1542/peds.2023-061894. Online ahead of print. PMID: 37278199

["We're kind of on the back burner": Psychological distress and coping among medical social workers during the COVID-19 pandemic.](#)

Lewinson TD, Washington TR, Allen SE, Murphey JM, Onsando WM. *Soc Work Health Care*. 2023 Jun 12:1-20. doi: 10.1080/00981389.2023.2221718. Online ahead of print. PMID: 37303230

[Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.](#)

Lehmann HC, Oberle D, Keller-Stanislawski B, Rieck T, Streit R. *Euro Surveill*. 2023 Jun;28(24). doi: 10.2807/1560-7917.ES.2023.28.24.2200744. PMID: 37318764

[COVID-19 BNT162b2 mRNA vaccine induced myocarditis with left ventricular thrombus in a young male.](#)

Yeni M. *Acta Cardiol*. 2023 Jun;78(4):483-485. doi: 10.1080/00015385.2023.2165271. Epub 2023 Jan 23. PMID: 36688840

[Autoimmunity-related neutrophilic dermatosis after coronavirus disease 2019 vaccination: A case report and literature review.](#)

Kishibe M, Koike K, Kanno K, Ishida-Yamamoto A. *J Dermatol.* 2023 Jun;50(6):820-823. doi: 10.1111/1346-8138.16718. Epub 2023 Jan 5. PMID: 36606292

[Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.](#)

Tang Q, Li F, Tian J, Kang J, He J. *Clin Exp Med.* 2023 Jun;23(2):457-463. doi: 10.1007/s10238-022-00832-1. Epub 2022 May 25. PMID: 35612692

[Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.](#)

Makanut S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, Pongcharoen S. *Vaccine.* 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.06.017. Online ahead of print. PMID: 37301707

[A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients.](#)

Naveed Z, Li J, Naus M, Velásquez García HA, Wilton J, Janjua NZ; Canadian Immunization Research Network Provincial Collaborative Network investigators. *Int J Infect Dis.* 2023 Jun;131:75-78. doi: 10.1016/j.ijid.2023.03.027. Epub 2023 Mar 24. PMID: 36967038

[Cases of acquired hemophilia A following COVID-19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy.](#)

Roberto G, Paoletti O, Ferraro S, Hyeraci G, Franchini M, Gini R, Focosi D, Tuccori M. *Pharmacoepidemiol Drug Saf.* 2023 Jun;32(6):694-699. doi: 10.1002/pds.5615. Epub 2023 Mar 27. PMID: 36930740

[COVID-19 Vaccine Tolerability in a Patient With a Delayed Allergic Reaction to Polyethylene Glycol: A Case Report.](#)

Loli-Ausejo D, Gómez-Armayones S, Sáez-Peñataro J, González-Matamala MF, Mascaró B, Muñoz-Cano R, Bartra J. *J Investig Allergol Clin Immunol.* 2023 Jun 15;33(3):232-233. doi: 10.18176/jiaci.0843. Epub 2022 Jul 14. PMID: 35833860

[Genomic surveillance of severe acute respiratory syndrome coronavirus 2 in Burundi, from May 2021 to January 2022.](#)

Nduwimana C, Nzoyikorera N, Ndiokubwayo A, Ihorimbere T, Nibogora C, Ndoreroaho A, Hajayandi O, Bizimana JC, Diawara I, Niyonizigiye D, Nyandwi J. *BMC Genomics.* 2023 Jun 10;24(1):312. doi: 10.1186/s12864-023-09420-3. PMID: 37301830

[Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.](#)

Maurya R, Shamim U, Mishra P, Swaminathan A, Raina A, Tarai B, Budhiraja S, Pandey R. *Microbiol Spectr.* 2023 Jun 15;11(3):e0429222. doi: 10.1128/spectrum.04292-22. Epub 2023 Apr 6. PMID: 37022180

["It kinda has like a mind": Children's and parents' beliefs concerning viral disease transmission for COVID-19 and the common cold.](#)

Labotka D, Gelman SA. Cognition. 2023 Jun;235:105413. doi: 10.1016/j.cognition.2023.105413. Epub 2023 Feb 21. PMID: 36842249

[Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.](#)

Ou BS, Saouaf OM, Yan J, Bruun TUJ, Baillet J, Zhou X, King NP, Appel EA. Adv Healthc Mater. 2023 Jun 6:e2301495. doi: 10.1002/adhm.202301495. Online ahead of print. PMID: 37278391

[Severe Hepatitis-associated Aplastic Anemia Following COVID-19 mRNA Vaccination.](#)

Yamamoto M, Keino D, Sumii S, Yokosuka T, Goto H, Inui A, Sogo T, Kawakami M, Tanaka M, Yanagimachi M. Intern Med. 2023 Jun 15;62(12):1813-1816. doi: 10.2169/internalmedicine.1308-22. Epub 2023 Mar 22. PMID: 36948624

[Public sector's misinformation debunking during the public health campaign: a case of Hong Kong.](#)

Zhu R, Zhang X. Health Promot Int. 2023 Jun 1;38(3):daad053. doi: 10.1093/heapro/daad053. PMID: 37279470

[RE: "RISK AND BENEFIT OF mRNA COVID-19 VACCINES FOR THE OMICRON VARIANT BY AGE, SEX, AND PRESENCE OF COMORBIDITY: A QUALITY-ADJUSTED LIFE YEARS ANALYSIS".](#)

Kleebayoon A, Wiwanitkit V. Am J Epidemiol. 2023 Jun 2;192(6):1031. doi: 10.1093/aje/kwad069. PMID: 36958820

[Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.](#)

Bordalo Ferreira F, Rafael MA, Coimbra L, Boavida N, Arrobas F, Pereira Correia F, Martins Figueiredo L, Carvalho E Branco J, Carvalho Lourenço L, Santos L, Oliveira AM. Vaccine. 2023 Jun 13;41(26):3862-3871. doi: 10.1016/j.vaccine.2023.05.012. Epub 2023 May 8. PMID: 37202269

[Risk factors for reduction in adherence to protective measures following coronavirus disease 2019 \(COVID-19\) vaccination and vaccine perceptions among healthcare workers, in São Paulo, Brazil.](#)

Mello López A, Borges IC, Luna-Muschi A, Mesquita Peres CH, Carreño PG, de Oliveira AM, de Almeida HBS, de Castro Marques VH, Corchs F, Levin AS, Costa SF, Sartori AMC. Infect Control Hosp Epidemiol. 2023 Jun;44(6):1019-1021. doi: 10.1017/ice.2022.142. Epub 2022 May 26. PMID: 35615951

[Myositis unrelated to the inoculation site after COVID-19 vaccination: a case report.](#)

Han JW, Oh JM, Lee DH, Jeon YD. Clin Shoulder Elb. 2023 Jun;26(2):208-211. doi: 10.5397/cise.2022.00983. Epub 2022 Nov 11. PMID: 37088882

[Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.](#)

Iwamura N, Eguchi K, Koga T, Tsutsumi K, Araki T, Aramaki T, Takatani A, Terada K, Ueki Y. Immunol Med. 2023 Jun;46(2):97-107. doi: 10.1080/25785826.2023.2193286. Epub 2023 Mar 23. PMID: 36950829

[Heterologous versus homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real-life, multicenter, case-control study.](#)

Mercuri SR, Pacifico A, Malagoli P, Bianchi VG, Pregliasco FE, Del Fabbro M, Damiani G. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e693-e694. doi: 10.1111/jdv.18943. Epub 2023 Feb 15. PMID: 36734591

[Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron \(B.1.1.529\) variant predominance.](#)

O'Leary AL, Wattengel BA, Carter MT, Drye AF, Mergenhagen KA. Am J Infect Control. 2023 Jun;51(6):603-606. doi: 10.1016/j.ajic.2022.08.033. Epub 2022 Sep 6. PMID: 36075298

[Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults.](#)

Dedroogh S, Schmiedl S, Thürmann PA, Graf K, Appelbaum S, Koß R, Theis C, Zia Z, Tebbenjohanns J, Thal SC, Dedroogh M. Sci Rep. 2023 Jun 3;13(1):9036. doi: 10.1038/s41598-023-34961-8. PMID: 37270632

[Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster.](#)

Lloren KKS, Jawalagatti V, Hewawaduge C, Chandran S, Park JY, Lee JH. Microbes Infect. 2023 Jun;25(5):105101. doi: 10.1016/j.micinf.2023.105101. Epub 2023 Jan 16. PMID: 36657635

[High-Throughput SARS-CoV-2 Antiviral Testing Method Using the Celigo Image Cytometer.](#)

St Clair LA, Chan LL, Boretsky A, Lin B, Spedding M, Perera R. J Fluoresc. 2023 Jun 13. doi: 10.1007/s10895-023-03289-x. Online ahead of print. PMID: 37310590

[Testing persuasive messages about booster doses of COVID-19 vaccines on intention to vaccinate in Australian adults: A randomised controlled trial.](#)

Steffens MS, Bullivant B, Kaufman J, King C, Danchin M, Hoq M, Marques MD. PLoS One. 2023 Jun 2;18(6):e0286799. doi: 10.1371/journal.pone.0286799. eCollection 2023. PMID: 37267399

[Real time monitoring of COVID-19 intervention effectiveness through contact tracing data.](#)

Gibson GC, Woody S, James E, Weldon M, Fox SJ, Meyers LA, Bhavnani D. Sci Rep. 2023 Jun 9;13(1):9371. doi: 10.1038/s41598-023-35892-0. PMID: 37296143

[The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia.](#)

Kovačić B, Pavičić M, Skvrce NM, Tomić S. Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1. PMID: 37307371

[Impact of vaccination against the novel coronavirus infection \(COVID-19\) with Sputnik V on mortality during the delta variant surge.](#)

Dmitrieva K, Maslennikov R, Vasilieva E, Aliev S, Bakhitov V, Marcinkevich V, Levshina A, Kozlov E, Ivashkin V, Poluektova E. J Infect Public Health. 2023 Jun;16(6):922-927. doi: 10.1016/j.jiph.2023.04.008. Epub 2023 Apr 13. PMID: 37086551

[Willingness of Older Adults From Culturally Diverse Populations to Participate in COVID-19 Related Treatment Trials and Associated Factors.](#)

Brown EL, Paul-Ward A, Felber Neff D, Webb FJ, Vieira ER, Gaillard T. Gerontol Geriatr Med. 2023 Jun 9;9:23337214231179826. doi: 10.1177/23337214231179826. eCollection 2023 Jan-Dec. PMID: 37324645

[Late onset granulomatous interstitial nephritis after booster dose of COVID-19 vaccination: Case report and review of literature.](#)

Ghanekar K, Ghanekar H, Saxena R. Clin Nephrol. 2023 Jun;99(6):299-306. doi: 10.5414/CN110965. PMID: 36999525

[Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration.](#)

Zhang C, Berg A, Joe CCD, Dalby PA, Douglas AD. NPJ Vaccines. 2023 Jun 5;8(1):85. doi: 10.1038/s41541-023-00674-2. PMID: 37277337

[Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations.](#)

Ahmed El-Arabey A, Abdalla M, Rashad Abd-Allah A, Marenga HS, Modafar Y, Aloufi AS. Saudi J Biol Sci. 2023 Jul;30(7):103699. doi: 10.1016/j.sjbs.2023.103699. Epub 2023 Jun 3. PMID: 37292255

[Development of Dermatomyositis after Pfizer BioNTech COVID-19 Vaccine: A Case Report.](#)

Aouintia I, Daly W, Lakhoua G, Kaabi W, Charfi O, Debbeche S, Kastalli S, Zaiem A, El Aidli S. Curr Drug Saf. 2023 Jun 14. doi: 10.2174/1574886318666230614164607. Online ahead of print. PMID: 37317919

[Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned.](#)

Bank TC, Stika CS, Venkataramanan R, Field C, Costantine MM. J Clin Pharmacol. 2023 Jun;63 Suppl 1:S117-S125. doi: 10.1002/jcph.2226. PMID: 37317490

[Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.](#)

Kaur U, Fatima Z, Maheshwari K, Sahni V, Dehade A, KI A, Yadav AK, Kansal S, Jaisawal V, Chakrabarti SS. Drug Saf. 2023 Jun;46(6):553-563. doi: 10.1007/s40264-023-01301-8. Epub 2023 May 3. PMID: 37133805

[Vaccine-induced protection against SARS-CoV-2 requires IFN- \$\gamma\$ -driven cellular immune response.](#)

Wang X, Yuen TT, Dou Y, Hu J, Li R, Zeng Z, Lin X, Gong H, Chan CH, Yoon C, Shuai H, Ho DT, Hung IF, Zhang BZ, Chu H, Huang JD. Nat Commun. 2023 Jun 10;14(1):3440. doi: 10.1038/s41467-023-39096-y. PMID: 37301910

[The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.](#)

Brzuska G, Zimna M, Baranska K, Szewczyk B, Strakova P, Ruzek D, Krol E. Microbiol Spectr. 2023 Jun 15;11(3):e0256422. doi: 10.1128/spectrum.02564-22. Epub 2023 May 18. PMID: 37199661

[A sting in the tail-are antibodies against the C-terminus of Plasmodium falciparum circumsporozoite protein protective?](#)

Murdoch J, Baum J. EMBO Mol Med. 2023 Jun 7;15(6):e17556. doi: 10.15252/emmm.202317556. Epub 2023 Apr 21. PMID: 37082835

[A randomized controlled trial of an information intervention to bolster COVID-19 vaccination intention among people with purity concerns.](#)

Chen C, Cui Z, Chen Y. Health Psychol. 2023 Jun 1. doi: 10.1037/hea0001295. Online ahead of print. PMID: 37261752

[New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report.](#)

Fekih-Romdhane F, Ghrissi F, Hallit S, Cheour M. BMC Psychiatry. 2023 Jun 12;23(1):419. doi: 10.1186/s12888-023-04924-4. PMID: 37308940

[Immune priming with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission.](#)

Ye C, Park JG, Chiem K, Dravid P, Allué-Guardia A, Garcia-Vilanova A, Pino Tamayo P, Shivanna V, Kapoor A, Walter MR, Kobie JJ, Plemper RK, Torrelles JB, Martinez-Sobrido L. Microbiol Spectr. 2023 Jun 15;11(3):e0065323. doi: 10.1128/spectrum.00653-23. Epub 2023 May 16. PMID: 37191507

[Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave.](#)

Wee LE, Pang D, Chiew C, Tan J, Lee V, Ong B, Lye DC, Tan KB. Clin Infect Dis. 2023 Jun 6:ciad345. doi: 10.1093/cid/ciad345. Online ahead of print. PMID: 37280047

[Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment.](#)

Böger S, van Bergen I, Beaudart C, Cheung KL, Hilgsmann M. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun 14:1-11. doi: 10.1080/14737167.2023.2223983. Online ahead of print. PMID: 37294709

[Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study.](#)

Andreica I, Roman I, Redeker I, Baraliakos X, Braun J, Kiltz U. RMD Open. 2023 Jun;9(2):e002875. doi: 10.1136/rmdopen-2022-002875. PMID: 37295840

[The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study.](#)

Howe S, Szanyi J, Blakely T. Int J Epidemiol. 2023 Jun 6;52(3):677-689. doi: 10.1093/ije/dyad033. PMID: 37011639

[Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study.](#)

Aydin MA, Janapatla RP, Chen CL, Li HC, Su LH, Chiu CH. J Microbiol Immunol Infect. 2023 Jun;56(3):598-604. doi: 10.1016/j.jmii.2023.01.013. Epub 2023 Feb 2. PMID: 36774315

[Correspondence on "Effect of female COVID-19 vaccination on assisted reproductive outcomes: a systematic review and meta-analysis".](#)

Kleebayoon A, Wiwanitkit V. Fertil Steril. 2023 Jun;119(6):1087. doi: 10.1016/j.fertnstert.2023.02.017. Epub 2023 Feb 17. PMID: 36805043

[Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination.](#)

Whelan MG, Santacroce L, Masto L, Qian G, Kowalski E, Vanni K, Kanjilal S, Weinblatt ME, Sparks JA, Tedeschi SK. Clin Rheumatol. 2023 Jun;42(6):1695-1700. doi: 10.1007/s10067-023-06512-z. Epub 2023 Jan 19. PMID: 36656454

[Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.](#)

Kashiwado Y, Kimoto Y, Ohshima S, Sawabe T, Irino K, Nakano S, Hiura J, Yonekawa A, Wang Q, Doi G, Ayano M, Mitoma H, Ono N, Arinobu Y, Niuro H, Hotta T, Kang D, Shimono N, Akashi K, Takeuchi T, Horiuchi T. Rheumatology (Oxford). 2023 Jun 8:kead275. doi: 10.1093/rheumatology/kead275. Online ahead of print. PMID: 37289506

[Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.](#)

Shaw RH, Greenland M, Stuart ASV, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Libri V, Lillie PJ, Morey E, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screamon GR, Singh N, Turner DPJ, Turner PJ, White R, Nguyen-Van-Tam JS, Liu X, Snape MD; Com-COV2 Study Group. J Infect. 2023 Jun;86(6):574-583. doi: 10.1016/j.jinf.2023.03.027. Epub 2023 Apr 6. PMID: 37028454

[Clinical trial facilitators: A novel approach to support the execution of clinical research at the study site level.](#)

McClure J, Asghar A, Krajec A, Johnson MR, Subramanian S, Caroff K, McBurney C, Perusich S, Garcia A, Beck DJ, Huang GD. Contemp Clin Trials Commun. 2023 Jun;33:101106. doi: 10.1016/j.conctc.2023.101106. Epub 2023 Mar 21. PMID: 37063166

[IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose.](#)

Bochnia-Bueno L, Ferreira LH, Genelhoud G, Nogueira MB, Raboni SM. Braz J Microbiol. 2023 Jun;54(2):921-927. doi: 10.1007/s42770-023-00935-1. Epub 2023 Mar 2. PMID: 36862369

[Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.](#)

Caixeta DA, do Carmo MAV, da Fonseca FG, Nogueira DA, Coelho LFL, Malaquias LCC. Braz J Microbiol. 2023 Jun;54(2):859-871. doi: 10.1007/s42770-023-00966-8. Epub 2023 Apr 13. PMID: 37052752

[Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.](#)

Milevoj Kopicinovic L, Unic A, Nikolac Gabaj N, Miler M, Vrtaric A, Bozovic M, Stefanovic M. Lab Med. 2023 Jun 9:lmad044. doi: 10.1093/labmed/lmad044. Online ahead of print. PMID: 37294928

[From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.](#)

Pelletier C, Labbé F, Bettinger JA, Curran J, Graham JE, Greyson D, MacDonald NE, Meyer SB, Steenbeek A, Xu W, Dubé É. Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.06.002. Online ahead of print. PMID: 37302965

[Time of day for COVID vaccine administration linked to clinical effectiveness.](#)

Rasmussen-Torvik LJ. J Clin Invest. 2023 Jun 1;133(11):e168233. doi: 10.1172/JC1168233. PMID: 37259919

[Perceived high risk of COVID-19 vaccination: The revealing power of placebo.](#)

Beyens M, Toscano A, Van Damme P, Dogné JM, Ebo DG, Sabato V. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1954-1956. doi: 10.1016/j.jaip.2023.03.031. Epub 2023 Mar 24. PMID: 36965707

[Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology.](#)

Kihara K, Kinoshita M, Sugimoto T, Okazaki S, Murata H, Beppu S, Shiraishi N, Sugiyama Y, Koda T, Okuno T, Mochizuki H. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):495-497. doi: 10.1136/jnnp-2022-330478. Epub 2023 Jan 3. PMID: 36596701

[High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.](#)

Groenheit R, Bacchus P, Galanis I, Sondén K, Bujila I, Efimova T, Garli F, Lindsjö OK, Mansjö M, Moverit E, Pettke A, Rapp M, Sperk M, Söderholm S, Asin KV, Zanetti S, Karlberg ML, Bråve A, Blom K, Klingström J. Emerg Infect Dis. 2023 Jun;29(6):1240-1243. doi: 10.3201/eid2906.221862. Epub 2023 May 4. PMID: 37141616

[Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination.](#)

Shen CF, Fu YC, Ho TS, Chen PL, Lee NY, Tsai BY, Tsai PJ, Ko WC, Liu CC, Cheng CM, Shieh CC. Clin Immunol. 2023 Jun;251:109342. doi: 10.1016/j.clim.2023.109342. Epub 2023 Apr 24. PMID: 37100338

[In response to Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.](#)

Cosentino M, Marino F. J Perinatol. 2023 Jun;43(6):827. doi: 10.1038/s41372-023-01669-6. Epub 2023 Apr 25. PMID: 37185365

[Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA.](#)

Graso M, Aquino K, Chen FX, Bardosh K. J Med Ethics. 2023 Jun 9;jme-2022-108825. doi: 10.1136/jme-2022-108825. Online ahead of print. PMID: 37295936

[Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study.](#)

Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahon-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM. BMJ Med. 2023 Jun 6;2(1):e000421. doi: 10.1136/bmjmed-2022-000421. eCollection 2023. PMID: 37303490

[Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.](#)

Mambelli F, Marinho FV, Andrade JM, de Araujo ACVSC, Abuna RPF, Fabri VMR, Santos BPO, da Silva JS, de Magalhães MTQ, Homan EJ, Leite LCC, Dias GBM, Heck N, Mendes DAGB, Mansur DS, Báfica A,

Oliveira SC. J Immunol. 2023 Jun 15;210(12):1925-1937. doi: 10.4049/jimmunol.2200731. PMID: 37098890

[Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan.](#)

Hosogaya N, Takazono T, Kurazono K, Hiroi S, Iwasaki K, Takeshima T, Ha C, Mukae H. Adv Ther. 2023 Jun 12. doi: 10.1007/s12325-023-02564-4. Online ahead of print. PMID: 37303032

[Comparison of Clinical Characteristics of Children Infected With Coronavirus Disease 2019 Between Omicron Variant BA.5 and BA.1/BA.2 in Japan.](#)

Ikuse T, Aizawa Y, Yamanaka T, Hasegawa S, Hayashi T, Kon M, Tamura T, Saitoh A. Pediatr Infect Dis J. 2023 Jun 1;42(6):503-509. doi: 10.1097/INF.0000000000003894. Epub 2023 Mar 2. PMID: 36916865

[High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity.](#)

Nuñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa-Pereira S, Ingelfinger F; InmunoCovidCba; InViV working group; Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-Vesga J, Mundt S, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B. Nat Immunol. 2023 Jun;24(6):941-954. doi: 10.1038/s41590-023-01499-w. Epub 2023 Apr 24. PMID: 37095378

[Pathways to Immunity: Patterns of Excess Death Across the United States and Within Closed Religious Communities.](#)

Stein RE, Colyer CJ, Corcoran KE, Mackay AM. J Relig Health. 2023 Jun 1:1-16. doi: 10.1007/s10943-023-01838-z. Online ahead of print. PMID: 37261578

[On a collision course: SARS-CoV-2 variants and CAR T cells.](#)

Auletta JJ. Blood Adv. 2023 Jun 13;7(11):2643-2644. doi: 10.1182/bloodadvances.2023010371. PMID: 37310762

[Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.](#)

Bea S, Choi A, Kim JH, Cho YM, Choi WS, Jung J, Shin JY. Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15163. Online ahead of print. PMID: 37312652

[Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.](#)

Amdany H, Koech B. JBI Evid Implement. 2023 Jun 1;21(2):146-155. doi: 10.1097/XEB.0000000000000362. PMID: 36545897

[RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication.](#)

Ong EZ, Koh CWT, Tng DJH, Ooi JSG, Yee JX, Chew VSY, Leong YS, Gunasegaran K, Yeo CP, Oon LLE, Sim JXY, Chan KR, Low JG, Ooi EE. Med. 2023 Jun 9;4(6):353-360.e2. doi: 10.1016/j.medj.2023.04.001. Epub 2023 Apr 26. PMID: 37105176

[Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.](#)

Nakahara H, Cheedarla N, Verkerke HP, Cheedarla S, Wu SC, Hendrickson JE, Chang A, McLemore ML, El Rassi F, Roback JD, Neish AS, Fasano RM, Stowell SR. Br J Haematol. 2023 Jun 7. doi: 10.1111/bjh.18899. Online ahead of print. PMID: 37287128

[Editorial response to Cosentino and Marino RE: detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.](#)

Stafford LS, Valcarce V, Henry M, Neu J, Parker L, Mueller M, Vicuna V, Gowen T, Cato E, Kosik I, Yewdell JW, Atkinson M, Cacho N, Li N, Larkin J 3rd. J Perinatol. 2023 Jun;43(6):828-829. doi: 10.1038/s41372-023-01660-1. Epub 2023 Apr 6. PMID: 37024528

[Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.](#)

Filippatos F, Tatsi EB, Papagiannopoulos C, Syriopoulou V, Michos A. J Virol Methods. 2023 Jun;316:114728. doi: 10.1016/j.jviromet.2023.114728. Epub 2023 Apr 5. PMID:

[Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial \(LF-COVID\).](#)

Navarro R, Paredes JL, Tuco L, Medina C, Angles-Yanqui E, Nario JC, Ruiz-Cabrejos J, Quintana JL, Turpo-Espinoza K, Mejia-Cordero F, Aphan-Lam M, Florez J, Carrasco-Escobar G, Ochoa TJ. Biometals. 2023 Jun;36(3):463-472. doi: 10.1007/s10534-022-00477-3. Epub 2022 Dec 7. PMID: 36474100

[Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022.](#)

Jones JM, Manrique IM, Stone MS, Grebe E, Saa P, Germanio CD, Spencer BR, Notari E, Bravo M, Lanteri MC, Green V, Briggs-Hagen M, Coughlin MM, Stramer SL, Opsomer J, Busch MP. MMWR Morb Mortal Wkly Rep. 2023 Jun 2;72(22):601-605. doi: 10.15585/mmwr.mm7222a3. PMID: 37262007

[Safety of COVID-19 vaccines: A comparison between adverse drug reactions among vaccines marketed in Europe.](#)

Pardo-Cabello AJ, Manzano-Gamero V, Luna JD. Eur J Intern Med. 2023 Jun;112:122-125. doi: 10.1016/j.ejim.2023.02.014. Epub 2023 Feb 13. PMID: 36792428

[Status of HBV birth dose vaccination in Africa: the impact of COVID-19 and Gavi support on policy development.](#)

Njuguna HN, Hiebert L, Gupta N, Ward JW. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):502-503. doi: 10.1016/S2468-1253(23)00071-7. Epub 2023 Mar 27. PMID: 36996854

[An equity-focused approach to improving access to COVID-19 vaccination using mobile health clinics.](#)

Mayfield CA, Priem JS, Inman M, Legare T, Snow J, Wallace E. Healthc (Amst). 2023 Jun;11(2):100690. doi: 10.1016/j.hjdsi.2023.100690. Epub 2023 Mar 23. PMID: 36996736

[Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis.](#)

Rafati A, Pasebani Y, Jameie M, Yang Y, Jameie M, Ilkhani S, Amanollahi M, Sakhaei D, Rahimlou M, Kheradmand A. JAMA Otolaryngol Head Neck Surg. 2023 Jun 1;149(6):493-504. doi: 10.1001/jamaoto.2023.0160. PMID: 37103913

[VITT two years later: should it still be in the scientific agenda?](#)

Petito E, Gresele P. *Thromb Haemost.* 2023 Jun 7. doi: 10.1055/a-2107-0891. Online ahead of print. PMID: 37285904

[A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.](#)

Xia M, López K, Vago FS, Huang P, Auguste DI, Jiang W, Auguste AJ, Tan M. *Biotechnol J.* 2023 Jun 10:e2300130. doi: 10.1002/biot.202300130. Online ahead of print. PMID: 37300425

[Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis.](#)

Morita I, Kurazono K, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Ha C, Igarashi A. *J Med Econ.* 2023 Jun 14:1-33. doi: 10.1080/13696998.2023.2224167. Online ahead of print. PMID: 37313724

[Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.](#)

Moon P, Zammit CM, Shao Q, Dovala D, Boike L, Henning NJ, Knapp M, Spradlin JN, Ward CC, Wolleb H, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD, Nomura DK. *Chembiochem.* 2023 Jun 1;24(11):e202300116. doi: 10.1002/cbic.202300116. Epub 2023 May 3. PMID: 37069799

[Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.](#)

Gumber L, Gomez N, Hopkins G, Tucis D, Bartlett L, Ayling K, Vedhara K, Steers G, Chakravorty M, Rutter M, Jackson H, Tighe P, Ferraro A, Power S, Pradère MJ, Onion D, Lanyon PC, Pearce FA, Fairclough L. *Rheumatology (Oxford).* 2023 Jun 1;62(6):2294-2303. doi: 10.1093/rheumatology/keac574. PMID: 36250898

[Severe acute respiratory coronavirus virus 2 \(SARS-CoV-2\) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 \(COVID-19\) vaccine series-13 US jurisdictions, July-November 2021.](#)

Wyatt Wilson W, Keaton AA, Ochoa LG, Hatfield KM, Gable P, Walblay KA, Teran RA, Shea M, Khan U, Stringer G, Colletti JG, Grogan EM, Calabrese C, Hennenfent A, Perlmutter R, Janiszewski KA, Kamal-Ahmed I, Strand K, Berns E, MacFarquhar J, Linder M, Tran DJ, Kopp P, Walker RM, Ess R, Read JS, Yingst C, Baggs J, Jernigan JA, Kallen A, Hunter JC; MOVIN Surveillance Team. *Infect Control Hosp Epidemiol.* 2023 Jun;44(6):1005-1009. doi: 10.1017/ice.2022.123. Epub 2023 Jan 16. PMID: 36645205

[Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines.](#)

Ekobena P, Rothuizen LE, Bedussi F, Guilcher P, Meylan S, Ceschi A, Girardin F, Dao K. *Int J Audiol.* 2023 Jun;62(6):587-591. doi: 10.1080/14992027.2022.2056721. Epub 2022 May 5. PMID: 35510657

[Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an *in-silico* study.](#)

Ahmad S, Pasha Km M, Raza K, Rafeeq MM, Habib AH, Eswaran M, Yadav MK. *J Biomol Struct Dyn.* 2023 Jun;41(9):4013-4023. doi: 10.1080/07391102.2022.2060308. Epub 2022 Apr 22. PMID: 35451934

[Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study.](#)

Deguchi H, Sakamoto A, Nakamura N, Okabe Y, Miura Y, Iida T, Yoshimura M, Haga N, Nabeshima S, Masutani K. Clin Exp Nephrol. 2023 Jun;27(6):574-582. doi: 10.1007/s10157-023-02334-0. Epub 2023 Mar 13. PMID: 36914824

[Subacute monomelic radiculoplexus neuropathy following Comirnaty® \(Pfizer-BioNTech COVID-19\) vaccination: A case report.](#)

Coly M, Balcerac A, Brasseur N, Sallansonnet-Froment M, Tafani C, Taifas I, Bréchemier ML, Drouard E, Foissaud V, Vest P, Vandendries C, Bompaire F, Bihan K, Ricard D. Rev Neurol (Paris). 2023 Jun;179(6):636-639. doi: 10.1016/j.neurol.2023.02.063. Epub 2023 Mar 14. PMID: 36925320

[The WHO pandemic treaty: where are we on our scepticism?](#)

Evaborhene NA, Oga JO, Nneli OV, Mburu S. BMJ Glob Health. 2023 Jun;8(6):e012636. doi: 10.1136/bmjgh-2023-012636. PMID: 37316254

[Postoperative mortality and complications in patients with and without pre-operative SARS-CoV-2 infection: a service evaluation of 24 million linked records using OpenSAFELY.](#)

McInerney CD, Kotzé A, Bacon S, Cutting JE, Fisher L, Goldacre B, Johnson OA, Kua J, McGuckin D, Mehrkar A; OpenSAFELY Collaborative; Moonesinghe SR. Anaesthesia. 2023 Jun;78(6):692-700. doi: 10.1111/anae.16001. Epub 2023 Mar 23. PMID: 36958018

[A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols.](#)

Shamsi Gamchi N, Esmaeili M. Eur J Health Econ. 2023 Jun;24(4):633-646. doi: 10.1007/s10198-022-01491-5. Epub 2022 Jul 28. PMID: 35900675

[High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey.](#)

Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Chinoy H, Cavagna L, Agarwal V, Aggarwal R, Gupta L; COVAD study group. Rheumatol Int. 2023 Jun 14. doi: 10.1007/s00296-023-05344-z. Online ahead of print. PMID: 37314497

[Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.](#)

Meador CB, Naranbhai V, Hambelton G, Rivera J, Nabel CS, Lewinsohn R, Sakhi M, Balazs AB, Iafrate AJ, Gainor JF. Clin Lung Cancer. 2023 Jun;24(4):353-359. doi: 10.1016/j.clcc.2023.01.007. Epub 2023 Jan 25. PMID: 36792425

[SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.](#)

Monin MB, Baier L, Berger M, Gorny JG, Zhou T, Mahn R, Sadeghlar F, Möhring C, van Bremen K, Boesecke C, Rockstroh J, Strassburg C, Eis-Hübinger AM, Gonzalez-Carmona MA. Gut. 2023 Jun;72(6):1227-1229. doi: 10.1136/gutjnl-2022-328169. Epub 2022 Jul 26. PMID: 35882561

[Invasive meningococcal disease in Norway in the two decades before the COVID-19 pandemic.](#)

Brynildsrud OB, Wattle SV, Alfsnes K, Caugant DA. Int J Infect Dis. 2023 Jun;131:130-139. doi: 10.1016/j.ijid.2023.04.005. Epub 2023 Apr 7. PMID: 37030654

[Myocarditis in Australian children following SARS-CoV-2 infection or COVID-19 vaccination: a retrospective case series.](#)

Walker P, Lai TC, Schrader S, Crawford N, Cheng DR. Med J Aust. 2023 Jun 5;218(10):482-483. doi: 10.5694/mja2.51922. Epub 2023 Apr 15. PMID: 37061225

[Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.](#)

Mok CKP, Chen C, Zhao S, Sun Y, Yiu K, Chan TO, Lai HL, Lai KC, Lau KM, Ling KC, Chan KKP, Ng SS, Ko FW, Peiris M, Hui DS. Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20. PMID: 37086735

[A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma.](#)

Suzuki T, Kusumoto S, Kamezaki Y, Hashimoto H, Nishitarumizu N, Nakanishi Y, Kato Y, Kawai A, Matsunaga N, Ebina T, Nakamura T, Marumo Y, Oiwa K, Kinoshita S, Narita T, Ito A, Inagaki A, Ri M, Komatsu H, Aritsu T, Iida S. Int J Hematol. 2023 Jun;117(6):900-909. doi: 10.1007/s12185-023-03550-w. Epub 2023 Feb 15. PMID: 36790667

[Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans.](#)

Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai L, Chang SE, Feng A, Dhingra S, Shah M, Lee AS, Chinthrajah S, Sindher SB, Mallajosyula V, Gao F, Sigal N, Kowli S, Gupta S, Pellegrini K, Tharp G, Maysel-Auslender S, Hamilton S, Aoued H, Hrusovsky K, Roskey M, Bosinger SE, Maecker HT, Boyd SD, Davis MM, Utz PJ, Suthar MS, Khatri P, Nadeau KC, Pulendran B. Nature. 2023 Jun;618(7964):E18. doi: 10.1038/s41586-023-05977-x. PMID: 37225997

[Intranasal administration of sodium nitroprusside augments antigen-specific mucosal and systemic antibody production in mice.](#)

Tada R, Yamazaki H, Nagai Y, Takeda Y, Ohshima A, Kunisawa J, Negishi Y. Int Immunopharmacol. 2023 Jun;119:110262. doi: 10.1016/j.intimp.2023.110262. Epub 2023 May 5. PMID: 37150015

[Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test \(sVNT\) 9 months after BNT162b2 primary vaccination.](#)

Pezzati L, Milazzo L, Carrozzo G, Kullmann C, Oreni L, Beltrami M, Caronni S, Lai A, Caberlotto L, Ottomano C, Antinori S, Ridolfo AL. J Infect Chemother. 2023 Jun;29(6):624-627. doi: 10.1016/j.jiac.2023.03.002. Epub 2023 Mar 11. PMID: 36914095

[Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.](#)

Aleissa MM, Little JS, Davey S, Saucier A, Zhou G, Gonzalez-Bocco IH, Crombie JL, Looka A, Baden LR, Issa NC, Hammond SP, Jacobson CA, Sherman AC. Transplant Cell Ther. 2023 Jun;29(6):398.e1-398.e5. doi: 10.1016/j.jtct.2023.03.005. Epub 2023 Mar 9. PMID: 36906276

[The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant SARS-CoV-2 infection under the age of 6 months: a prospective cohort study.](#)

Oz-Alcalay L, Elron E, Davidovich R, Chodick G, Osovsky M, Chen R, Ashkenazi-Hoffnung L. Clin Microbiol Infect. 2023 Jun;29(6):789-794. doi: 10.1016/j.cmi.2023.01.023. Epub 2023 Feb 4. PMID: 36739973

[Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.](#)

Bacova B, Kohutova Z, Zubata I, Gaherova L, Kucera P, Heizer T, Mikesova M, Karel T, Novak J. Clin Exp Med. 2023 Jun;23(2):371-379. doi: 10.1007/s10238-022-00809-0. Epub 2022 Mar 29. PMID: 35352210

[Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines \[Letter\].](#)

Ali A, Zafar SA, Zehra SS. J Blood Med. 2023 Jun 2;14:377-378. doi: 10.2147/JBM.S419849. eCollection 2023. PMID: 37288287

[Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease.](#)

Hong X, Pan H, Su Y, Hu Q, Sun Y, Liu H, Cheng X, Ye J, Shi H, Meng J, Zhou Z, Jia J, Liu T, Wang M, Chen X, Ma Y, Tang Z, Wang F, Zhang H, You Y, Zhu D, Chen L, Yang C, Teng J, Chi H. Rheumatology (Oxford). 2023 Jun 1;62(6):2262-2266. doi: 10.1093/rheumatology/keac620. PMID: 36282541

[Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD.](#)

Li D, Debbas P, Mujukian A, Cheng S, Braun J, McGovern DPB, Melmed GY; CORALE-IBD Study Group. Inflamm Bowel Dis. 2023 Jun 1;29(6):883-887. doi: 10.1093/ibd/izac174. PMID: 35998072

[Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 \(Tixagevimab/Cilgavimab\) Resistant Variants.](#)

Tuffy KM, Ahani B, Aksyuk AA, Avila M, Brady T, Kijak GH, Koh G, Levin MJ, Roe TL, Schuko N, Thissen J, Ustianowski A, Zhang T, Kelly EJ, Streicher K. J Infect Dis. 2023 Jun 6;jjad210. doi: 10.1093/infdis/jjad210. Online ahead of print. PMID: 37280116

[SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study.](#)

Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. Lancet Microbe. 2023 Jun;4(6):e409-e417. doi: 10.1016/S2666-5247(23)00005-8. Epub 2023 Apr 18. PMID: 37084751

[Lower frequency of SARS-CoV-2-associated severe respiratory infections among adults vaccinated against the 2021/22 season influenza.](#)

Domnich A, Milano G, Capitani E, Camarri A, Bova G, Capecchi PL, Montomoli E, Manini I. Respir Med Res. 2023 Jun;83:100979. doi: 10.1016/j.resmer.2022.100979. Epub 2022 Nov 25. PMID: 36565562

[The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies.](#)

Monge S, Pastor-Barriuso R, Hernán MA. BMJ. 2023 Jun 7;381:e074404. doi: 10.1136/bmj-2022-074404. PMID: 37286211

[Diagnosing SARS-CoV-2 vaccination-related rhabdomyolysis requires the exclusion of all differential causes.](#)

Finsterer J, Scorza FA. Pediatr Nephrol. 2023 Jun;38(6):1991-1992. doi: 10.1007/s00467-023-05890-5. Epub 2023 Jan 27. PMID: 36705756

[Sex-specific differences in immune response to SARS-CoV-2 vaccination vanish with age.](#)

Brigger D, Guntern P, Jonsdottir HR, Pennington LF, Weber B, Taddeo A, Zimmer G, Leborgne NGF, Benarafa C, Jardetzky TS, Eggel A. Allergy. 2023 Jun;78(6):1683-1686. doi: 10.1111/all.15652. Epub 2023 Jan 31. PMID: 36680391

[Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.](#)

Kelleni MT. Inflammopharmacology. 2023 Jun;31(3):1559-1560. doi: 10.1007/s10787-023-01180-6. Epub 2023 Mar 16. PMID: 36928633

[Promoting and Building Long-Term Care Health Research Networks: GeroCovid Observational and GeroCovid Vax Initiatives.](#)

GeroCovid Observational and GeroCovid Vax group. J Am Med Dir Assoc. 2023 Jun;24(6):926-927.e2. doi: 10.1016/j.jamda.2023.01.026. Epub 2023 Mar 3. PMID: 36878261

[Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.](#)

Yoshida M, Kobashi Y, Kawamura T, Shimazu Y, Nishikawa Y, Omata F, Saito H, Yamamoto C, Zhao T, Takita M, Ito N, Tatsuno K, Kaneko Y, Nakayama A, Kodama T, Wakui M, Takahashi K, Tsubokura M. Sci Rep. 2023 Jun 7;13(1):9264. doi: 10.1038/s41598-023-36429-1. PMID: 37286720

[Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination.](#)

Kim H, Ahn HS, Hwang N, Huh Y, Bu S, Seo KJ, Kwon SH, Lee HK, Kim JW, Yoon BK, Fang S. Sci Rep. 2023 Jun 1;13(1):8926. doi: 10.1038/s41598-023-36070-y. PMID: 37264110

[704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates.](#)

Colombani T, Haudebourg T, Pitard B. Mol Ther Nucleic Acids. 2023 May 4;32:743-757. doi: 10.1016/j.omtn.2023.04.029. eCollection 2023 Jun 13. PMID: 37251693

[Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.](#)

Di Girolamo L, Ferrara M, Trevisan G, Longo BM, Alice T, Burdino E, Alladio F, Fantino S, Di Perri G, Calcagno A, Bonora S. Virol J. 2023 Jun 13;20(1):123. doi: 10.1186/s12985-023-02086-z. PMID: 37312093

[Immunization with messenger RNA vaccines against COVID-19 in adolescents with a history of multisystem inflammatory syndrome: a case series.](#)

Curti T, Agrimbau Vázquez J, Yori S, Kantarovsky A, Torolla J, Di Santo M, Hammermüller E, Urrutia L, Parra A. Arch Argent Pediatr. 2023 Jun 1;121(3):e202202757. doi: 10.5546/aap.2022-02757.eng. Epub 2022 Oct 6. PMID: 36194695

[Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.](#)

Werbel WA, Karaba AH, Chiang TP, Massie AB, Brown DM, Watson N, Chahoud M, Thompson EA, Johnson AC, Avery RK, Cochran WV, Warren D, Liang T, Fribourg M, Huerta C, Samaha H, Klein SL, Bettinotti MP, Clarke WA, Sitaras I, Roupheal N, Cox AL, Bailey JR, Pekosz A, Tobian AAR, Durand CM,

Bridges ND, Larsen CP, Heeger PS, Segev DL; CPAT investigators. Am J Transplant. 2023 Jun;23(6):744-758. doi: 10.1016/j.ajt.2023.03.014. Epub 2023 Mar 24. PMID: 36966905

[GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.](#)

Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, Uriel A, Gitlin L, Klein J, Davis MJ, Venkatraman H, Hart MG, Jaroslavsky JR, Kounlavouth S, Marrali M, Nganje CN, Bae K, Yan T, Leodones K, Egorova M, Hong SJ, Kuan J, Grappi S, Garbes P, Jooss K, Ustianowski A. Nat Commun. 2023 Jun 6;14(1):3274. doi: 10.1038/s41467-023-39053-9. PMID: 37280238

[Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study.](#)

Xu H, Zheng J, Zhao X, Zhou Q, Fan B, Wu H, Zhang S, Ge J. Cardiovasc Res. 2023 Jun 13;119(6):1352-1360. doi: 10.1093/cvr/cvad031. PMID: 36756815

[Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study.](#)

Montori M, Martini F, DE Blasio F, Buono T, Quatraccioni C, Guardati P, Calzolari M, Rossi C, Bendia E, Menzo S, Valenza C, Pellicano R, Maroni L, Benedetti A. Minerva Gastroenterol (Torino). 2023 Jun;69(2):268-276. doi: 10.23736/S2724-5985.22.03134-5. Epub 2022 Oct 18. PMID: 36255283

[Response to Letter to the Editor: Post-Vaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.](#)

Bronsky J. J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):e90. doi: 10.1097/MPG.0000000000003760. Epub 2023 Mar 12. PMID: 36913707

[Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugation.](#)

Bepperling A, Richter G. Eur Biophys J. 2023 Jun 8;1-8. doi: 10.1007/s00249-023-01663-y. Online ahead of print. PMID: 37289289

[Syndrome of inappropriate antidiuretic hormone and status epilepticus associated with mRNA-based SARS-CoV-2 vaccination.](#)

Yang JW, Kim YR, Hong YA. Int Urol Nephrol. 2023 Jun;55(6):1645-1646. doi: 10.1007/s11255-022-03451-7. Epub 2022 Dec 30. PMID: 36581709

[Ocular motility disorders after SARS-CoV-2 vaccination require the exclusion of all differential causes.](#)

Finsterer J, Scorza FA. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1765-1766. doi: 10.1007/s00417-023-05991-9. Epub 2023 Feb 4. PMID: 36738346

[Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.](#)

Fallet B, Foglierini M, Porret R, Alcaraz A, Sauvage C, Jenelten R, Caplanusi T, Gilliet M, Perez L, Fenwick C, Genolet R, Harari A, Bobisse S, Gotardo R, Pantaleo G, Muller YD. J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.06.005. Online ahead of print. PMID: 37321353

[More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.](#)

Monach PA, Branch-Elliman W. Lancet Infect Dis. 2023 Jun;23(6):654-655. doi: 10.1016/S1473-3099(23)00274-8. Epub 2023 Apr 26. PMID: 37119830

[An isotope dilution mass spectrometry assay to track Norovirus-like particles in vaccine process intermediates by quantifying capsid protein VP1.](#)

Jhingree JR, Boisvert J, Mercier G. Anal Methods. 2023 Jun 8;15(22):2729-2735. doi: 10.1039/d3ay00411b. PMID: 37199095

[Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2.](#)

Gau BC, Dawdy AW, Wang HL, Bare B, Castaneda CH, Friese OV, Thompson MS, Lerch TF, Cirelli DJ, Rouse JC. Sci Rep. 2023 Jun 3;13(1):9038. doi: 10.1038/s41598-023-36193-2. PMID: 37270636

[Commentary to Ocular dysmotility after SARS-CoV-2 vaccination requires the exclusion of all differential causes.](#)

Park KA, Jeon H, Choi DG, Jung JH. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1767-1768. doi: 10.1007/s00417-023-05992-8. Epub 2023 Feb 15. PMID: 36790679

[Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination.](#)

Ishii T, Hamada K, Jubishi D, Hashimoto H, Okamoto K, Hisasue N, Sunohara M, Saito M, Shinohara T, Yamashita M, Wakimoto Y, Otani A, Ikeda M, Harada S, Okugawa S, Moriya K, Yanagimoto S. Sci Rep. 2023 Jun 13;13(1):9607. doi: 10.1038/s41598-023-36397-6. PMID: 37311763

[Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.](#)

Dai C, Dong ZY, Wang YN, Huang YH, Jiang M. Rev Esp Enferm Dig. 2023 Jun;115(6):306-314. doi: 10.17235/reed.2022.9264/2022. PMID: 36353949

[Construction of Gene Expression Patterns to Identify Critical Genes under SARS-CoV-2 Infection Conditions.](#)

Yu X, Li W, Wang J, Wu X, Sheng B. IEEE/ACM Trans Comput Biol Bioinform. 2023 Jun 7;PP. doi: 10.1109/TCBB.2023.3283534. Online ahead of print. PMID: 37285245

[China's rolling COVID waves could hit every six months - infecting millions.](#)

Ye Y. Nature. 2023 Jun;618(7965):442-443. doi: 10.1038/d41586-023-01872-7. PMID: 37286677

[Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.](#)

Solimani F, Mesas-Fernández A, Bodner E, Carevic-Neri M, Hasheminasab M, Jakovljevicova T, Philipp A, Nast A, Worm M, Hilke FJ, Meier K, Ghoreschi K. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e695-e697. doi: 10.1111/jdv.18967. Epub 2023 Feb 27. PMID: 36786360

[Empyema with an extensive retroperitoneal abscess after the first dose of the COVID-19 vaccine, a case report.](#)

Yazdi SAM, Eshraghi N, Mirzaei S, Nazar E. Int J Surg Case Rep. 2023 Jun;107:108323. doi: 10.1016/j.ijscr.2023.108323. Epub 2023 May 13. PMID: 37201360

[RNA editing: Expanding the potential of RNA therapeutics.](#)

Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, Huss DJ, Mali P. Mol Ther. 2023 Jun 7;31(6):1533-1549. doi: 10.1016/j.ymthe.2023.01.005. Epub 2023 Jan 7. PMID: 36620962

[Continuous surveillance and viral discovery in animals and humans are a core component of a one-health approach to address recent viral reverse zoonoses.](#)

Kibenge FSB. J Am Vet Med Assoc. 2023 Apr 18;261(6):789-797. doi: 10.2460/javma.23.03.0148. Print 2023 Jun 1. PMID: 37072119

[Investigating the association between the COVID-19 vaccination and incident gastrointestinal symptomology: A comprehensive dataset.](#)

Houston KD, Hartnett J, Rose SJ. Data Brief. 2023 Jun;48:109287. doi: 10.1016/j.dib.2023.109287. Epub 2023 Jun 1. PMID: 37287691

[Myocarditis and autoimmunity.](#)

Matsumori A. Expert Rev Cardiovasc Ther. 2023 Jun;21(6):437-451. doi: 10.1080/14779072.2023.2219895. Epub 2023 Jun 2. PMID: 37243585

[Highly attenuated poxvirus-based vaccines against emerging viral diseases.](#)

Perdiguero B, Pérez P, Marcos-Villar L, Albericio G, Astorgano D, Álvarez E, Sin L, Elena Gómez C, García-Arriaza J, Esteban M. J Mol Biol. 2023 Jun 8:168173. doi: 10.1016/j.jmb.2023.168173. Online ahead of print. PMID: 37301278

[Acute angle closure glaucoma following COVID-19 vaccination.](#)

Salem Mahjoubi Y, Dahmani I, Souilem I, Aouinti I, Kastalli S, Daghfous R, El Aidli S. Therapie. 2023 Jun 7:S0040-5957(23)00082-3. doi: 10.1016/j.therap.2023.06.002. Online ahead of print. PMID: 37321945

[Development of Nanopackaging for Storage and Transport of Loaded Lipid Nanoparticles.](#)

Kaur A, Darvill D, Xiang S, Heng JYY, Petrov PK, Hoye RLZ, Chen R. Nano Lett. 2023 Jun 6. doi: 10.1021/acs.nanolett.3c01271. Online ahead of print. PMID: 37279451

[Symmetrical Drug-Related Intertriginous Flexural Exanthema Induced by the Pfizer/BioNTech Comirnaty COVID-19 Vaccine.](#)

Román Mendoza NM, Luna Bastante L, Sánchez Gil A, Vicente Martín FJ. Actas Dermosifiliogr. 2023 Jun 5:S0001-7310(23)00420-9. doi: 10.1016/j.ad.2023.05.019. Online ahead of print. PMID: 37286077

[Role of non-coding RNAs in tuberculosis and their potential for clinical applications.](#)

Jumat MI, Sarmiento ME, Acosta A, Chin KL. J Appl Microbiol. 2023 Jun 1;134(6):lxad104. doi: 10.1093/jambio/lxad104. PMID: 37197901

[Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID-19 pandemic.](#)

Redlberger-Fritz M, Springer DN, Aberle SW, Camp JV, Aberle JH. J Med Virol. 2023 Jun;95(6):e28830. doi: 10.1002/jmv.28830. PMID: 37282809

[Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies.](#)

Bodner K, Irvine MA, Kwong JC, Mishra S. Int J Infect Dis. 2023 Jun;131:111-114. doi: 10.1016/j.ijid.2023.03.022. Epub 2023 Mar 27. PMID: 36990200

[Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility.](#)

Hale BG. Eur J Immunol. 2023 Jun;53(6):e2250164. doi: 10.1002/eji.202250164. PMID: 37027328

[A Mobile-Based Preventive Intervention for Young, Arabic-Speaking Asylum Seekers During the COVID-19 Pandemic in Germany: Design and Implementation.](#)

Frick U, Sipar D, Bücheler L, Haug F, Haug J, Almeqbaali KM, Pryss R, Rosner R, Comtesse H. JMIR Form Res. 2023 Jun 5;7:e44551. doi: 10.2196/44551. PMID: 37134019

[Design and characterization of chimeric Rabies-SARS-CoV-2 virus-like particles for vaccine purposes.](#)

Garay E, Fontana D, Villaraza J, Fuselli A, Gugliotta A, Antuña S, Tardivo B, Rodríguez MC, Gastaldi V, Battagliotti JM, Alvarez D, Castro E, Cassataro J, Ceaglio N, Prieto C. Appl Microbiol Biotechnol. 2023 Jun;107(11):3495-3508. doi: 10.1007/s00253-023-12545-w. Epub 2023 May 1. PMID: 37126083

[\[A national overview of the topics covered by young people in epidemiology: a comparison before and after the Covid-19.\]](#)

Ottone M, Petri D, Listorti E, Macciotta A, Moirano G, Murtas R, Renzi M, Asta F. Recenti Prog Med. 2023 Jun;114(6):309-315. doi: 10.1701/4042.40217. PMID: 37229671

[Analysis of individual characteristics influencing user polarization in COVID-19 vaccine hesitancy.](#)

Xie L, Wang D, Ma F. Comput Human Behav. 2023 Jun;143:107649. doi: 10.1016/j.chb.2022.107649. Epub 2023 Jan 17. PMID: 36683861

[How to debunk misinformation? An experimental online study investigating text structures and headline formats.](#)

Kotz J, Giese H, König LM. Br J Health Psychol. 2023 Jun 1. doi: 10.1111/bjhp.12670. Online ahead of print. PMID: 37263771

[Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.](#)

Zheng Y, Pan J, Jin M, Wang J, Tung TH, Chen S, Bi X, Zhou K, Chen M, Wang D, Li J, Shen B, Ying L. Int Immunopharmacol. 2023 Jun;119:110151. doi: 10.1016/j.intimp.2023.110151. Epub 2023 Apr 5. PMID: 37044040

[Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.](#)

Cassetti MC, Pierson TC, Patterson LJ, Bok K, DeRocco AJ, Deschamps AM, Graham BS, Erbeling EJ, Fauci AS. J Infect Dis. 2023 Jun 15;227(12):1433-1441. doi: 10.1093/infdis/jiac296. PMID: 35876700

[The "humanized" N-glycosylation pathway in CRISPR/Cas9-edited Nicotiana benthamiana significantly enhances the immunogenicity of a S/preS1 Hepatitis B Virus antigen and the virus-neutralizing antibody response in vaccinated mice.](#)

Pantazica AM, van Eerde A, Dobrica MO, Caras I, Ionescu I, Costache A, Tucureanu C, Steen H, Lazar C, Heldal I, Haugslien S, Onu A, Stavaru C, Branza-Nichita N, Liu Clarke J. *Plant Biotechnol J*. 2023 Jun;21(6):1176-1190. doi: 10.1111/pbi.14028. Epub 2023 Mar 10. PMID: 36779605

[Reasons for COVID-19 vaccine hesitancy in ethnic minority groups: A systematic review and thematic synthesis of initial attitudes in qualitative research.](#)

Shearn C, Krockow EM. *SSM Qual Res Health*. 2023 Jun;3:100210. doi: 10.1016/j.ssmqr.2022.100210. Epub 2022 Dec 22. PMID: 36573229

[History of the discovery and development of Biomodulina T \(InmunyVital®\), a useful immunomodulator with a broad range of clinical applications.](#)

Rodriguez Martin RR, Gonzalez Gonzalez O, Rodriguez Gonzalez C, Rodriguez Gonzalez RR. *Int Immunopharmacol*. 2023 Jun;119:110167. doi: 10.1016/j.intimp.2023.110167. Epub 2023 Apr 20. PMID: 37086680

[An unusual occurrence of autoimmune pancreatitis after Gam-Covid-Vac \(Sputnik V\): A case report and literature review.](#)

Chahed F, Ben Fadhel N, Maamri K, Abdelali M, Ben Romdhane H, Chadli Z, Ben Fredj N, Zrig A, Aouam K, Chaabane A. *Br J Clin Pharmacol*. 2023 Jun 13. doi: 10.1111/bcp.15817. Online ahead of print. PMID: 37311707

[Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart.](#)

Girardi V, Gularte JS, Demoliner M, da Silva MS, Filippi M, de Abreu Góes Pereira VM, Hansen AW, Rosa RB, Fleck JD, Spilki FR. *Braz J Microbiol*. 2023 Jun 3:1-5. doi: 10.1007/s42770-023-01018-x. Online ahead of print. PMID: 37269428

[Potential differentiation of successive SARS-CoV-2 mutations by RNA: DNA hybrid analyses.](#)

He L, Xie Z, Long X, Zhang C, Ma K, She L. *Biophys Chem*. 2023 Jun;297:107013. doi: 10.1016/j.bpc.2023.107013. Epub 2023 Mar 31. PMID: 37030215

[Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.](#)

Abhold J, Wozniak A, Mulcahy J, Walsh S, Zepeda E, Demmer R, Yendell S, Hedberg C, Ulrich A, Wurtz R, Beebe T. *PLoS One*. 2023 Jun 15;18(6):e0279660. doi: 10.1371/journal.pone.0279660. eCollection 2023. PMID: 37319239

[Genotype Diversity of Enteric Viruses in Wastewater Amid the COVID-19 Pandemic.](#)

Hoque SA, Kotaki T, Pham NTK, Onda Y, Okitsu S, Sato S, Yuki Y, Kobayashi T, Maneekarn N, Kiyono H, Hayakawa S, Ushijima H. *Food Environ Virol*. 2023 Jun;15(2):176-191. doi: 10.1007/s12560-023-09553-4. Epub 2023 Apr 14. PMID: 37058225

[Racial Discrimination, Social Disadvantage, and Racial-Ethnic Disparities in COVID-19 Vaccine Uptake.](#)

Haro-Ramos AY, Bacong AM, Rodriguez HP. *AJPM Focus*. 2023 Jun;2(2):100072. doi: 10.1016/j.focus.2023.100072. Epub 2023 Feb 1. PMID: 36744154

[Fear of fertility side effects is a major cause for COVID-19 vaccine hesitance in infertile patients.](#)

Kern J, Schippert C, Fard D, Bielfeld AP, von Versen-Höynck F. Front Med (Lausanne). 2023 Jun 1;10:1178872. doi: 10.3389/fmed.2023.1178872. eCollection 2023. PMID: 37324157

[Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity.](#)

Williams JA, Biancucci M, Lessen L, Tian S, Balsaraf A, Chen L, Chesterman C, Maruggi G, Vandepaer S, Huang Y, Mallett CP, Steff AM, Bottomley MJ, Malito E, Wahome N, Harshbarger WD. Sci Adv. 2023 Jun 9;9(23):eadg0330. doi: 10.1126/sciadv.adg0330. Epub 2023 Jun 7. PMID: 37285422

[Analyzing immune responses to varied mRNA and protein vaccine sequences.](#)

Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, Bae SH, Kim JY, Kwak HW, Kim Y, Yoo S, Kim D, Keum G, Bang EK, Hong SH, Nam JH. NPJ Vaccines. 2023 Jun 5;8(1):84. doi: 10.1038/s41541-023-00684-0. PMID: 37271785

[Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions.](#)

Vandervaart JP, Inniss NL, Ling-Hu T, Minasov G, Wiersum G, Rosas-Lemus M, Shuvalova L, Achenbach CJ, Hultquist JF, Satchell KJF, Bachtta KER. Microbiol Spectr. 2023 Jun 15;11(3):e0032423. doi: 10.1128/spectrum.00324-23. Epub 2023 May 16. PMID: 37191546

[Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.](#)

Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ. Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.06.007. Online ahead of print. PMID: 37316409

[Identification of nurse shark V_{NAR} single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2.](#)

Buffington J, Duan Z, Kwon HJ, Hong J, Li D, Feng M, Xie H, Ho M. FASEB J. 2023 Jun;37(6):e22973. doi: 10.1096/fj.202202099RR. PMID: 37191949

[A Rare Case of COVID-19 Vaccination-Induced Cholangiopathic Liver Injury.](#)

Taj S, Sanekommu H, Johal A, Ravilla J, Imburgio S, Dandu S, Vedire A, Miller B, Hossain M. ACG Case Rep J. 2023 Jun 14;10(6):e01079. doi: 10.14309/crj.0000000000001079. eCollection 2023 Jun. PMID: 37324828

[Racial and Ethnic Disparities in Excess Deaths after COVID-19 Vaccine Deployment among Persons with Kidney Failure.](#)

Kim D, Swaminathan S, Lee Y, Wang V, Mehrotra R, Trivedi AN. Clin J Am Soc Nephrol. 2023 Jun 14. doi: 10.2215/CJN.0000000000000226. Online ahead of print. PMID: 37314763

[Immunogenicity Evaluation of Thermostable Microparticles Entrapping Receptor Binding Domain of SARS-CoV-2 by Single Point Administration.](#)

Ahuja R, Srichandan S, Meena J, Biswal BK, Panda AK. J Pharm Sci. 2023 Jun;112(6):1664-1670. doi: 10.1016/j.xphs.2023.01.024. Epub 2023 Feb 2. PMID: 36736778

[Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4\(3H\)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.](#)

Ko M, Lee JY, Shin YS, Jeon S, Myung S, Cho JE, Jang MS, Song JH, Kim HR, Park HG, Park CM, Kim S. J Med Virol. 2023 Jun;95(6):e28863. doi: 10.1002/jmv.28863. PMID: 37310127

[COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.](#)

Mayer D, Barun B, Lazibat K, Lasić S, Adamec I, Gabelić T, Krbot Skorić M, Habek M. *Acta Neurol Belg.* 2023 Jun 1:1-7. doi: 10.1007/s13760-023-02296-w. Online ahead of print. PMID: 37261658

[Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea.](#)

Noh H, Yoon S, Kim SH, Kim J, Seo JS, Kim JJ, Park IH, Oh J, Bae JY, Lee GE, Woo SJ, Seo SM, Kim NW, Lee YW, Jang HJ, Hong SM, An SH, Lyoo KS, Yeom M, Lee H, Jung B, Yoon SW, Kang JA, Seok SH, Lee YJ, Kim SY, Kim YB, Hwang JY, On D, Lim SY, Kim SP, Jang JY, Lee H, Kim K, Lee HJ, Kim HB, Kim SB, Park JW, Jeong DG, Song D, Choi KS, Lee HY, Choi YK, Choi JA, Song M, Park MS, Seo JY, Shin JS, Yun JW, Nam KT, Seong JK. *Pulm Pharmacol Ther.* 2023 Jun;80:102189. doi: 10.1016/j.pupt.2023.102189. Epub 2023 Jan 10. PMID: 36634813

[Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study.](#)

Kemp TJ, Hempel HA, Pan Y, Roy D, Cherry J, Lowy DR, Pinto LA. *Microbiol Spectr.* 2023 Jun 15;11(3):e0535322. doi: 10.1128/spectrum.05353-22. Epub 2023 May 16. PMID: 37191544

[Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network \(EMN\).](#)

Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H. *Leukemia.* 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4. PMID: 37142661

[Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.](#)

Chu X, Ding X, Yang Y, Lu Y, Li T, Gao Y, Zheng L, Xiao H, Yang T, Cheng H, Huang H, Liu Y, Lou Y, Wu C, Chen Y, Yang H, Ji X, Guo H. *Biochem Biophys Res Commun.* 2023 Jun 11;660:43-49. doi: 10.1016/j.bbrc.2023.04.002. Epub 2023 Apr 5. PMID: 37062240

[Predicting the antigenic evolution of SARS-COV-2 with deep learning.](#)

Han W, Chen N, Xu X, Sahil A, Zhou J, Li Z, Zhong H, Gao E, Zhang R, Wang Y, Sun S, Cheung PP, Gao X. *Nat Commun.* 2023 Jun 13;14(1):3478. doi: 10.1038/s41467-023-39199-6. PMID: 37311849

[Aptamer-based nanointerferometer enables amplification-free ultrasensitive detection and differentiation of SARS-CoV-2 variants.](#)

Chen C, Song X, Yu Y, Wang X, Xu H, Ji W, Ma J, Zhao C, Feng S, Wang Y, Su XD, Wang W. *Anal Chim Acta.* 2023 Jun 15;1260:341207. doi: 10.1016/j.aca.2023.341207. Epub 2023 Apr 11. PMID: 37121656

[The Nucleocapsid Proteins of SARS-CoV-2 and Its Close Relative Bat Coronavirus RaTG13 Are Capable of Inhibiting PKR- and RNase L-Mediated Antiviral Pathways.](#)

LeBlanc K, Lynch J, Layne C, Vendramelli R, Sloan A, Tailor N, Deschambault Y, Zhang F, Kobasa D, Safronetz D, Xiang Y, Cao J. *Microbiol Spectr.* 2023 Jun 15;11(3):e0099423. doi: 10.1128/spectrum.00994-23. Epub 2023 May 8. PMID: 37154717

[CoronaVac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities.](#)

Wang L, Li C, Li W, Zhao L, Zhao T, Chen L, Li M, Fan J, Li J, Wu C, Chen Y. *Emerg Microbes Infect.* 2023 Jun 13:2225640. doi: 10.1080/22221751.2023.2225640. Online ahead of print. PMID: 37309826

[Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 \(SARS-CoV-2\) and middle east respiratory syndrome coronavirus \(MERS-CoV\).](#)

Dampalla CS, Miller MJ, Kim Y, Zabiegala A, Nguyen HN, Madden TK, Thurman HA, Machen AJ, Cooper A, Liu L, Battaile KP, Lovell S, Chang KO, Groutas WC. Eur J Med Chem. 2023 Jun 5;254:115376. doi: 10.1016/j.ejmech.2023.115376. Epub 2023 Apr 15. PMID: 37080108

[Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.](#)

Overheu O, Lendowski S, Quast DR, Kühn D, Vidal Blanco E, Kraeft AL, Steinmann E, Kourti E, Lugnier C, Steinmann J, Reinacher-Schick A, Pfaender S. J Cancer Res Clin Oncol. 2023 Jun 10:1-12. doi: 10.1007/s00432-023-04961-2. Online ahead of print. PMID: 37300723

[Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.](#)

Stauff CB, Selvaraj P, D'Agnillo F, Meseda CA, Liu S, Pedro CL, Sangare K, Lien CZ, Weir JP, Starost MF, Wang TT. Nat Commun. 2023 Jun 9;14(1):3393. doi: 10.1038/s41467-023-39090-4. PMID: 37296125

[Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.](#)

Kim WJ, Roberts CC, Song JY, Yoon JG, Seong H, Hyun HJ, Lee H, Gil A, Oh Y, Park JE, Lee JE, Jeon B, Kane D, Spruill S, Kudchodkar SB, Muthumani K, Park YK, Kwon I, Maslow JN. Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.06.013. Online ahead of print. PMID: 37296017

[Pediatric Myocarditis.](#)

Williams JL, Jacobs HM, Lee S. Cardiol Ther. 2023 Jun;12(2):243-260. doi: 10.1007/s40119-023-00309-6. Epub 2023 Mar 11. PMID: 36906691

[Optimization and Deoptimization of Codons in SARS-CoV-2 and Related Implications for Vaccine Development.](#)

Wu X, Shan KJ, Zan F, Tang X, Qian Z, Lu J. Adv Sci (Weinh). 2023 Jun 2:e2205445. doi: 10.1002/advs.202205445. Online ahead of print. PMID: 37267926

[A novel consensus-based computational pipeline for screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including Omicron variant.](#)

Kumar N, Kaushik R, Zhang KYJ, Uversky VN, Sahu U, Sood R, Bhatia S. Proteins. 2023 Jun;91(6):798-806. doi: 10.1002/prot.26467. Epub 2023 Jan 16. PMID: 36629264

[A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2.](#)

Carbo EC, Mourik K, Boers SA, Munnink BO, Nieuwenhuijse D, Jonges M, Welkers MRA, Matamoros S, van Harinxma Thoe Slooten J, Kraakman MEM, Karelioti E, van der Meer D, Veldkamp KE, Kroes ACM, Sidorov I, de Vries JJC. Eur J Clin Microbiol Infect Dis. 2023 Jun;42(6):701-713. doi: 10.1007/s10096-023-04590-0. Epub 2023 Apr 5. PMID: 37017810

[The Efficacy of SARS-CoV-2 Vaccination in the Elderly: A Systemic Review and Meta-analysis.](#)

Yang XH, Bao WJ, Zhang H, Fu SK, Jin HM. J Gen Intern Med. 2023 Jun 2;1-9. doi: 10.1007/s11606-023-08254-9. Online ahead of print. PMID: 37266884

[Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.](#)

Khaitov M, Nikonova A, Kofiadi I, Shilovskiy I, Smirnov V, Elisytina O, Maerle A, Shatilov A, Shatilova A, Andreev S, Sergeev I, Trofimov D, Latysheva T, Ilyna N, Martynov A, Rabdano S, Ruzanova E, Savelev N, Pletiuikhina I, Safi A, Ratnikov V, Gorelov V, Kaschenko V, Kucherenko N, Umarova I, Moskaleva S, Fabrichnikov S, Zuev O, Pavlov N, Kruchko D, Berzin I, Goryachev D, Merkulov V, Shipulin G, Udin S, Trukhin V, Valenta R, Skvortsova V. Allergy. 2023 Jun;78(6):1639-1653. doi: 10.1111/all.15663. Epub 2023 Feb 14. PMID: 36721963

[Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.](#)

Ragonnet-Cronin M, Nutalai R, Huo J, Dijokaite-Guraliuc A, Das R, Tuekprakhon A, Supasa P, Liu C, Selvaraj M, Groves N, Hartman H, Ellaby N, Mark Sutton J, Bahar MW, Zhou D, Fry E, Ren J, Brown C, Klenerman P, Dunachie SJ, Mongkolsapaya J, Hopkins S, Chand M, Stuart DI, Screaton GR, Rokadiya S. Nat Commun. 2023 Jun 7;14(1):3334. doi: 10.1038/s41467-023-37826-w. PMID: 37286554

[Use of the Improvement Index to Evaluate Equitable COVID-19 Vaccine Allocation in the San Francisco Bay Area.](#)

Jumamil RB, Rutherford G. AJPM Focus. 2023 Jun;2(2):100075. doi: 10.1016/j.focus.2023.100075. Epub 2023 Feb 4. PMID: 36776788

[Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.](#)

Guenthoer J, Lilly M, Starr TN, Dadonaite B, Lovendahl KN, Croft JT, Stoddard CI, Chohan V, Ding S, Ruiz F, Kopp MS, Finzi A, Bloom JD, Chu HY, Lee KK, Overbaugh J. Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220948120. doi: 10.1073/pnas.2220948120. Epub 2023 May 30. PMID: 37253011

[The Cost We Bear: Financial Implications for Hip Fracture Care Amidst the COVID-19 Pandemic.](#)

Konda SR, Esper GW, Meltzer-Bruhn AT, Ganta A, Egol KA. J Am Acad Orthop Surg. 2023 Jun 5. doi: 10.5435/JAAOS-D-22-00611. Online ahead of print. PMID: 37279163

[Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers.](#)

Nakai M, Yokoyama D, Sato T, Sato R, Kojima C, Shimosawa T. Heliyon. 2023 Jun;9(6):e16547. doi: 10.1016/j.heliyon.2023.e16547. Epub 2023 May 22. PMID: 37235203

[Seasonality, mass vaccination and critical policy evaluation on global exit strategy of COVID-19 crisis.](#)

Roy I, Chapungu L, Nyambiya I. Phys Chem Earth (2002). 2023 Jun;130:103388. doi: 10.1016/j.pce.2023.103388. Epub 2023 Mar 5. PMID: 36923070

[COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.](#)

Wesselink AK, Lovett SM, Weinberg J, Geller RJ, Wang TR, Regan AK, Willis MD, Perkins RB, Yland JJ, Koenig MR, Rothman KJ, Hatch EE, Wise LA. Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.06.012. Online ahead of print. PMID: 37301706

[Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination.](#)

Nv B, McCollum S, Faherty E, Steele JM, Karnik R. *Pediatr Cardiol.* 2023 Jun 9:1-9. doi: 10.1007/s00246-023-03200-2. Online ahead of print. PMID: 37294336

[The global challenges of the long COVID-19 in adults and children.](#)

Rodriguez-Morales AJ, Lopez-Echeverri MC, Perez-Raga MF, Quintero-Romero V, Valencia-Gallego V, Galindo-Herrera N, López-Alzate S, Sánchez-Vinasco JD, Gutiérrez-Vargas JJ, Mayta-Tristan P, Husni R, Moghnieh R, Stephan J, Faour W, Tawil S, Barakat H, Chaaban T, Megarbane A, Rizk Y, Sakr R, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Camacho-Moreno G, Mendoza H, Rodriguez-Sabogal IA, Millán-Oñate J, Lopardo G, Barbosa AN, Cimerman S, Chaves TDSS, Orduna T, Lloveras S, Rodriguez-Morales AG, Thormann M, Zambrano PG, Perez C, Sandoval N, Zambrano L, Alvarez-Moreno CA, Chacon-Cruz E, Villamil-Gomez WE, Benites-Zapata V, Savio-Larriera E, Cardona-Ospina JA, Rísquez A, Forero-Peña DA, Henao-Martínez AF, Sah R, Barboza JJ, León-Figueroa DA, Acosta-España JD, Carrero-Gonzalez CM, Al-Tawfiq JA, Rabaan AA, Leblebicioglu H, Gonzales-Zamora JA, Ulloa-Gutiérrez R. *Travel Med Infect Dis.* 2023 Jun 7:102606. doi: 10.1016/j.tmaid.2023.102606. Online ahead of print. PMID: 37295581

[SARS-CoV-2 Omicron \(B.1.1.529\) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage.](#)

Yu W, Wang J, Yang Y, Tang C, Yang C, Li B, Wang H, Zhou Y, Huang Q, Yang H, Wu D, Luo Z, Gao J, Kuang D, Long H, Peng X, Xie Z, Lu S. *J Med Virol.* 2023 Jun;95(6):e28846. doi: 10.1002/jmv.28846. PMID: 37282766

[Time-to-survival from COVID-19 disease and its associated factors in Osun State, Nigeria.](#)

Olugbenga O, O A, Peter O, Rita O, O O, Od E, At O, James A. *Infect Disord Drug Targets.* 2023 Jun 13. doi: 10.2174/1871526523666230613122108. Online ahead of print. PMID: 37312448

[COVID-19 induced anorexia nervosa: A case series and brief review of literature.](#)

Esmaeeli ST, Rahimi Z, Saeed F, Shoib S. *Clin Case Rep.* 2023 Jun 13;11(6):e7534. doi: 10.1002/ccr3.7534. eCollection 2023 Jun. PMID: 37323292

[Three to four mRNA COVID-19 vaccine in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variants neutralization.](#)

Louapre C, Belin L, Marot S, Hippolyte A, Januel E, Ibrahim M, Jeantin L, Zafilaza K, Malet I, Charbonnier-Beaupel F, Rosenzweig M, Soulié C, Marcelin AG, Pourcher V. *Eur J Neurol.* 2023 Jun 13. doi: 10.1111/ene.15925. Online ahead of print. PMID: 37310391

[Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study.](#)

Damkier P, Cleary B, Hallas J, Schmidt JH, Ladebo L, Jensen PB, Lund LC. *Otolaryngol Head Neck Surg.* 2023 Jun 8. doi: 10.1002/ohn.394. Online ahead of print. PMID: 37288514

[Lessons From the Wrong Isolation Policy Violating Human Rights for Leprosy in Japan.](#)

Horikoshi Y, Toizumi M. *Pediatr Infect Dis J.* 2023 Jun 1;42(6):e212-e216. doi: 10.1097/INF.0000000000003897. Epub 2023 Mar 2. PMID: 36916867

[Risk factors for long coronavirus disease 2019 \(long COVID\) among healthcare personnel, Brazil, 2020-2022.](#)

Marra AR, Sampaio VS, Ozahata MC, Lopes R, Brito AF, Bragatte M, Kalil J, Miraglia JL, Malheiro DT, Guozhang Y, Teich VD, Victor EDS, Pinho JRR, Cypriano A, Vieira LW, Polonio M, de Oliveira SM, Ricardo VCV, Maezato AM, Callado GY, Schettino GPP, de Oliveira KG, Santana RAF, Malta FM, Amgarten D, Boechat AL, Kobayashi T, Perencevich E, Edmond MB, Rizzo LV. *Infect Control Hosp Epidemiol.* 2023 Jun 5:1-7. doi: 10.1017/ice.2023.95. Online ahead of print. PMID: 37272468

[The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.](#)

Xu J, Lan X, Zhang L, Zhang X, Zhang J, Song M, Liu J. *Front Public Health.* 2023 Jun 1;11:1165611. doi: 10.3389/fpubh.2023.1165611. eCollection 2023. PMID: 37325336

[The Role of Interleukin-21 in COVID-19 Vaccine-Induced B Cell-Mediated Immune Responses in Kidney Disease Patients and Kidney Transplant Recipients.](#)

Malahe SRK, den Hartog Y, Rietdijk WJR, van Baarle D, de Kuiper R, Reijkerkerk D, Ras AM, Geers D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JS, GeurtsvanKessel CH, Kho MML, de Vries RD, Reinders MEJ, Baan CC; RECOVAC Consortium. *Am J Transplant.* 2023 Jun 1:S1600-6135(23)00492-6. doi: 10.1016/j.ajt.2023.05.025. Online ahead of print. PMID: 37270109

[Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants.](#)

Gonzalez-Reiche AS, Alshammary H, Schaefer S, Patel G, Polanco J, Carreño JM, Amoako AA, Rooker A, Cognigni C, Floda D, van de Guchte A, Khalil Z, Farrugia K, Assad N, Zhang J, Albuquerque B; PARIS/PSP study group; Sominsky LA, Gleason C, Srivastava K, Sebra R, Ramirez JD, Banu R, Shrestha P, Krammer F, Paniz-Mondolfi A, Sordillo EM, Simon V, van Bakel H. *Nat Commun.* 2023 Jun 3;14(1):3235. doi: 10.1038/s41467-023-38867-x. PMID: 37270625

[The effect of early childhood respiratory infections and pneumonia on lifelong lung function: a systematic review.](#)

Collaro AJ, McElrea MS, Marchant JM, Chatfield MD, Sondergeld P, Perret JL, Vicendese D, Anuntaseree W, Dharmage SC, Chang AB. *Lancet Child Adolesc Health.* 2023 Jun;7(6):429-440. doi: 10.1016/S2352-4642(23)00030-5. Epub 2023 Apr 7. PMID: 37037210

[Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.](#)

Wolf J, Johnston RB, Ambelu A, Arnold BF, Bain R, Brauer M, Brown J, Caruso BA, Clasen T, Colford JM Jr, Mills JE, Evans B, Freeman MC, Gordon B, Kang G, Lanata CF, Medlicott KO, Prüss-Ustün A, Troeger C, Boisson S, Cumming O. *Lancet.* 2023 Jun 5:S0140-6736(23)00458-0. doi: 10.1016/S0140-6736(23)00458-0. Online ahead of print. PMID: 37290458

[Paediatric inflammatory multisystem syndrome in Canada: population-based surveillance and role of SARS-CoV-2 linkage.](#)

El Tal T, Morin MP, Morris SK, Farrar DS, Berard RA, Kakkar F, Moore Hepburn C, Baerg K, Beaufilets C, Bennett TL, Benseler SM, Beaudoin-Bussièrès G, Chan K, Cyr C, Dahdah N, Donner EJ, Drouin O, Edjoc R, Eljaouhari M, Embree JE, Farrell C, Finzi A, Forgie S, Giroux R, Kang KT, King M, Laffin Thibodeau M, Lang B, Laxer RM, Luu TM, McCrindle BW, Orkin J, Papenburg J, Pound CM, Price VE, Proulx-Gauthier

JP, Purewal R, Sadarangani M, Salvadori MI, Thibeault R, Top KA, Viel-Thériault I, Haddad E, Scuccimarri R, Yeung RSM. *Pediatr Res.* 2023 Jun 5:1-10. doi: 10.1038/s41390-023-02668-1. Online ahead of print. PMID: 37277605 Free PMC article.

Patients with positive versus negative SARS-CoV-2 linkages were compared, with positive linkage defined as any positive molecular or serologic test or close contact with confirmed **COVID-19**. ICU risk factors were identified with multivariable modified Poisson regress ...

Patentes registradas en Patentscope

Estrategia de búsqueda: *Vaccine in the title or abstract AND 20230601:20230615 as the publication date 76 records*

1. [20230173058](#)SARS-COV-2 VACCINE

US - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 17922328 Solicitante CANSINO BIOLOGICS INC. Inventor/a Junqiang LI

Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.

2. [WO/2023/098711](#)VACCINE QUALITY CONTROL METHOD, VACCINE QUALITY CONTROL REAGENT, AND USE THEREOF

WO - 08.06.2023

Clasificación Internacional [G01N 33/68](#) N° de solicitud PCT/CN2022/135343 Solicitante TSINGHUA UNIVERSITY Inventor/a ZHANG, Jingren

A vaccine quality control method, a vaccine quality control reagent, and the use thereof. The vaccine quality control method comprises: detecting a vaccine to be detected and determining detection results. The detection comprises antibody titer detection, detection of the clearance half-time of pathogenic bacteria in the blood, detection of the capture rate of pathogenic bacteria in the liver, detection of the capture number of pathogenic bacteria in hepatic sinusoidal cells, and detection of animal survival rate; and when the preliminary detection results of all the detection modes show that the quality of said vaccine reaches the standard, indicating that the final quality of said vaccine reaches the standard.

3. [20230173044](#)RECOMBINANT PROTEIN FOR REMOVING BOAR TAIN AND VACCINE COMPOSITION COMPRISING THE SAME

US - 08.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 16964632 Solicitante BIOAPPLICATIONS INC. Inventor/a Eun-Ju SOHN

The present invention relates to a vaccine composition for removing boar taint, the vaccine composition including a recombinant protein in which a cholera toxin B subunit (CTB) and n gonadotropin-releasing hormones (GnRH) are fused, and more specifically, provides a recombinant protein for removing boar taint to induce antibodies against GnRH, a recombinant vector for producing the same, a vaccine composition for removing boar taint, the vaccine composition including the recombinant protein, and a method for removing boar taint using the same. The vaccine composition according to the present

invention induces antibodies against GnRH in an individual and has the effect of atrophying the testes through the induction of antibodies. Therefore, the present invention can be usefully used to remove boar taint by immunologically castrating a boar at low cost and with high safety and minimal side effects.

4. [4190902](#) REKOMBINANTES VACCINIAVIRUS

EP - 07.06.2023

Clasificación Internacional [C12N 15/50](#) N° de solicitud 21848897 Solicitante TOKYO METROPOLITAN INST MEDICAL SCIENCE Inventor/a KOHARA MICHINORI

The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc. The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.

5. [WO/2023/092863](#) RECOMBINANT VIRUS COMBINATION BASED ON AFRICAN SWINE FEVER VIRUS (ASFV) GENES, AND VACCINE PREPARED THEREFROM

WO - 01.06.2023

Clasificación Internacional [C07K 14/01](#) N° de solicitud PCT/CN2022/074457 Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, ACADEMY OF MILITARY SCIENCES, PEOPLE'S LIBERATION ARMY OF CHINA Inventor/a HU, Rongliang

Disclosed in the present invention are a recombinant virus combination based on African swine fever virus (ASFV) genes, and a vaccine prepared therefrom. Provided in the present invention is an African swine fever virus protein combination, which comprises the following three proteins: MGF 110-5L-6L protein, B119L protein and DP96R protein. The above-mentioned ASFV protein combination also comprises at least one of the following 13 proteins: MGF 110-9L, I329L, MGF 505-5R, B438L, O61R, E199L, M448R, MGF 505-7R, A137R, I177L, I226R, DP71L and K196R. Provided in the present invention are a recombinant virus combination based on ASFV genes, and a vaccine prepared therefrom. After pigs are immunized with the vaccine, susceptible pigs can be protected from natural infection or artificial attack of ASFV. The vaccine is used for the prevention of African swine fever.

6. [WO/2023/101381](#) VACCINE PLATFORM FOR PRODUCING FOOT AND MOUTH DISEASE VIRUS-LIKE PARTICLES

WO - 08.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud PCT/KR2022/019148 Solicitante WATSON RND, INC. Inventor/a KIM, Bong Yoon

The present invention relates to a polynucleotide in which the 3C, 3D cleavage site, VP4, VP2, VP3, and VP1 base sequences of foot and mouth disease virus (FMDV) are sequentially connected, a recombinant vector carrying same, a transformant transformed with the recombinant vector, a method for producing foot and mouth disease virus-like particles using the transformant, and a vaccine composition using a foot and mouth disease virus-like particle protein that assembles by itself using the polynucleotide. When a vaccine is prepared using the FMDV VLP of the present invention as an antigen, the period of antibody production in mice is short, the survival rate against foot and mouth disease virus challenge is high, and the neutralizing antibody titer is high. In addition, it was observed that antibody production started within about 2 weeks in pigs as well as mice and the PI value was more than 50% even after 6 weeks, so that the vaccine can be applied as a vaccine platform for producing foot and mouth disease virus-like particles.

7. [WO/2023/098456](#) VACCINE ADJUVANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF

WO - 08.06.2023

Clasificación Internacional [A61K 39/39](#) N° de solicitud PCT/CN2022/131616 Solicitante CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY, CHINESE ACADEMY OF SCIENCE Inventor/a XU, Weiguo

An immunologic adjuvant, which is a terminal group-modified polylactic acid, and the terminal group of the terminal group-modified polylactic acid is a group containing NH₂ and/or a tertiary amine. Compared with the prior art, the amino-modified polylactic acid is used as a vaccine adjuvant, and a vaccine obtained by means of compounding the vaccine adjuvant with a vaccine antigen complex is more easily phagocytized by dendritic cells and initiates an immune response, and has a good immune effect and a high biocompatibility.

8. [WO/2023/094967](#) ORAL THERAPEUTIC VACCINE COMPOSITIONS, METHODS AND TREATMENT OF COVID

WO - 01.06.2023

Clasificación Internacional [C12N 15/113](#) N° de solicitud PCT/IB2022/061224 Solicitante IMMUNITOR (THAILAND) CO. LTD. Inventor/a JIRANTHITIKAL, Vichai

Described herein are oral vaccine compositions for preventing and treating COVID and COVID related complications (e.g., cytokine storm related complications). These oral vaccine compositions comprise hydrolyzed and heat inactivated anti-viral antisense and other nucleic acid components that target the expression of SARS-CoV-2 viral proteins. Such oral vaccine compositions are room temperature stable and stimulate humoral (antibody), cellular and mucosal immunity.

9. [WO/2023/106839](#) RECOMBINANT VACCINIA VIRUS EXPRESSING IL-12 AND USE THEREOF

WO - 15.06.2023

Clasificación Internacional [C12N 7/00](#) N° de solicitud PCT/KR2022/019840 Solicitante THE ASAN FOUNDATION Inventor/a SON, Woo-Chan

The present invention relates to a recombinant Vaccinia virus expressing IL-12 and a use thereof. The recombinant vaccinia virus having a B8R gene deleted therefrom and an IL-12 gene inserted into the site of the deleted B8R increases in IFN- γ activity and IL-12 activity to exhibits an immunologically synergistic effect, resulting in an improvement in anti-tumor immunity and thus is expected to be advantageously used for preventing, alleviating, or treating cancer.

10. [20230173043](#) KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS

US - 08.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 17865080 Solicitante UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor/a Jay K. Kolls

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as *Pneumocystis* spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

11. [WO/2023/094713](#) CORONAVIRUS VACCINE

WO - 01.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud PCT/EP2022/083740 Solicitante BIONTECH SE Inventor/a MUIK, Alexander

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

12. [WO/2023/098679](#) NOVEL CORONAVIRUS MRNA VACCINE AGAINST MUTANT STRAINS

WO - 08.06.2023

Clasificación Internacional [C12N 15/50](#) N° de solicitud PCT/CN2022/135107 Solicitante CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD. Inventor/a WEI, Lifan

Provided is a novel coronavirus mRNA vaccine against mutant strains, main components thereof comprising mRNA having mutation sites and lipid nanoparticles. The mRNA vaccine has a good immune effect against various mutant strains of the new coronavirus.

13. [WO/2023/102375](#) NANT COVID VACCINE CROSS REACTIVITY

WO - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud PCT/US2022/080561 Solicitante IMMUNITYBIO, INC. Inventor/a SOON-SHIONG, Patrick

Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoVI, MERS-CoV, OC43-CoV, and HKUI-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.

14. [WO/2023/101508](#) 5'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE INCLUDING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION INCLUDING THE SAME

WO - 08.06.2023

Clasificación Internacional [C12N 15/113](#) N° de solicitud PCT/KR2022/019491 Solicitante MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH Inventor/a SHIN, Min-Kyung

Disclosed are a synthetic nucleic acid molecule including 5'-UTR with improved translation efficiency and a vaccine/therapeutic composition including the same, and more particularly, a 5'-UTR polynucleotide that is imparted with improved translation efficiency based on the specific motif thereof, a synthetic nucleic acid molecule including the same and a vaccine/therapeutic composition including the synthetic nucleic acid molecule. The 5'-UTR polynucleotide effectively induces expression of target proteins due to improved translation efficiency thereof and thus is useful for various RNA-based applications, for example, vaccines, in vivo/ex vivo gene therapy, etc.

15. [20230173057](#) METHOD FOR IMPROVING ANTIGEN IMMUNOGENICITY, CORONAVIRUS ANTIGEN, USE THEREOF, RECOMBINANT VECTOR, EXPRESSION KIT, TRANSGENIC CELL LINE, RECOMBINANT BACTERIUM, CORONAVIRUS VACCINE, PREPARATION METHOD OF ANTIGEN AND NUCLEOTIDE SEQUENCE

US - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 17912525 Solicitante GUANGZHOU QIANYANG BIO-TECHNOLOGY PHARMACEUTICAL CO., LTD. Inventor/a Hui ZHANG

Provided is a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano-vaccine. According to the present invention, a receptor binding domain (RBD) of a virus is used as an antigen and is connected with a Helicobacter pylori multimeric protein (HP_Ferritin) to form a fusion protein RBD-HP_Ferritin, such that antigen multimerization is realized; and an eukaryotic cell expression system is then utilized for expression, so as to form a 24-mer nano-antigen by means of the self-assembly action of the HP_Ferritin. According to the solution, the defect that RBD monomers are insufficient in immunogenicity can be overcome; the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses; and the generated antibodies have the capacity to strongly prevent the viruses from invading target cells.

16. [20230173048](#) ANTI-CANCER VACCINES AND RELATED THERAPY

US - 08.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 17921837 Solicitante The Institute of Cancer Research: Royal Cancer Hospital Inventor/a Stephen Pettitt

The present invention provides an anti-cancer vaccine comprising: (i) at least one peptide comprising the amino acid sequence of a neoantigen encoded by a mutant homologous recombination (HR) DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation; and/or (ii) at least one polynucleotide encoding the at least one peptide of (i). Also provided are engineered T cells that recognise said neoantigen. Related methods and medical uses of the vaccine and/or engineered T cell are provided, including for the treatment of cancers, such as homologous recombination (HR) deficient cancers that acquire PARP inhibitor resistance or platinum resistance by development of reversion mutations in an HR DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D.

17. [WO/2023/100984](#) NASAL VACCINE-SPRAYING FORMULATION FOR SIMULTANEOUSLY TARGETING NASAL MUCOSA AND NASOPHARYNX

WO - 08.06.2023

Clasificación Internacional [A61K 47/32](#) N° de solicitud PCT/JP2022/044399 Solicitante TOKO YAKUHI KOGYO CO., LTD. Inventor/a KAMISHITA, Taizou

The present invention pertains to a formulation that for spraying a nasal vaccine, that contains an antigen and a base agent obtained by adding polyethylene glycol to a crosslinkable polyacrylic acid, and that has an optimized spray pattern for simultaneously targeting the nasal mucosa and the nasopharynx.

18. [20230178174](#) METHOD AND SYSTEM FOR IDENTIFYING ONE OR MORE CANDIDATE REGIONS OF ONE OR MORE SOURCE PROTEINS THAT ARE PREDICTED TO INSTIGATE AN IMMUNOGENIC RESPONSE, AND METHOD FOR CREATING A VACCINE

US - 08.06.2023

Clasificación Internacional [G16B 15/30](#) N° de solicitud 17996615 Solicitante NEC ONCOIMMUNITY AS Inventor/a Boris Simovski

A computer-implemented method of identifying one or more candidate regions of one or more source proteins that are predicted to instigate an adaptive immunogenic response across a plurality of human leukocyte antigen, HLA, types, wherein the one or more source proteins has an amino acid sequence is disclosed. The method comprises (a) accessing the amino acid sequence of the one or more source proteins; (b) accessing a set of HLA types; (c) predicting an immunogenic potential of a plurality of candidate epitopes within the amino acid sequence, for each of the set of HLA types; (d) dividing the amino acid sequence into a plurality of amino acid sub-sequences; (e) for each of the plurality of amino acid sub-sequences, generating a region metric that is indicative of a predicted ability of the amino acid sub-sequence to instigate an immunogenic response across the set of HLA types, wherein the region epitopes, for each of the set of HLA types; and (f) applying a statistical model to identify whether any of the generated region metrics are statistically significant, whereby an amino acid sub-sequence identified as having a statistically significant region metric corresponds to a candidate region of the amino acid sequence that is predicted to instigate an immunogenic response across at least a subset of the set of HLA types. A corresponding system is also disclosed, as well as a method for creating a vaccine.

19. [20230165951](#) Engineering, production and characterization of plant produced Nucleocapsid and Spike structural proteins of SARS CoV 2 as vaccine candidates against COVID19

US - 01.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 17457138 Solicitante Tarlan Mamedov Inventor/a Tarlan Mamedov

This document relates to materials and methods for engineering and production of highly soluble, functional active recombinant Nucleocapsid (N) and Spike (S) based vaccine candidates against highly pandemic SARS-CoV-2 infection, in *Nicotiana benthamiana* plant using a transient expression system.

20. [20230172852](#) Neopeptide Vaccine Delivery Vehicle and Methods of Making the Same
US - 08.06.2023

Clasificación Internacional [A61K 9/06](#) N° de solicitud 18062416 Solicitante ImmunityBio, Inc. Inventor/a Philip T. Liu

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

21. [20230174588](#) A VACCINE AGAINST SARS-COV-2 AND PREPARATION THEREOF
US - 08.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud 17920158 Solicitante ZYDUS LIFESCIENCES LIMITED Inventor/a Pankaj PATEL

The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide or a gene encoding t-PA signal peptide. The DNA construct according to the present invention is further used in the preparation of an immunogenic composition or a vaccine for treating or preventing corona virus or its related diseases.

22. [WO/2023/102388](#) HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES
WO - 08.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud PCT/US2022/080588 Solicitante SANOFI PASTEUR INC. Inventor/a CHAN, Yvonne

The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

23. [WO/2023/104114](#) RNA FORMULATIONS AND LIPIDS
WO - 15.06.2023

Clasificación Internacional [A61K 9/51](#) N° de solicitud PCT/CN2022/137326 Solicitante IMMORNA (HANGZHOU) BIOTECHNOLOGY CO., LTD. Inventor/a WANG, Zihao

The disclosure relates to the method of lyophilizing RNA and mixing with a liquid LNP solution, e. g., to make an RNA vaccine or therapeutic. Included are methods for preparing and administering the vaccine or therapeutic.

24. [WO/2023/094839](#) PEPTIDE VACCINE
WO - 01.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud PCT/GB2022/053012 Solicitante ARGONAUT THERAPEUTICS LIMITED Inventor/a LA THANGUE, Nicholas

The present invention provides one or more immunogenic peptides derived from a PRMT5-E2F1 axis regulated long non-coding RNA gene or a derivative thereof; a pharmaceutical composition comprising one or more of said peptides; a vaccine comprising one or more of said peptides and their use in therapy, including a method for eliciting an immune response in a mammalian subject by administration of an agent capable of presenting the peptides to the host. The invention also relates to the use of a PRMT5 inhibitor for use in treating cancer by stimulating host immunity.

25. [WO/2023/106319](#) VACCINE COMPOSITION FOR INDUCING ANTI-IL-23 ANTIBODY
WO - 15.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud PCT/JP2022/045045 Solicitante OSAKA UNIVERSITY Inventor/a NAKAGAMI, Hironori

The present invention provides a vaccine composition which contains a complex of a T-cell receptor antigen peptide and a B-cell receptor antigen peptide and which can induce the production of an antibody against IL-23, wherein the B-cell receptor antigen peptide is represented by formula (I): X1-X2-X3-X4-X5-X6-X7-X8 (in the formula: X1 is S, A, G, T, K or R; X2 is P, A, G, S, T, K or R; X3 is S, A, G, T, K or R; X4 is Q, A, G, T or N; X5 is P, A, G, S, T, Q or N; X6 is W, A, Y or F; X7 is Q, A, G, T or N; and X8 is R, A, G or K).

26. [WO/2023/098755](#) RECOMBINANT HEGF-CRM197 TUMOR THERAPEUTIC VACCINE FORMULATION

WO - 08.06.2023

Clasificación Internacional [A61K 39/05](#) N° de solicitud PCT/CN2022/135608 Solicitante SHANGHAI HUIMMUTECH BIOTECHNOLOGY CO., LTD Inventor/a ZHANG, Wenyao

Provided in the present invention is a recombinant hEGF-CRM197 tumor therapeutic vaccine formulation. Specifically, the formulation of the present invention contains a therapeutically effective amount of a conjugate of a recombinant human epidermal growth factor (hEGF) and a diphtheria toxin mutant (CRM197), a phosphate base buffer solution with the pH in a range of 7.5-8.5, a polysorbate 20 surfactant and optionally a monosaccharide or disaccharide. The protein conjugate molecule in the formulation of the present invention can break immune tolerance and induce the production of an anti-human epidermal growth factor antibody in the human body; In addition, the protein conjugate molecule produces a lower proportion of polymers, and has a more uniform molecular weight distribution in the buffer, and better stability. Therefore, the formulation of the present invention can achieve large-scale production and can be stably stored for a long time.

27. [WO/2023/097265](#) MODIFIED GENE VACCINES AGAINST AVIAN CORONAVIRUSES AND METHODS OF USING THE SAME

WO - 01.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud PCT/US2022/080415 Solicitante WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor/a TALAAT, Adel

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated NA vaccine compositions and viral vaccine compositions that encode an Infectious Bronchitis Virus (IBV) spike (S) protein, an IBV nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against IBV or to vaccinate the subject against IBV.

28. [WO/2023/107951](#) NEOEPITOPE VACCINE DELIVERY VEHICLE AND METHODS OF MAKING THE SAME

WO - 15.06.2023

Clasificación Internacional [A61K 39/385](#) N° de solicitud PCT/US2022/081025 Solicitante IMMUNITYBIO, INC. Inventor/a LIU, Philip T.

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

29. [20230172175](#) RECOMBINANT PROTEIN PRODUCTION IN INSECTS

US - 08.06.2023

Clasificación Internacional [A01K 67/033](#) N° de solicitud 17911930 Solicitante Proteinea, Inc. Inventor/a Mahmoud Eljendy

The present disclosure relates to the field of commercial scale production and processing of pharmaceutical liquid or solid compositions derived from insects, wherein the compositions include a purified recombinant protein, vaccine, antibody, peptide, or chemical. Systems and methods to produce

the insects and a purified insect-derived recombinant protein, vaccine, antibody, peptide, insecticide, fungicide, or chemical within a bioreactor are also described.

30. [WO/2023/094885](#) ANTIGENIC DETERMINANTS, PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-COV-2

WO - 01.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud PCT/IB2022/000699 Solicitante ARABIAN GULF UNIVERSITY Inventor/a FATHALLAH, Mohamed-dahmani

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity.

31. [20230165952](#) BETACORONAVIRUS PROPHYLAXIS AND THERAPY

US - 01.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 17997407 Solicitante Nykode Therapeutics ASA Inventor/a Agnete Brunsvik Fredriksen

Disclosed is a vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein the antigenic unit comprises at least one betacoronavirus epitope. The vaccine is ideal for pandemic and epidemics as it can induce rapid, strong immune response with lower/fewer doses because the antigen is targeted to antigen presenting cells and the antigen is produced in the body.

32. [WO/2023/108083](#) NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODS

WO - 15.06.2023

Clasificación Internacional [A61K 47/60](#) N° de solicitud PCT/US2022/081199 Solicitante YALE UNIVERSITY Inventor/a IWASAKI, Akiko

Compositions and methods for inducing a protective mucosal immunity against an antigen in a subject include the step of administering to a mucosal tissue an effective amount of a vaccine composition including the antigen or polynucleotide encoding an antigen associated or encapsulated within carriers such as poly(amine-co-ester) polymers in the form of particles (e.g., solid nanoparticles formed of PACE) or PACE copolymers and/or blends. Typically, the subject has previously been exposed to the antigen, for example, by administering to the same subject via a systemic or mucosal route of administration a priming antigen. In some embodiments, the polynucleotides-based vaccines are messenger RNAs encoding a viral antigen such as a coronavirus spike protein sequence, or a portion thereof. In preferred embodiments, the vaccine composition is administered intranasally.

33. [20230173045](#) RANKING NEOANTIGENS FOR PERSONALIZED CANCER VACCINE

US - 08.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 17764074 Solicitante Amazon Technologies, Inc. Inventor/a Layne Christopher PRICE

Disclosed herein are methods for ranking tumor-specific neoantigens from a tumor of a subject that are suitable for subject-specific immunogenic compositions. Suitable tumor-specific neoantigens are tumor-specific neoantigens that are likely presented on the cell surface of the tumor, are likely to be immunogenic, are predicted to be expressed in sufficient amounts to elicit an immune response in the subject, optionally represent sufficient diversity across the tumor, and have relatively high manufacture feasibility. The present methods take a set of neoantigens (peptide vaccine candidates) and ranks the neoantigens in a way such that a group of top-ranked neoantigens simultaneously promotes cell-surface

presentation of important neoantigens for Class I and Class II MHC molecules. The top-ranked neoantigens can then be further narrowed according manufacturability and/or other criteria.

34. [20230173062](#) SMALLPOX VACCINE FOR CANCER TREATMENT

US - 08.06.2023

Clasificación Internacional [A61K 39/285](#) N° de solicitud 18103214 Solicitante CALIDI BIOTHERAPEUTICS, INC. Inventor/a Aladar SZALAY

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.

35. [20230173049](#) FUSION PROTEINS AND METHODS OF USE THEREOF

US - 08.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 17789858 Solicitante The Johns Hopkins University Inventor/a Mark Yarchoan

The invention features compositions and methods for treating and preventing cancer. In one aspect, isolated fusion proteins are provided that comprise a DNAJBI portion and a PRKACA portion. In a further aspect, compositions are provided, including immunogenic compositions that comprise an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion. In a yet further aspect, a cancer vaccine is provided that comprises an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion.

36. [20230165950](#) IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE

US - 01.06.2023

Clasificación Internacional [A61K 39/02](#) N° de solicitud 17814988 Solicitante GENKYOTEX Inventor/a Rémi PALMANTIER

The invention relates to the use of a polypeptide derived from the adenylate cyclase of a *Bordetella* sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of *Bordetella pertussis*, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by *Bordetella* sp. or in a combination composition encompassing said acellular immunogenic composition.

37. [WO/2023/100159](#) MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

WO - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud PCT/IB2022/061742 Solicitante KASHIV BIOSCIENCES, LLC Inventor/a GUPTA, Sudharti

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants. Further, the present invention the expression vector comprises spike protein of SARS-CoV-2 and one or more structural protein selected from membrane protein, envelope protein and nucleocapsid protein of SARS-CoV-2. The expression vector expressed mRNA capable to encode more than one structural protein to provide immune response against SARS-CoV-2 virus.

38. [20230174996](#) REASSORTED ISA VIRUS

US - 08.06.2023

Clasificación Internacional [C12N 15/63](#) N° de solicitud 17785223 Solicitante Intervet Inc. Inventor/a Stephane Villoing

The present invention is directed to a reassorted ISA virus comprising Genome segments 1-8 wherein at least one genome segment is from Genotype I and at least one genome segment is from genotype II, wherein genome segment 6 is of Genotype II. The reassorted ISA virus was found to grow well in suspension culture. The present invention is also directed to method to make the reassorted virus as well as vaccination methods using the reassorted ISA virus and to vaccine compositions comprising the reassorted ISA virus.

39. [4190894](#) VERFAHREN ZUR IN-VITRO-HERSTELLUNG VON REIFEN DENDRITISCHEN ZELLEN UNTER VERWENDUNG EINES BAKTERIELLEN LYSATS
EP - 07.06.2023

Clasificación Internacional [C12N 5/0784](#) N° de solicitud 21212360 Solicitante CIMAAS B V Inventor/a GERMERAAD WILFRED THOMAS VINCENT

The invention is in the field of cell biology and immunology. The invention provides methods for the production of a vaccine for cancer and infectious diseases. More in particular it provides a method for the improved production of mature dendritic cells. This improved production includes the use of a bacterial lysate produced by a new method.

40. [WO/2023/094980](#) ANTIBODIES TO CORONAVIRUS
WO - 01.06.2023

Clasificación Internacional [C07K 16/10](#) N° de solicitud PCT/IB2022/061257 Solicitante FONDAZIONE TOSCANA LIFE SCIENCES Inventor/a ANDREANO, Emanuele

The present disclosure provides human monoclonal antibodies that have potent neutralizing activity against SARS-CoV-2. The present disclosure also provides prevention methods, treatment methods, compositions, pharmaceutical compositions, and vaccine compositions that comprise or utilize the human monoclonal antibodies provided herein.

41. [20230167157](#) ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2
US - 01.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud 18058403 Solicitante ARABIAN GULF UNIVERSITY Inventor/a Mohamed-Dahmani FATHALLAH

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity,

42. [WO/2023/102359](#) A MAPS VACCINE TARGETING SALMONELLA ENTERICA SEROVARS
WO - 08.06.2023

Clasificación Internacional [A61K 39/112](#) N° de solicitud PCT/US2022/080531 Solicitante THE CHILDREN'S MEDICAL CENTER CORPORATION Inventor/a MALLEY, Richard
Technologies for the prevention and/or treatment of *Salmonella* infections.

43. [20230167159](#) SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATES
US - 01.06.2023

Clasificación Internacional [C07K 14/165](#) N° de solicitud 17906825 Solicitante Kansas State University Research Foundation Inventor/a Waithaka Mwangi

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

44. [20230174937](#)METHOD FOR THE PRODUCTION OF MATURE DENDRITIC CELLS IN VITRO USING A BACTERIAL LYSATE
US - 08.06.2023

Clasificación Internacional [C12N 5/0784](#) N° de solicitud 18073914 Solicitante CiMaas B.V. Inventor/a Wilfred Thomas Vincent GERMERAAD

The invention is in the field of cell biology and immunology. The invention provides methods for the production of a vaccine for cancer and infectious diseases. More in particular it provides a method for the improved production of mature dendritic cells. This improved production includes the use of a bacterial lysate produced by a new method.

45. [4189686](#)VERFAHREN ZUR HERSTELLUNG VON NEOPENEPITOP-HALTIGEN IMPFSTOFFEN
EP - 07.06.2023

Clasificación Internacional [G16B 20/20](#) N° de solicitud 21755404 Solicitante EVAXION BIOTECH AS Inventor/a TROLLE THOMAS

The present invention presents an improved method for identification of neoepitopes useful in active immunotherapy targeting malignant neoplasms. The method integrates identification of somatic variants of expression product with a balanced evaluation of such variants' 1) ability to bind MHC, 2) ability to induce immune responses, 3) clonal coverage in the tumour tissue, and 4) ability to evade immune responses. Also, the method is complemented by a method for purposive deselection of neoepitopes that could induced undesired immune response against normal cells. Also disclosed is a method for preparing immunogenic compositions, a method for treatment of cancer, and a computer system for identifying neoepitopes and neopeptides.

46. [4190348](#)VERWENDUNG VON EPIDERMALLEN WACHSTUMSFAKTOR-DEPLETIONSMITTELN BEI DER BEHANDLUNG DER CHRONISCH OBSTRUKTIVEN LUNGENERKRANKUNG
EP - 07.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 21759232 Solicitante CT INMUNOLOGIA MOLECULAR Inventor/a MACÍAS ABRAHAM AMPARO EMILIA

The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein.

47. [WO/2023/101007](#)ANTIGEN-PROTEIN EXPRESSION VECTOR AND UTILIZATION THEREOF
WO - 08.06.2023

Clasificación Internacional [C12N 15/63](#) N° de solicitud PCT/JP2022/044526 Solicitante I'ROM GROUP CO., LTD. Inventor/a SUZUKI, Shinnosuke

The present invention provides: a vector that expresses a fusion protein containing a secretion signal, an antigen-protein fragment, and a trimer forming domain; and usages thereof. Said vector has an excellent ability to secrete and release an antigen-protein fragment to the cell exterior. The present invention is capable of: maximizing the expression by minimizing a vaccine antigen and adding a trimer forming domain thereto; and maximizing secreted and released amounts of expression products by additionally adding a secretion signal. The present technology is assumed to be useful as a vector technology that can be programmed so as to induce both humoral immunity and cell-mediated immunity.

48. [4188436](#)SARS-COV-2-REZEPTORBINDUNGSDOMÄNE IN NATIVEN AUSSENMEMBRANVESIKELN
EP - 07.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 21849046 Solicitante OMVAX INC Inventor/a MOE GREGORY

The disclosure provides native outer membrane vesicle (NOMV) vaccines containing a coronavirus receptor binding domain (RBD) modified to be a lipoprotein. Also provided are compositions comprising a meningococcal strain having a plasmid-borne gene encoding the SARS-CoV-2 RBD modified to be a lipoprotein. Also provided are a meningococcal strain and a NOMV vaccine containing a plasmid coding for the SARS-CoV-2 RBD with a promoter/enhancer and polyA sequence that provide for expression of the RBD in mammalian cells.

49. [WO/2023/097102](#) SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

WO - 01.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud PCT/US2022/051178 Solicitante AEGIS LIFE, INC. Inventor/a JIANG, Hong

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

50. [WO/2023/107672](#) PHYSIOLOGICAL METRICS AS CANDIDATE PREDICTORS OF ANTIBODY RESPONSE FOLLOWING VACCINATION AGAINST COVID-19

WO - 15.06.2023

Clasificación Internacional [C12N 7/00](#) N° de solicitud PCT/US2022/052356 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a MASON, Ashley E.

Methods, systems, and devices are provided for predicting the robustness of an antibody response of a subject to the SARS-CoV-2 spike protein receptor binding domain based on measurement of physiological metrics following vaccination. In particular, one or more physiological metrics of the subject selected from dermal temperature deviation, heart rate, respiratory rate, heart rate variability, and deep sleep duration are measured with a wearable device before and after vaccinating the subject, wherein increases in dermal temperature deviation, heart rate, and respiratory rate, and decreases in heart rate variability on the first night after administration of the vaccine to the subject are correlated with greater antibody responses to the SARS-CoV-2 spike protein.

51. [WO/2023/105247](#) METHODS AND COMPOSITIONS TO POTENTIATE THE IMMUNE RESPONSE WITH LYSINE DEACETYLASE INHIBITORS

WO - 15.06.2023

Clasificación Internacional [A61K 31/167](#) N° de solicitud PCT/GB2022/053173 Solicitante CAMBRIDGE ENTERPRISE LIMITED Inventor/a MCKINNEY, Eoin F.

The invention relates to methods and compositions to boost immune responses to both infection and vaccination against and infection. In particular, the present invention is aimed at providing a method to boost immune responses to both infection with an infectious agent and vaccination against an infection with an infectious agent. It is also aimed at providing a treatment of infectious disease and vaccine adjuvant for the prevention of infection with an infectious agent.

52. [WO/2023/102448](#) CORONAVIRUS VACCINE FORMULATIONS

WO - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud PCT/US2022/080700 Solicitante NOVAVAX, INC. Inventor/a SMITH, Gale

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

53. [20230173054](#) TARGET SEQUENCE OF RNA VIRUS AND USE THEREOF

US - 08.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud 17453574 Solicitante SHANGHAI PUBLIC HEALTH CLINICAL CENTER Inventor/a Wenqiang Yu

The present invention provides a target sequence of an RNA virus. The target sequence is a nucleic acid sequence fragment in the gene sequence in the RNA virus containing 20-40 bases and having not less than 95% similarity to genome sequence of human or related species such as livestock and poultry. The above-mentioned target sequence of the RNA virus is selected from SEQ ID NO. 1 - SEQ ID NO. 615. The present invention also relates to a primer composition for constructing the above-mentioned target sequence, biomaterials such as antisense RNA related to the above-mentioned target sequence, and related uses such as design of a vaccine lacking the target sequence. The virus fragment with the above-mentioned sequence constructed in the present invention has the function of interacting with human genomic DNA and is similar to viral miRNA. Moreover, the effect of overexpression of the target sequence of the RNA virus on the expression level of surrounding genes is verified, and a new concept that the above-mentioned target fragment is an important pathogenic substance of the RNA virus is proposed. The above-mentioned target sequence has important application value for the detection and diagnosis of RNA viruses, drug screening, as well as the treatment of diseases caused by RNA viruses and the design/optimization of vaccines and methods.

54. [20230173060](#) LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS

US - 08.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 18046875 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a Lbachir BenMohamed

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

55. [WO/2023/108117](#) ENGINEERED FC DOMAINS AND ENGINEERED HCMV VIRAL FC RECEPTORS

WO - 15.06.2023

Clasificación Internacional [C07K 16/10](#) N° de solicitud PCT/US2022/081258 Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor/a MAYNARD, Jennifer

Recombinant antibodies are provided that comprise engineered human IgG1 Fc domains that have reduced affinity for viral FcγRs, such as HCMV gp34 and gp68, as compared to a wild-type human IgG1 Fc domain. The engineered human IgG1 Fc domains have equivalent affinity for CD16A and FcRn as compared to a wild-type human IgG1 Fc domain. Also provided are engineered forms of HCMV gp34 and their use in a vaccine.

56. [4188426](#) KONSENSUSSEQUENZ DER ANTIGEN-TELOMERASE UND IHRE VERWENDUNG ZUR PRÄVENTIVEN UND THERAPEUTISCHEN IMPFUNG

EP - 07.06.2023

Clasificación Internacional [A61K 39/00](#) N° de solicitud 21762530 Solicitante EVVIVAX S R L Inventor/a AURISICCHIO LUIGI

The present invention relates to the generation of a consensus sequence of the antigen telomerase (ConTRt) and the use thereof in preventive and therapeutic vaccination, wherein the consensus sequence of telomerase was generated by the fusion of two sequences, one belonging to human telomerase

(hTERT) and the other to dog telomerase (dTERT), with the aim of developing an effective vaccine for the treatment of tumours expressing both human and dog telomerase, hence in both the human and veterinary sectors.

57. [20230172902](#) METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19
US - 08.06.2023

Clasificación Internacional [A61K 31/357](#) N° de solicitud 18047432 Solicitante Lloyd Hung Loi Tran
Inventor/a Lloyd Hung Loi Tran

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

58. [20230173051](#) COMPOSITIONS COMPRISING THREE OSP A FUSION PROTEINS FOR MEDICAL USE

US - 08.06.2023

Clasificación Internacional [A61K 39/02](#) N° de solicitud 17917624 Solicitante Valneva Austria GmbH
Inventor/a Nicole Bézay

The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.

59. [2613460](#) Methods for the prophylaxis and treatment of Covid and Covid-19

GB - 07.06.2023

Clasificación Internacional [A61K 39/215](#) N° de solicitud 202217355 Solicitante LLOYD HUNG LOI TRAN
Inventor/a LLOYD HUNG-LOI TRAN

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

60. [20230173053](#) Lyophilized Live Bordetella Vaccines

US - 08.06.2023

Clasificación Internacional [A61K 39/02](#) N° de solicitud 18159550 Solicitante ILiAD Biotechnologies, LLC
Inventor/a Marcel Thalen

Formulations of lyophilized *Bordetella* bacteria which are stable for at least two years when stored at temperatures between -20° and 22.5° C., and which exhibit sufficient homogeneity (no bacterial

clumping) bacterial viability and potency to be used as a live vaccine are made by harvesting *Bordetella* bacteria from a culture at an OD600 between 0.4 and 1.6; mixing the harvested *Bordetella* bacteria with a lyophilization buffer comprising 5-65% by weight a cryoprotectant sugar and having a temperature between 2-3 5° C., wherein the ratio of harvested *Bordetella* bacteria to lyophilization buffer is between 5:1 and 1:5 by volume; lyophilizing the mixture of the *Bordetella* bacteria and the lyophilization buffer; wherein the hold time between the harvesting and lyophilization steps is less than 48 hours; and collecting the lyophilized *Bordetella* bacteria.

61. [20230174589](#) STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEIN

US - 08.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud 17924177 Solicitante GENEMATRIX, INC.

Inventor/a Soo Ok KIM

The present invention relates to a chimeric recombinant protein having a therapeutic effect on cervical cancer by fusing genetic modified E6 and E7, which are carcinogenesis-inducing proteins of human papillomavirus high-risk group type 16, with a fusion protein for increasing immunogenicity, the HPV type 16 E6, E7 chimeric recombinant protein fused with the flagellin fusion protein of the present invention showed the lowest tumor cell volume, and the immune response of specific T cells according to the recombinant antigen was significantly confirmed, and when the prophylactic effect was measured, it was confirmed that the volume of tumor cells was low and the antibody titer was increased, therefore human papillomavirus recombinant antigen of the present invention shows tumor treatment and prophylaxis and can be applied as a therapeutic/prophylactic vaccine composition.

62. [4188405](#) PHARMAZEUTISCHE FORMULIERUNG MIT EINER KOMBINATION AUS REKOMBINANTEN NEWCASTLE-KRANKHEITSVIREN ZUR BEHANDLUNG VON KREBS

EP - 07.06.2023

Clasificación Internacional [A61K 35/768](#) N° de solicitud 21742155 Solicitante THALLER TRISTAN

WOLFRAM Inventor/a THALLER ARNO

The invention relates to a pharmaceutical formulation comprising at least three recombinant transgene expressing Newcastle Disease Virus (NDV) strains, which have been demonstrated to possess significant oncolytic activity against mammalian cancers and an improved safety profile, a non-recombinant NDV strain, a reovirus type-3 and optionally a vaccinia virus. At least one of the recombinant NDV strains comprises in its viral genome a nucleic acid sequence comprising at least one foreign gene, the at least one foreign gene encoding a checkpoint modulator, and at least one of the recombinant NDV strains comprises in its viral genome a nucleic acid sequence comprising at least one foreign gene, the at least one foreign gene encoding an angiogenesis inhibitor. The viral genome of each of the at least three recombinant NDV strains comprises a mutation in the HN gene, said mutation allowing replication of said rgNDV in a cancer cell to a higher level than replication of an otherwise identical NDV not having said mutation in the HN gene. The pharmaceutical formulation provides an improved treatment of cancer, because instead of a monotherapy, a mixture of oncolytic viruses is applied.

63. [20230173061](#) HUMAN CYTOMEGALOVIRUS POLYPEPTIDE VACCINE COMPOSITION

US - 08.06.2023

Clasificación Internacional [A61K 39/245](#) N° de solicitud 17921945 Solicitante The Council of the Queensland Institute of Medical Research Inventor/a Rajiv Khana

Disclosed is a human herpesvirus immunotherapy. More particularly, disclosed is a composition that includes one or more recombinant proteins that include a plurality of epitopes derived from multiple human cytomegalovirus antigens, a CMV envelope glycoprotein, and a TLR agonist.

64. [WO/2023/102520](#) PARENTERALLY ADMINISTRABLE INFLUENZA VACCINE AND USES THEREOF
WO - 08.06.2023
Clasificación Internacional [A61K 39/145](#) N° de solicitud PCT/US2022/080808 Solicitante CODAGENIX INC. Inventor/a COLEMAN, John Robert
The present invention provides for parenterally administrable live attenuated influenza immune compositions. Methods of using parenterally administrable live attenuated influenza immune compositions to elicit an immune response, and particularly, a protective immune response are also provided.
65. [20230173046](#) MULTICOMPONENT CHEMICAL COMPOSITION OF A PEPTIDE-BASED NEOANTIGEN VACCINE
US - 08.06.2023
Clasificación Internacional [A61K 39/00](#) N° de solicitud 17788651 Solicitante AMAZON TECHNOLOGIES, INC. Inventor/a Frank Wilhelm SCHMITZ
Provided herein are immunogenic compositions comprising tumor-specific neoantigen long peptides, tumor-specific neoantigen short peptides, and adjuvant, optionally a helper peptide, and optionally a tumor-specific peptide. The disclosure also provides methods of using these immunogenic compositions for treating cancer.
66. [4188437](#) IMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON
EP - 07.06.2023
Clasificación Internacional [A61K 39/215](#) N° de solicitud 21850622 Solicitante UNIV LELAND STANFORD JUNIOR Inventor/a MASSOUD TARIK F
Provided herein, *inter alia*, are complexes comprising nanoparticles attached to viral proteins or nucleic acids encoding said viral proteins. Methods for making and using said complexes are provided. Compositions including the complexes are contemplated to be useful for treating and/or preventing viral infections.
67. [WO/2023/105221](#) VACCINE BOOST METHODS AND COMPOSITIONS
WO - 15.06.2023
Clasificación Internacional [A61K 39/395](#) N° de solicitud PCT/GB2022/053122 Solicitante VACCITECH (UK) LIMITED Inventor/a EVANS, Thomas
The invention relates to combinations, compositions, methods and dosage regimes for use in medicine, optionally wherein the use may be the treatment of chronic hepatitis B virus (HBV) infection or cancer, including inducing an improved immune response and improvement in the performance of therapeutic vaccines.
68. [20230174602](#) NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 08.06.2023
Clasificación Internacional [C07K 14/47](#) N° de solicitud 17820824 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells *ex vivo* and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
69. [WO/2023/094595](#) CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES
WO - 01.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud PCT/EP2022/083289 Solicitante CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor/a ENJUANES SÁNCHEZ, Luis
A propagation-defective, replication-competent RNA replicon derived from the SARS-CoV-2 coronavirus that comprises a polynucleotide sequence SEQ_ID 2 or a variant of SEQ_ID 2 having at least 80 % identity, more preferably 85% identity, even more preferably at least 90 % identity, and even more preferably 91 % or 92 % or 93 % or 94 % or 95 % or 96 % or 97 % or 98 % or even up to 99 % identity with respect to the SEQ_ID 2 polynucleotide sequence, wherein the variant of SEQ_ID2 does not comprise sequences suitable for expressing an ORF8 protein, wherein the ORF8 protein is encoded by a gene having at least 80% identity to the sequence of SEQ_ID36, methods of preparation thereof and the use in vaccine compositions.

70.[4188939](#)REPLIKATIONSDEFIZIENTER ADENOVIRUS
EP - 07.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud 21755406 Solicitante LEIBNIZ INST FUER VIROLOGIE Inventor/a BODDIN JANA

The present invention generally relates to the field of adenoviruses and adenoviral vectors that can be used as vaccines and gene therapy vectors. More specifically, the present invention relates to an adenovirus or an adenoviral vector that comprises a mutated DNA-binding protein that inhibits adenoviral DNA replication in a cell infected with a virus expressing said protein. The invention further relates to a nucleotide sequence encoding the mutated DNA-binding protein. In another aspect, the invention provides pharmaceutical compositions, vaccines and cells that comprise the mutated protein, a nucleotide sequence encoding same, or a modified adenovirus or adenoviral vector comprising any of those. The invention also relates to the use of the mutated protein, a nucleotide sequence encoding the same, or an adenovirus or recombinant adenoviral vector comprising any of those for the preparation of a vaccine.

71.[20230174586](#)STRAIN DIS-DERIVED RECOMBINANT VACCINIA VIRUS HAVING NOVEL INFLUENZA VIRUS-DERIVED HEMAGGLUTININ PROTEIN GENE
US - 08.06.2023

Clasificación Internacional [C07K 14/005](#) N° de solicitud 17293378 Solicitante TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE Inventor/a Fumihiko YASUI

Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.

72.[WO/2023/096896](#)DETECTION OF COVID-19 ASSOCIATED CARDIAC INJURY AND VACCINE-ASSOCIATED MYOCARDITIS
WO - 01.06.2023

Clasificación Internacional [C12Q 1/70](#) N° de solicitud PCT/US2022/050706 Solicitante NREFERENCE, INC. Inventor/a SOUNDARARAJAN, Venkataramanan

This application relates to methods of treating and/or preventing a coronavirus infection in a subject in need thereof, and treating cardiac injury in said subjects.

73.[20230167462](#)RECOMBINANT ADENOVIRUS EXPRESSING AFRICAN SWINE FEVER VIRUS EP153R-EP402R PROTEIN AND CONSTRUCTION METHOD THEREOF
US - 01.06.2023

Clasificación Internacional [C12N 15/86](#) N° de solicitud 18057765 Solicitante Institute of Animal Sciences of Chinese Academy of Agricultural Sciences Inventor/a HONG JIA

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

74. [20230173050](#) VACCINE IMMUNOGENS

US - 08.06.2023

Clasificación Internacional [A61K 39/015](#) N° de solicitud 17610380 Solicitante OXFORD UNIVERSITY INNOVATION LIMITED Inventor/a Adrian Vivian Sinton Hill

An immunogenic composition comprising: a) one or more *Plasmodium*-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are *Plasmodium*-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

75. [WO/2023/096766](#) METHODS OF BLOCKING ASFV INFECTION THROUGH INTERRUPTION OF CELLULAR AND VIRAL RECEPTOR INTERACTIONS

WO - 01.06.2023

Clasificación Internacional [A61K 39/12](#) N° de solicitud PCT/US2022/049832 Solicitante CHEN, Dalu Inventor/a CHEN, Dalu

A method of preventing and treating viral infections in animals (and preferably ASFV in porcine), by inhibiting viral ligand interactions with critical cellular receptors that are involved either directly (endocytosis and/or macropinocytosis) or indirectly (phagocytosis of RBCs that have been aggregated by viral interactions) with cellular entry in an animal, and preventing and treating the viral infection in the animal. A method of treating a viral infection in an individual with a virus that is both lysogenic and lytic. A composition for treating a viral infection in an individual with a virus that is both lysogenic and lytic. A vaccine for preventing viral infection, including whole and/or partial domains of proteins of both a lysogenic and lytic phase of a virus.

76. [4188482](#) SYSTEME UND VERFAHREN FÜR VORGEFÜLLTE MEDIZINISCHE ABGABEANORDNUNGEN

EP - 07.06.2023

Clasificación Internacional [A61M 5/24](#) N° de solicitud 21850313 Solicitante KOSKA FAMILY LTD Inventor/a CHA JAE-HYOK

A pre-filled medical delivery assembly assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery assembly generally includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu



FINLAY EDICIONES